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GENETIC OVERLAP AND CAUSAL MEDIATION RELATIONSHIP BETWEEN PSYCHIATRIC AND 
NON-PSYCHIATRIC PHENOTYPES 
 
ABSTRACT 
Genome-wide genotyping studies are providing evidence that psychiatric disorders are truly 
polygenic, that is they have a genetic architecture of many genetic variants. Cross-trait 
polygenic analysis has been applied to identifying genetic correlations between psychiatric and 
non-psychiatric phenotypes. However, causal models between shared genetic factors and the 
genetically-correlated phenotypes are mostly unclear. We used cross-trait polygenic risk score 
(PRS) association analysis to examine the genetic overlap between two phenotypes. We then 
performed causal mediation analysis to identify the causal relationship between common 
genetic variants and two genetically correlated traits. We examined if the effect of polygenic 
risk on one trait (i.e., the outcome) was mediated by the other trait (i.e., the mediator).  
 
In Chapter 1, we examined the relationship between PRS for psychotic illness or cognitive 
ability, event-related potential (ERP), and severity of psychotic symptoms. A phenotype of 
global impairment on multiple ERP measures is associated with positive symptoms of psychosis 
as well as polygenic influences on educational attainment and, to a lesser extent, schizophrenia. 
We also observed a positive association between education PRS and positive symptoms that 
was almost entirely mediated by effects on the globally impaired ERP phenotype. 
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In Chapter 2, we examined the relationship between PRS for Alzheimer’s dementia, vascular 
pathologies, and late-life cognitive function. Our findings support the hypothesis of a genetic 
overlap, mostly due to APOE, between vascular pathologies and AD dementia. The polygenic 
genetic effect on late-life cognition is partially but significantly mediated by cerebral 
microbleeds, white matter lesion load, and coronary artery calcification. 
 
In Chapter 3, we examined the relationship between PRS for coronary heart disease, 
psychological attitudes, and liability to coronary heart disease. Our findings suggest a genetic 
overlap between optimism and CHD in older women of European ancestry. The polygenic 
genetic effect on CHD is modestly though significantly mediated by optimism. 
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ABSTRACT  
OBJECTIVE: Event-related portential (ERP) components have been used to assess cognitive 
functions in patients with psychotic illness. Evidence suggests that among patients with 
psychosis there is a distinct heritable neurophysiologic phenotypic subtype captured by 
impairments across a range of ERP measures. In this study, we investigated the genetic basis of 
this “globally impaired” ERP cluster and its relationship to psychosis and cognitive abilities.  
 
METHODS: We used the K means algorithm applied to six ERP measures to empirically re-derive 
the globally impaired (n=60) and the non-globally impaired ERP clusters (n=323) in our study 
sample of cases with schizophrenia (SCZ=136) or bipolar disorder (BPD=121) and healthy 
controls (n=126). We used published genome-wide association study (GWAS) results for SCZ, 
BPD, college completion, and childhood intelligence as the discovery datasets to derive 
polygenic risk scores (PRS) for each of these discovery phenotypes in our study sample and 
tested associations between each PRS and the globally impaired ERP. We conducted causal 
mediation analyses to estimate the proportion of each PRS effect on psychotic symptoms (as 
measured by PANSS positive subscale score) that is mediated through membership in the 
globally impaired ERP. 
 
RESULTS: Individuals in the globally impaired cluster had significantly higher PANSS-positive 
scores (β=3.95, P=0.005). The SCZ-PRS was nominally associated with globally impaired ERP 
(unadjusted P=0.01; R2=3.07%). We also found a significant positive association between the 
college-PRS and globally impaired ERP (FDR-corrected P=0.004; R2=6.15%). The effect of 
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college-PRS on PANSS-positivity was almost entirely mediated through globally impaired ERP 
(proportion mediated=97.1%). 
 
CONCLUSION: A phenotype of global impairment on multiple ERP measures is associated with 
positive symptoms of psychosis as well as polygenic influences on educational attainment and, 
to a lesser extent, schizophrenia. We also observed a positive association between education 
PRS and positive symptoms that was almost entirely mediated by effects on the globally 
impaired ERP phenotype. These results suggest that the globally impaired ERP phenotype may 
represent some aspects of brain physiology on the causal path between genetic influences on 
educational attainment and psychotic symptoms  
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INTRODUCTION 
In recent years, traditional psychiatric diagnostic constructs have been increasingly challenged. 
This is particularly evident in psychotic spectrum disorders such as schizophrenia (SCZ), 
schizoaffective disorder (SA), and psychotic bipolar disorder (BPD). These disorders overlap 
substantially in symptoms, neurobiology, cognitive features, treatment response, and liability 
risk factors (N Craddock, O'Donovan, & Owen, 2005; N. Craddock, O'Donovan, & Owen, 2009; 
Ivleva et al., 2010; Keshavan, Clementz, Pearlson, Sweeney, & Tamminga, 2013). Moreover, 
large-scale genetic studies have consistently found overlap in susceptibility across BPD, SA, SCZ, 
and related phenotypes (Cross-Disorder Group of the Psychiatric Genomics, 2013; Cross-
Disorder Group of the Psychiatric Genomics et al., 2013; Ripke et al., 2011; Ruderfer et al., 
2014). In line with shared genetic susceptibility, the endophenotype-biomarker literatures on 
BPD-SCZ indicate differences in degree, rather than differences in kind, across various domains 
of brain function, both in patients and in their clinically unaffected relatives (Clementz et al., 
2016; M. H. Hall, F. Rijsdijk, S. Kalidindi, et al., 2007; M. H. Hall, F. Rijsdijk, M. Picchioni, et al., 
2007; Hall et al., 2009; S. K. Hill et al., 2013; Skudlarski et al., 2013; Tamminga et al., 2014; 
Thaker, 2008). These observations challenge the traditional dichotomous model of SCZ and BPD 
and support a dimensional approach to understanding how genetic and neurobiological 
underpinnings cut across diagnostic boundaries.  
 
Auditory event related potential (ERP) components--including P50 sensory gating, N1, P2, and 
P3--have been extensively investigated in the psychoses and are putative endophenotypes for 
psychotic spectrum disorders (M.-H. Hall et al., 2007; Hall et al., 2015; Hall et al., 2009; Hall et 
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al., 2006; O'Connor, Morzorati, Christian, & Li, 1994; O'Donnell, Vohs, Hetrick, Carroll, & 
Shekhar, 2004; Salisbury, Collins, & McCarley, 2010).  Each of these ERP components measures 
specific aspects of brain function and is reliably quantifiable across diverse clinical and 
laboratory settings (Owens, Bachman, Glahn, & Bearden, 2016; Tamminga et al., 2014; Turetsky 
et al., 2007). P50 sensory gating probes inhibitory mechanisms thought to be crucial for 
protecting the brain from information overload (Freedman et al., 1994). Response to S1 
stimulus assesses basic brain functions associated with auditory perception (Javitt, Spencer, 
Thaker, Winterer, & Hajos, 2008). N1 ERP indexes sensory processing at the level of auditory 
cortex (Salisbury et al., 2010). P2 and P3 components are associated with higher-order cognitive 
processes relevant to attention, working memory, and information processing speed (Donchin 
& Coles, 1988; Polich, 2007) (see Supplementary Information for details on ERPs). In twin 
analyses, we have shown that ERP phenotypes are heritable and genetically correlated with 
BPD and SCZ (Hall, 2006, Hall 2007).  
 
We have also identified multivariate clusters of ERP phenotypes that appear to aggregate 
among individuals with psychotic BPD and SCZ, independent of diagnosis(Hall et al., 2012). In 
that study, various domains of brain function, ranging from the early pre-attentive stage of 
information processing to higher complex cognitive processes (including P50 sensory gating, 
gamma band response, mismatch negativity, and the N1, P2, and P3 ERPs), were included to 
allow us to empirically derive homogenous subgroups based on these features. One of the 
clusters was termed “globally impaired” because this group of subjects exhibited functional 
abnormalities on all of these ERP measures. Such data-driven clustering holds promise for 
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parsing the neurobiological and genetic heterogeneity of psychotic illness, and the analysis of 
phenotypes based on these clusters may enhance the power of genetic association analyses 
(Allison et al., 1998; Marlow et al., 2003; Yang, Williams, & Buu, 2017). Importantly, the neuro-
clusters identified in our study resembled the “Biotypes” recently reported by the Bipolar-
Schizophrenia Network for Intermediate Phenotypes [BSNIP] consortium (Clementz et al., 
2016), even though somewhat different biomarker panels were used in each study. Taken 
together, these results represent a diagnosis-free approach to integrate information across 
biomarkers, yielding neurobiologically distinct subgroups, and provide evidence supporting the 
potential role of neurobiological classification in differentiating individuals with psychotic 
disorders. The “globally impaired” ERP cluster identified in our prior work was found to be 
associated with psychotic illness and symptoms across diagnostic boundaries, but its genetic 
relationship to psychotic illness is unclear. 
 
Findings from well-powered GWAS indicate that psychiatric disorders are highly polygenic, 
reflecting the influence of thousands of common variants (SNPs) of small effect. Although the 
individually modest effects of common variants make them uninformative as risk biomarkers, 
genome-wide polygenic risk scores (PRS), which aggregate the effects of multiple SNPs from 
GWAS, can capture a substantial liability to disease risk (Krapohl et al., 2016; Rzhetsky, 
Wajngurt, Park, & Zheng, 2007). The PRS for SCZ and BPD could be used to examine the degree 
to which multiple risk loci for psychotic illness overlap with those influencing the globally 
impaired ERP cluster, and such polygenic overlap could provide support for the globally 
impaired ERP as a putative endophenotype for psychotic illness. 
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ERP components have been used to assess cognitive functions in patients with psychotic illness. 
Although cognitive impairment is considered as a core feature of SCZ (Elvevag & Goldberg, 
2000) and psychotic BPD (Bortolato, Miskowiak, Kohler, Vieta, & Carvalho, 2015; Daban et al., 
2006; Martinez-Aran et al., 2000), the relationship between cognitive performance and SCZ-
BPD disorders is complex and controversial. Several epidemiological studies have reported low 
cognitive ability and poor school performance as risk factors for SCZ and BPD (Agnew-Blais et 
al., 2015; Glahn, Bearden, Bowden, & Soares, 2006; Jones, Rodgers, Murray, & Marmot, 1994; 
Loewenstein, Czaja, Bowie, & Harvey, 2012; MacCabe et al., 2008; Osler, Lawlor, & Nordentoft, 
2007). However, other studies have found a higher risk of developing psychotic illness among 
individuals with high levels of cognitive performance and creativity (Andreasen, 1987; Kaufman 
& Paul, 2014; Kyaga et al., 2013; Kyaga et al., 2011; MacCabe et al., 2010). In addition, recent 
analysis of cross-trait genetic correlation found a positive genetic correlation between 
psychotic illness and higher educational attainment (Bulik-Sullivan et al., 2015; Hagenaars et al., 
2016; Le Hellard et al., 2016; Okbay et al., 2016), which has been used as a proxy for adolescent 
and young adult cognitive ability in genetic research (Deary & Johnson, 2010; Rietveld et al., 
2013). PRS for both SCZ and BPD were also reported to be highly positively associated with 
creativity and educational attainment (Power et al., 2015). Therefore, it is worthwhile to further 
examine the genetic relationship between cognitive ability and ERPs, an electrophysiological 
index of cognitive functions in psychotic illness.   
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In the present study, we first used a new sample with a similar panel of ERP phenotypes as 
those used in our previous study, performing K-means multivariate analyses to derive empirical 
clusters and see if we could replicate the previously derived neuro-clusters and the association 
between globally impaired ERP and psychotic symptoms (Hall et al., 2012). We then 
constructed genome-wide polygenic risk scores (PRS) for psychiatric and cognitive phenotypes, 
including SCZ, BPD, educational attainment, and childhood intelligence (our discovery 
phenotypes), to examine the shared genetic components between globally impaired neuro-
cluster and each discovery phenotype. Finally, we used a novel approach combining polygenic 
profiling and causal mediation methods to test the hypothesis that the ‘globally impaired’ ERP 
profile represents an intermediate phenotype that mediates genetic influences on the 
symptomatology of SCZ and BPD. We performed causal mediation analyses to explore whether 
the ‘globally impaired profile’ is a mediator between PRS and specific clinical features. 
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METHODS 
Study Sample 
The study sample consisted of 258 cases (SCZ =136 and psychotic BPD=122) and 125 healthy 
controls (prior to genetic quality control procedures). Cases were recruited from McLean 
Hospital, and healthy controls were recruited through local advertisements. All participants 
were assessed with the Structured Clinical Interview for DSM Disorders (SCID-I) (M. B. S. First, 
R.L.; Gibbon M.; Williams, J.B.W., 2002). All participants were of self-reported European 
ancestry, between 18 and 65 years of age, with no history of neurological disorders, no history 
of head injury, normal hearing conﬁrmed by audiometric testing, and normal intelligence based 
on the North American Adult Reading Test (NAART). All cases had no substance abuse (except 
nicotine) or dependence in the preceding 12 months, did not receive ECT treatment in the 
preceding 12 months, and were sufﬁciently stable to participate on an outpatient basis. All 
controls had no history of psychotic and mood disorders themselves or in a first degree relative, 
and no substance abuse or dependence in the preceding 12 months. Because of possible 
genetic overlap between psychosis and mood disorders, the healthy control group included 
only those free of mood disorders to optimize power to detect genetic risk factors. 
 
This study was approved by the Institutional Review Board at McLean Hospital. Written 
informed consent was obtained from all participants after fully explaining the aims and 
procedures of the studies.  
 
Clinical Assessments  
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All participants completed the SCID-IV diagnostic interview (M. B. First, Spitzer, Gibbon, & 
Williams, 2002), the Snaith-Hamilton Pleasure Scale (SHPS) (Snaith et al., 1995), and the Mood 
and Anxiety Symptom Questionnaire (MASQ) (Watson et al., 1995). Demographic (age, sex, 
years of education, smoking status) and medication information were also obtained from 
participants. Treatment with antipsychotic medication was quantified in terms of 
chlorpromazine (CPZ) equivalents (Baldessarini & Davis, 1980). Among the 258 cases, 161 (SCZ 
n=77, BPD n=84) had data on Positive and Negative Syndrome Scale (PANSS) scores (Kay, 
Fiszbein, & Opler, 1987), 243 (SCZ n=121, BPD n=122) had data on Young Mania Rating Scale 
(YMRS) scores (Young, Biggs, Ziegler, & Meyer, 1978) and 138 (SCZ n=66, BPD n=77) had data 
on Multnomah Community Ability Scale (MCAS) scores (Barker, Barron, McFarland, & Bigelow, 
1994). There was no observed association between globally impaired ERP and missing data on 
each of the rating scales (all P>0.20). 
 
Electrophysiological Phenotypic Measures 
All participants completed the following tasks: an auditory dual-click paradigm (Adler et al., 
1982) and an auditory ‘oddball’ paradigm (Squires, Squires, & Hillyard, 1975). We applied the 
same electroencephalogram (EEG) recording and processing procedures as described previously 
(Hall et al., 2006; Hall et al., 2012). Briefly, EEG was recorded using the BioSemi Active Two 
system at a digitization rate of 512 Hz, with a bandpass of DC–104 Hz and a Common Mode 
Sense (CMS) as the reference (PO2 site, parieto-occipital electrode 2) using an 18-channel 
electrode cap. Blinks and eye movements were monitored through electrodes placed on the 
left temple and above and below the left eye. The EEG data were re-referenced off-line to the 
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averaged mastoid. Subjects were not allowed to smoke for a minimum of 40 minutes prior to 
the recordings. P50 sensory gating and response to S1 stimulus were elicited using the dual-
click paradigm. The P50 sensory gating ERP was reported at the Cz site (C = central, z = midline 
of the head) and calculated as a ratio (S2/S1)×100, where higher ratios reflect more 
impairment. N1 and P2 amplitude ERPs were elicited by the response to the standard stimuli in 
the auditory Oddball paradigm and reported at the Cz site, whereas P3 amplitude and latency 
ERPs were elicited by the response to the target stimuli in the Oddball paradigm reported at the 
Pz site (P = parietal) (see Supplementary Methods for detail). 
 
K-means Cluster Analyses 
As in our previous study (Hall et al., 2012), we included all participants (cases and healthy 
controls) in the analysis to empirically identify homogeneous subgroups of individuals who 
share similar neurophysiological profiles, regardless of diagnostic status. Individuals were 
clustered into 3 distinct sub-groups using the K-means algorithm (Hartigan & Wong, 1979) 
implemented in JMP (version12.0, SAS Institute Inc.), according to six ERP measures: P50 
sensory gating, amplitude of S1 response, N1 amplitude, P2 amplitude, P3 amplitude, and P3 
latency. A globally impaired cluster, an intermediate cluster, and a high cognitive functioning 
cluster were empirically derived (Supplementary Table S1.2). The number of clusters was 
initially set at 3, based on our previous analysis (Hall et al., 2012). We also applied a V-fold 
cross-validation method (T. L. Hill, P., 2007) to a range of numbers of clusters (from 2 to 5)  and 
identified 3 as the optimal value of K for K-means. 
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In our analyses, individuals in the globally impaired cluster were compared to those in the other 
two clusters (globally impaired [n=60] vs. non-globally impaired [n=323]). We treated the ERP 
clusters as categories based on our hypothesis that the globally impaired ERP, in particular, may 
be a useful phenotype for genetic studies. 
 
Genotyping and Quality Control 
Genomic DNA from blood samples was extracted by standard procedures at the Massachusetts 
General Hospital Center for Genomic Medicine. Genotyping was performed at the Broad 
Institute using the Illumina Infinium OmniExpress array (Illumina Inc.; San Diego, CA, USA). The 
quality control (QC) procedures have been described elsewhere (Hall et al., 2015). Briefly, we 
excluded 9 individuals with discordant sex information, missing genotype rate >5% or 
heterozygosity rate >3 SD, shared IBD >0.125, or non-European ancestry based on principal 
component analyses. We removed ~45,000 SNPs on the X or Y chromosome, MAF<0.05, call 
rate <98%, and P < 1 × 10E-6 for deviation from Hardy-Weinberg equilibrium. The QC steps 
were carried out with PLINK (S. Purcell et al., 2007) and resulted in a total of 374 subjects with 
genotype data on 664,907 autosomal SNPs. 
 
We then performed genotype imputation, using the phased haplotypes from the 1,000 
Genomes Project dataset as the reference panel. Prephasing and imputation was done with 
SHAPEIT and IMPUTE2 (Delaneau, Marchini, & Zagury, 2012; Howie, Marchini, & Stephens, 
2011). The imputation was performed with the default parameters of the software. The final 
imputed dataset consisted of 9.7 million autosomal SNPs. 
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Statistical Analyses 
Phenotypic Association Analyses 
T-tests, chi-square tests, or multivariable linear regression analyses were used (STATA 
version12; Stata Corp., College Station, TX) to compare the demographic and clinical 
characteristics between the globally impaired ERP group and the non-globally impaired ERP 
group.  
 
PRS Association Analyses 
We used GWAS summary statistics for SCZ (Schizophrenia Working Group of the Psychiatric 
Genomics, 2014) and BPD (Psychiatric, 2011) from the Psychiatric Genomics Consortium (PGC), 
educational attainment (college completion) (Rietveld et al., 2013) from the Social Science 
Genetic Association Consortium (SSGAC), and childhood intelligence (Benyamin et al., 2014) 
from the Childhood Intelligence Consortium (CHIC) as the discovery datasets to derive genome-
wide polygenic risk scores (PRS) (S. M. Purcell et al., 2009) for each of the above discovery 
phenotypes in the study sample. The SCZ discovery sample consisted of 46 non-overlapping 
case-control samples (33,356 cases and 43,724 controls) and 3 family-based samples (1,396 
parent affected-offspring trios). The BPD discovery sample included 11 case-control samples 
(7,481 cases and 9,250 controls). The college completion discovery sample were combined 
from 42 GWAS samples (22,475 college and 78,594 non-college), and 95.8% of the individuals 
were older than 30 years. The childhood intelligence discovery sample consisted of six cohorts 
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with a total of 12,411 children aged 6 to 18 years. All subjects in the discovery samples were of 
European ancestry. 
 
To account for only independent association signals from these discovery GWAS, we applied a 
LD clumping procedure to each discovery dataset, in which we retained the SNP with smallest 
P-value in each 250 kb window and removed all those in LD (r2> 0.1) with this SNP. We also 
excluded the Major Histocompatibility Complex (MHC) region between 26 and 33Mb on 
chromosome 6 when calculating the PRSs, because of the complex haplotype and LD structure 
in this region. For each discovery phenotype, we used five different association P-value 
thresholds (PTs)-- 0.001, 0.01, 0.05, 0.1 and 0.5-- to select index SNPs from the clumped 
independent SNPs for calculating the PRSs. For each individual, we calculated the PRS for each 
discovery phenotype by summing the risk allele counts of the index SNPs, weighted by the log 
of their association odds ratios (for SCZ, BPD, and college completion) or the beta coefficients 
(for childhood intelligence) estimated from the discovery GWAS results. 
 
We used PRSice v1.23 (Euesden, Lewis, & O'Reilly, 2015) to calculate the PRSs and test the 
association between each PRS and the globally impaired ERP group. Associations were tested 
using logistic regression models including the top 3 principal components (PCs) of ancestry from 
the EIGENSTRAT analysis (Price et al., 2006) as covariates. We adjusted for the first 3 PCs 
because the 4th PC offers very little increase (< 2%) in the total explained variance. Wald test P-
values and Nagelkerke’s R2s are reported. We performed the above PRS association analyses on 
the entire study sample and then repeated the same analyses on the case-only subsample. We 
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used POLYGENESCORE software in R (Dudbridge, 2013) to calculate statistical power for the 
association between each PRS and the globally impaired ERP (see Supplementary Methods and 
Tables S3a-S3d.) 
 
Causal Mediation Analyses 
Relationship between PRS, Globally Impaired ERP, and PANSS-Positive Score 
For each discovery phenotype that gave evidence of PRS association with globally impaired ERP, 
we selected the PRS with a P-value threshold that showed the strongest association, and 
examined its relationship with globally impaired ERP and PANSS positive score in our study 
sample. We performed regression-based causal mediation analyses to examine whether 
globally impaired ERP might play a crucial mediating role in the polygenic effect on psychotic 
symptoms.  
 
In these analyses we estimated the direct effect of each associated PRS (highest vs. lowest 
quartile) on the PANSS positive score and the indirect effect mediated by globally impaired ERP 
(binary, globally impaired vs. non-globally impaired), adjusting for the top 3 PCs of ancestry, 
age, sex, daily chlorpromazine (CPZ) equivalent dose of antipsychotics, and current smoking 
status at the time of EEG recording, which were potential exposure-mediator, exposure-
outcome, or mediator-outcome confounders. The proportion mediated was obtained by 
dividing the estimated indirect effect by the estimated total effect, as an index of the degree of 
mediation. This method is based on the counterfactual framework for causal inference (Robins 
& Greenland, 1992), which is an extension of traditional regression-based mediation 
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approaches (Baron & Kenny, 1986), allowing binary mediators and outcomes as well as 
exposure-mediator interactions (T. J. VanderWeele, 2016).  
 
Relationship between PRS, Diagnosis, and Globally Impaired ERP 
Because PRS for any of the discovery phenotypes may be associated with the diagnosis of 
psychotic illness (Cross-Disorder Group of the Psychiatric Genomics, 2013; Okbay et al., 2016), it 
is possible that the observed relationship between a PRS and globally impaired ERP is a 
secondary consequence of the PRS effect on psychotic illness. To understand whether the 
effect of any associated PRS on globally impaired ERP is mediated through “case vs. control 
status” (i.e., presence vs. absence of psychotic illness) or through one specific major mental 
illness (SCZ vs. BPD among cases), we also performed mediation analyses to understand the 
relationships between PRS, diagnosis, and Globally impaired ERP (see Supplementary Methods). 
 
Sensitivity Analyses 
Finally, we conducted sensitivity analyses to evaluate the robustness of the above mediation 
analyses to unmeasured confounding (see Supplementary Methods). All mediation analyses 
were performed using the PARAMED module in STATA (Emsley & Liu, 2013; Valeri & 
Vanderweele, 2013). We used bootstrap procedures with 200 replications to compute a 95% 
bias-corrected bootstrap confidence interval (95% BCCI) for the direct and indirect effects.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
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RESULTS 
Phenotypic associations with globally impaired ERP 
The demographic and clinical characteristics of the globally impaired ERP and the non-globally 
impaired ERP are presented in Table 1.1. In the analysis of all participants, the globally impaired 
cluster consisted of primarily SCZ or BPD cases (91.7%, which included 48.3% of SCZ cases, 
43.3% of BPD cases, vs. 8.3% of controls). The small difference between the proportion of the 
two disorder groups classified as either globally impaired was not significant. Individuals in the 
globally impaired cluster were significantly older (P=0.007) and were more likely to be current 
smokers (P=0.005).  
 
In the analysis restricted to cases only, there was no significant difference in age or other 
demographic variables between the two ERP clusters. However, SCZ/BPD cases in the globally 
impaired cluster had significantly higher PANSS-positive scores than those in the non-globally 
impaired cluster (mean [SD]: 19.88 [7.49] vs. 16.13 [6.98]; P=0.007), and these differences 
persisted after adjusting for age, sex, daily chlorpromazine equivalent dose of antipsychotics, 
and smoking status at the time of EEG recording (multivariable linear regression: β=3.95, 
P=0.005). 
 
Supplementary Table S1.1 presents demographic and clinical information for the study sample 
by diagnostic group. 
   
PRS Association Analyses  
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Results of PRS associations between the globally impaired ERP cluster and SCZ-PRS, BPD-PRS, 
college-PRS, and childhood intelligence-PRS including all subjects are presented in Figure 1.1a 
and Table 1.2. Results restricted to cases only are presented in Figure 1.1b and Table 1.3. In the 
full sample analyses, the SCZ-PRS with a P-value threshold of 0.001 (SCZ-PRSPT=0.001) was 
significantly positively associated with risk of globally impaired ERP (unadjusted P=0.01; 
R2=3.07%). This association approached significance (FDR-corrected P=0.06) even after 
correcting for multiple testing by the false discovery rate (FDR) q-value method (J. D. Storey, 
2002; J. D. T. Storey, J.E.; Siegmund D., 2004). In the analyses restricted to cases only, results 
were not significant but were in the same direction (unadjusted P=0.09, R2=1.76%; FDR-
corrected P=0.17). For the BPD-PRS, no significant associations were found with the globally 
impaired ERP cluster in either the whole sample or the case-only subsample. 
 
In the full sample analyses, we found a significant positive association between the college-PRS 
and the globally impaired cluster across all five P-value thresholds (Table 1.2, unadjusted P 
values range from 2.95E-04 to 0.05), such that alleles associated with higher educational 
attainment were associated with being in the globally impaired cluster. After multiple testing 
correction, this association remained significant for the college-PRS with a PT= 0.01 (college-
PRSPT=0.01, FDR-corrected P=0.004; R2=6.15%). We also observed a nominally positive 
association between the childhood intelligence-PRS with PT= 0.05 and the globally impaired 
cluster (unadjusted P=0.02, R2=2.40%; FDR-corrected P=0.08). In the case-only subsample, we 
again found a significant positive association between the college-PRSPT=0.01 and globally 
impaired ERP membership (Table 1.3, unadjusted P=0.004; FDR-corrected P=0.04; R2=5.11%) 
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and a positive association between the childhood intelligence-PRSPT=0.05 and globally impaired 
ERP (unadjusted P=0.01; FDR-corrected P=0.06; R2=3.70%). 
 
Mediation analyses 
Relationship between SCZ-PRS, Globally Impaired ERP, and PANSS-Positive Score 
As noted above, the SCZ-PRS with a P-value threshold of 0.001 (SCZ-PRSPT=0.001) was nominally  
associated with the globally impaired cluster, and this association approached significance after 
correcting for multiple testing. Because of the observed association between globally impaired 
ERP and PANSS-positive scores among cases, we further examined whether SCZ-PRSPT=0.001 is 
also associated with PANSS-positive score and whether this relationship is mediated by globally 
impaired ERP (Figure 1.2). The estimated direct and indirect effects betas were 2.68 (95% BCCI: 
-0.37, 5.52) and 0.27 (95% BCCI: -0.34, 1.23), respectively. The proportion of estimated 
mediating effect of globally impaired ERP on the total effect of SCZ-PRS on PANSS-positive score 
was small (9.1%). Adding an exposure-mediator interaction term did not substantially change 
the effect estimates (direct effect β =2.30 [95% BCCI: -0.82, 5.18]; indirect effect β=0.44 [95% 
BCCI: -0.63, 1.92]). The minimal effect of including the interaction term suggests that exposure-
mediator interaction did not appear to be substantial (T.J. Vanderweele, 2015). 
 
Relationship between college-PRS, Globally Impaired ERP, and PANSS-Positive Score 
We found a significant positive association, even after multiple testing correction, between the 
globally impaired cluster and the college-PRS at the P-value threshold of 0.01. We further 
examined whether college-PRSPT=0.01 is also associated with PANSS-positive score and whether 
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this relationship is mediated by globally impaired ERP. Results of the analysis with globally 
impaired ERP cluster as a mediator between college-PRSPT=0.01 and PANSS positive symptoms 
are presented in Figure 1.3. The total effect of the college-PRSPT=0.01 on PANSS-positive score 
was estimated as 0.92 (95% BCCI: -2.62, 5.08). The direct effect was estimated to be β=0.03 
[95% BCCI: -3.57, 3.69] and the indirect effect mediated through globally impaired ERP was 
estimated to be β=0.90 [95% BCCI: 0.11, 2.24] (Figure 1.3). The proportion of mediating effect 
from college-PRS through globally impaired ERP to PANSS positive was estimated at 97.1%. 
These results suggest that the effect of the college-PRSPT=0.01 on PANSS-positive score was 
almost entirely mediated through globally impaired ERP. Adding an exposure-mediator 
interaction term did not substantially change the effect estimates (direct effect β =-0.22 [95% 
BCCI: -3.97, 3.59]; indirect effect β=1.12 [95% BCCI: 0.06, 3.34]). 
 
Relationship between PRS, Diagnosis, and Globally Impaired ERP 
We also examined whether the effect of any associated PRS on globally impaired ERP is 
mediated through “case vs. control status” or through one specific major mental illness among 
cases (see Supplementary Results). Nearly one-third (30.9%) of the total effect of SCZ-PRSPT=0.001 
on globally impaired ERP was mediated by the presence of psychotic illness (Figure S1.1a). 
Among cases, the proportion of estimated mediating effect of “SCZ vs. BPD” on the total effect 
of SCZ-PRSPT=0.001 on globally impaired ERP was very close to zero (Figure S1.1b). A small 
proportion (11%) of the total effect of college-PRSPT=0.01 on globally impaired ERP was mediated 
by the presence of psychotic illness (Figure S1.2a). For cases with psychotic illness, the 
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mediating effect due to having a specific diagnosis of SCZ or BPD was estimated to be zero 
(Figure S1.2b). 
 
Sensitivity Analyses of Unmeasured Confounding 
Sensitivity analyses of unmeasured confounding suggest that even in the presence of strong 
unmeasured confounding, results of the above mediation analyses would not substantially 
change (see Supplementary Results and Table S1.4-S1.9). For example, in the mediation analysis 
with college-PRS as the exposure, globally impaired ERP profile as the mediator, and PANSS 
positive score as the outcome, existence of unmeasured confounding would likely lead to 
overestimation of the indirect effect and underestimation of the direct effect. Nonetheless, the 
estimated indirect effect remained significant after controlling for a strong hypothetical 
confounder with correlations of 0.3 with both mediator and outcome, and the proportion 
mediated of 66.5% supported our conclusion that the majority of the effect of college-
PRSPT=0.01 on PANSS-positive score was indirect. 
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DISCUSSION 
In the present study, we successfully replicated the clustering of ERP components in an 
independent sample, including a globally impaired ERP cluster (defined as having abnormalities 
in all six ERP measures, including P50 sensory gating, amplitude of S1 response, N1 amplitude, 
P2 amplitude, P3 amplitude, and P3 latency). We also replicated our previous findings that 
individuals in the globally impaired cluster exhibited greater psychotic symptom severity than 
individuals in other clusters (Table 1.1) (Hall et al., 2012).  
 
Genetic Overlap between SCZ and globally impaired ERP 
Our results demonstrate possible polygenic pleiotropy between SCZ and globally impaired ERP. 
We found that higher SCZ polygenic risk was marginally associated (unadjusted P-value=0.01, 
FDR-corrected p = 0.06) with being in the globally impaired ERP cluster. However, there was no 
observed association between BPD-PRS and the globally impaired ERP cluster. 
 
Globally impaired ERP mediates a small proportion of the effect of SCZ-PRS on PANSS-positive 
score 
Globally impaired ERP was associated with both SCZ-PRS and PANSS positive symptoms score, 
showing potential to serve as an endophenotype for schizophrenia. Nevertheless, our 
mediation analysis indicates that only a small proportion (9.1%) of the effect of SCZ-PRS on 
PANSS-positive score was mediated by globally impaired ERP, suggesting that ERP cluster may 
not be an ideal intermediate phenotype between SCZ-related genetic variants and positive 
psychotic symptoms. In addition, we found that the relationship between SCZ-PRS and globally 
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impaired ERP was significantly mediated by the presence of psychotic illness (i.e., case vs. 
control status) (see Supplementary Figure S1.1a), implying that the observed association 
between SCZ-PRS and globally impaired ERP may be only secondary to the effects of SCZ-
associated SNPs on the presence of psychotic illness.  
 
Genetic Overlap between higher educational attainment and globally impaired ERP 
The evidence for polygenic overlap was strongest for college completion and globally impaired 
ERP. We found significant positive PRS correlations between greater college-PRS (i.e., greater 
polygenic loading for higher education) and the globally impaired cluster across all five P-value 
thresholds (Table 1.2), with the strongest signal at the PRS P-value threshold of 0.01, explaining 
6% of the variance in the globally impaired ERP in the full sample (n=383). A similar pattern of 
genetic overlap was also observed between greater childhood intelligence-PRS and being in the 
globally impaired cluster. These results were unexpected, as cognitive impairment is common 
among patients with SCZ and BPD and epidemiological studies have indicated that poor school 
performance and low cognitive ability are risk factors for SCZ and BPD (Agnew-Blais et al., 2015; 
Glahn et al., 2006; MacCabe et al., 2008). However, our results are compatible with findings for 
BPD from the Swedish National School Register of over 900,000 individuals showing that those 
with excellent school performance had a nearly fourfold increased risk of later BPD compared 
with those with average grades (MacCabe et al., 2010). Our results are also consistent with 
recent findings examining genetic overlap between psychiatric diseases and cognitive ability. 
Studies employing an LD score regression approach to estimate cross-trait genetic correlations 
found positive genetic correlations between BPD/SCZ risk and educational attainment (Bulik-
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Sullivan et al., 2015; Okbay et al., 2016). One possible explanation for the LD score regression 
results is "case ascertainment bias,” such that patients from more educated families were more 
likely to participate in research. However, in our study, we avoided such case ascertainment 
bias by using an objective physiological phenotype, which was not phenotypically associated 
with years of education, and found a significant positive genetic correlation between this 
psychosis-related trait and higher educational attainment. Further research is needed to 
replicate and explain the counterintuitive genetic correlation between higher educational 
attainment and globally impaired ERP. 
 
Globally impaired ERP mediates the effect of college-PRS on PANSS-positive score 
We found that the effect of the college-PRSPT=0.01 on PANSS-positive score was almost entirely 
mediated through globally impaired ERP membership (Figure 1.3). It has been suggested that a 
dimensional classification of psychopathology among patients with SCZ and BPD can better 
reflect the underlying genetic variation (N. Craddock et al., 2009); therefore, PANSS scores have 
been used in genetic research to identify the genetic underpinning of specific symptom 
dimensions of psychotic illness (Sengupta et al., 2016). However, the major disadvantage of 
using specific symptom-domain scores (e.g., PANSS scores) as the phenotype is that they are 
very likely to be influenced by treatment, stage of illness, and other environmental factors. 
Globally impaired ERP as an intermediate phenotype of positive symptoms may be less likely to 
be influenced by clinical or environmental factors. The nearly complete mediation of the 
association between college-PRS and PANSS-positive by globally impaired ERP implies that the 
globally impaired ERP may represent some aspects of brain physiology linking higher education 
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associated alleles and positive psychotic symptoms. By contrast, only a small proportion of the 
relationship between SCZ-PRS and PANSS positive score was mediated by globally impaired 
ERP. It is possible that SNPs affecting positive symptom severity partially overlap with both SCZ-
associated and education-associated SNPs, and globally impaired ERP may capture the 
component of positive symptoms that is genetically correlated with educational attainment. 
Thus, globally impaired ERP may help stratify the genetic components of psychotic symptoms. 
 
Limitations 
The present study has several limitations. First, the PRS approach assumes a linear additive 
model and does not consider gene-gene interactions that may contribute to the underlying 
genetic architecture of the phenotypes of interest. Second, the effect estimates from the 
mediation analyses might be biased due to violation of the un-measured confounding 
assumption (T. J. VanderWeele, 2016). However, our sensitivity analyses suggest that even with 
the existence of a strong unmeasured confounder for the mediator-outcome relationship, the 
results of mediation analyses remained robust. Third, the use of super controls may lead to 
overestimate the association between SCZ-PRS and globally impaired ERP, because a certain 
proportion of this association is mediated by the presence of psychotic illness. However, 
analyses for college-PRS would not be substantially influenced, and results of case-only analyses 
are robust. Forth, our analyses were restricted to individuals of European ancestry, thus limiting 
the generalizability of the findings to other ethnic populations. Future research should include a 
broader range of ethnic populations. Finally, although the causal mediation relationship 
identified by a statistical approach may imply a mechanistic causality, the true mechanisms 
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governing the processes from exposure to outcome can only be understood by considering the 
sufficient cause model (i.e., the identification of a set of minimal conditions that inevitably 
produce outcome). To look into the black box of causal mechanisms, closer observations, more 
detailed and extensive data, and more scientiﬁc knowledge will be needed. 
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CONCLUSION 
This is the first study, to our knowledge, to demonstrate a causal link between genetic risk 
scores, ERP phenotype, and positive psychotic symptoms. The results also support prior 
evidence that college education, a proxy for adolescent and young adult cognitive ability, is 
genetically correlated with psychotic illness, and suggest a potential physiological role for the 
multivariate ERP profile in the genetic link between cognitive ability and psychotic symptoms.  
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Table 1.1: Demographic and clinical characteristics of globally impaired and non-globally impaired clusters 
 
Phenotype Characteristics All Subjects 
Globally Impaired 
ERP 
Non-globally  
Impaired ERP 
P-value 
Diagnosis   X2=19.11, P=7.07E-5 
    SCZ, N(%) 29 (48.3) 107 (33.1)  
    BPD, N(%) 26 (43.3) 96 (29.7)  
    Unaffected, N(%) 5 (8.3) 120 (37.2)  
Sex   X2=0.18, P=0.68 
    Female, N(%) 30 (50.0) 171 (52.9)  
Age (years), mean(SD) 43.58 (14.68) 38.41 (13.25) t-test, P=0.007 
Education (years), mean(SD) 14.58 (2.22) 14.98 (2.27) t-test, P=0.22 
Current Smoker, N(%) 24 (42.1) 77 (24.2) X2=7.86, P=0.005 
MASQ Total, mean(SD) 121.27 (36.70) 130.53 (37.62) t-test, P=0.11 
MLR, P=0.62 
SHPS, mean(SD) 1.09 (1.92) 1.84 (2.87) t-test, P=0.02 
MLR, P=0.29 
    
 
Cases with SCZ or BPD 
Globally Impaired 
ERP 
Non-globally  
Impaired ERP 
P-value 
Diagnosis   X2<0.0001, P=1.00 
    SCZ, N(%) 29 (52.7) 107 (52.7)  
    BPD, N(%) 26 (47.3) 96 (47.3)  
Sex   X2=2.47, P=0.12 
    Female, N(%) 26 (47.3) 120 (59.1)  
Age (years), mean(SD) 45.02 (14.39) 41.38 (12.68) t-test, P=0.07 
Education (years), mean(SD) 14.38(2.2) 14.62(2.2) t-test, P=0.50 
Current Smoker, N(%) 24 (46.2) 69 (34.3) X2=2.48, P=0.12 
Age of Onset (years), mean(SD) 22.35(8.4) 22.87(8.3) t-test, P=0.70 
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CPZ Equivalent Dosage (mg), mean(SD) 286.06(336.70) 376.62(508.10) t-test, P=0.24 
PANSS Positive Total, mean(SD) 
19.88(7.49) 16.13(6.98) t-test, P=0.007 
MLR, P=0.005 
PANSS Negative Total, mean(SD) 
13.18(7.46) 12.22(5.64) t-test, P=0.42 
MLR, P=0.31 
PANSS General Total, mean(SD) 
32.82(8.61) 30.28(9.56) t-test, P=0.17 
MLR, P=0.11 
MCAS Total, mean(SD) 
44.54(8.19) 46.83(5.71) t-test, P=0.09 
MLR, P=0.28 
YMRS Total, mean(SD) 
7.81(12.22) 8.64(11.19) t-test, P=0.64 
MLR, P=0.91 
MASQ Total, mean(SD) 
134.93 (36.9) 136.49 (38.6) t-test, P=0.81 
MLR, P=0.83 
SHPS, mean(SD) 
2.02 (2.96) 1.65 (2.3) t-test, P=0.39 
MLR, P=0.31 
X2: Chi-square statistic. 
t-test: two-sample t-test for equal means 
MLR: multivariable linear regression for the association between clinical assessments and globally impaired ERP, adjusting for (1) age, sex, case-
control status, and current smoking status for all subjects; or (2) age, sex, daily chlorpromazine equivalent dose of antipsychotics, and current 
smoking status for cases with SCZ or BPD. 
All bold values are significant at P <0.05 
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Table 1.2: Polygenic score association analyses between globally impaired ERP and PRS for each 
discovery phenotype in all subjects (n=383) 
Discovery Phenotype (Dataset) PT NSNP R2 Unadjusted 
P-value 
FDR- corrected 
P-value 
SCZ (PGC) 0.001 2518 0.0307 0.01 0.06 
 0.01 7997 0.0108 0.12 0.23 
 0.05 19823 0.0076 0.20 0.28 
 0.1 29907 0.0026 0.45 0.50 
 0.5 76128 5.258E-05 0.91 0.70 
BPD (PGC) 0.001 660 0.0005 0.73 0.63 
 0.01 3827 0.0012 0.61 0.56 
 0.05 13113 1.823E-05 0.95 0.70 
 0.1 22162 0.0003 0.80 0.65 
 0.5 68772 0.0013 0.60 0.56 
College Completion (SSGAC) 0.001 730 0.0177 0.05 0.11 
 0.01 4151 0.0615 2.95E-04 0.004 
 0.05 13492 0.0291 0.01 0.06 
 0.1 22246 0.0179 0.05 0.11 
 0.5 64444 0.0182 0.05 0.11 
Childhood Intelligence (CHIC) 0.001 314 0.0014 0.58 0.56 
 0.01 2227 0.0081 0.18 0.28 
 0.05 8597 0.0240 0.02 0.08 
 0.1 14828 0.0071 0.21 0.28 
 0.5 47552 0.0056 0.27 0.33 
PT: the P-value threshold used in the training dataset. 
NSNP: different number of independent SNPs included for calculating the PRS, which is determined by 
the selection of PT. 
R2: Nagelkerke’s pseudo R², the proportion of variance in globally impaired ERP in our study sample 
explained by the PRS. 
Unadjusted P-value: the P-value of the test for association between the PRS and globally impaired ERP, 
before multiple testing correction 
FDR corrected P-value: the P-value after multiple testing correction by the FDR q-value method. 
All bold values are significant at P <0.05 
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Table 1.3: Polygenic score association analyses between globally impaired ERP and PRS for each 
discovery phenotype in cases with SCZ or BPD (n=258) 
Discovery Phenotype (Dataset) PT NSNP R2 Unadjusted 
P-value 
FDR- corrected 
P-value 
SCZ (PGC) 0.001 2518 0.0176 0.09 0.17 
 0.01 7997 0.0003 0.84 0.40 
 0.05 19823 0.0007 0.73 0.39 
 0.1 29907 0.0002 0.87 0.40 
 0.5 76128 0.0075 0.27 0.20 
BPD (PGC) 0.001 660 0.0001 0.88 0.40 
 0.01 3827 0.0077 0.26 0.20 
 0.05 13113 0.0041 0.41 0.25 
 0.1 22162 0.0053 0.35 0.23 
 0.5 68772 0.0010 0.69 0.39 
College Completion (SSGAC) 0.001 730 0.0073 0.27 0.20 
 0.01 4151 0.0511 0.004 0.04 
 0.05 13492 0.0234 0.05 0.16 
 0.1 22246 0.0110 0.18 0.20 
 0.5 64444 0.0164 0.10 0.17 
Childhood Intelligence (CHIC) 0.001 314 0.0056 0.34 0.23 
 0.01 2227 0.0156 0.11 0.17 
 0.05 8597 0.0370 0.01 0.06 
 0.1 14828 0.0109 0.18 0.20 
 0.5 47552 0.0102 0.20 0.20 
PT: the P-value threshold used in the training dataset. 
NSNP: different number of independent SNPs included for calculating the PRS, which is determined by 
the selection of PT. 
R2: Nagelkerke’s pseudo R², the proportion of variance in globally impaired ERP in patients of our study 
sample explained by the PRS. 
Unadjusted P-value: the P-value of the test for association between the PRS and globally impaired ERP, 
before multiple testing correction 
FDR corrected P-value: the P-value after multiple testing correction by the FDR q-value method. 
All bold values are significant at P <0.05 
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FIGURES 
Figure 1.1: Pair-wise polygenic association analyses between globally impaired ERP and PRS 
for each discovery phenotype 
(a) All Subjects  
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(b) Cases with SCZ or BPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We derived PRS for schizophrenia, bipolar disorder, college completion, and childhood intelligence from 
each of the discovery samples with five different P-value thresholds (PT used to select training set SNPs: 
0.001, 0.01, 0.05, 0.1, and 0.5; shown with different colors) and apply them to globally impaired ERP in 
(A) the entire sample and (B) those affected by SCZ or BPD. Each pair is shown on the x-axis and the 
proportion of variance explained for globally impaired ERP (estimated via Nagelkerke’s pseudo R²) on 
the y-axis. 
Single asterisk indicates unadjusted P-value <0.05; double asterisk indicates FDR-corrected P-value < 
0.05. 
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Figure 1.2: Causal Relationship between SCZ-PRS, Globally Impaired ERP, and PANSS-Positive 
Score for patients 
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Figure 1.3: Causal Relationship between College-PRS, Globally Impaired ERP, and PANSS-
Positive Score for patients 
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Polygenic Pleiotropy and Potential Causal Relationships between Educational Attainment, 
Neurobiological Profile, and Positive Psychotic Symptoms 
 
Supplementary Information 
 
 
SUPPLEMENTARY METHODS 
  
Neurophysiological Recordings and Signal Processing  
 
Event related potential (ERP) 
An ERP is a measured brain electrophysiological response to a specific sensory, cognitive, or 
motor event. ERPs can be reliably measured using electroencephalography (EEG), a procedure 
that records electrical activity of the brain over time using non-invasive electrodes placed along 
the scalp. 
 
Dual-Click Paradigm 
P50 Sensory Gating. The P50 sensory gating is the brain’s suppression of an evoked response to 
a brief stimulus, usually an auditory click, occurring approximately 50 milliseconds (ms) after 
receiving the stimulus. 
In our study, the P50 sensory gating ERP was elicited using the dual-Click paradigm (160 pairs of 
identical click stimuli, 5-ms duration; 2-ms rise/fall; 500-ms inter-click interval; 10-s inter-trial 
interval). Signal processing was performed off-line using NEUROSCAN software (4.3) (Hall et al., 
2006; Hall, Taylor, Salisbury, & Levy, 2011).EEG signals were segmented (–100 to 400 ms), 
filtered (1-Hz high-pass filter), baseline corrected, and artifact rejected if activity exceeding 50 
μV between 0 and 75 ms post-stimulus. S1 and S2 waveforms were averaged, digitally filtered 
(10-Hz high pass), and smoothed. P50 sensory gating ERP are reported at the Cz site and 
calculated as a ratio (S2/S1)×100. A higher ratio reflects more impairment. For the S1 response, 
the most prominent peak 40–80 ms post-stimulus was selected as the P50 peak. The preceding 
negative trough was used to calculate the amplitude. For the S2 response, the positive peak 
with the latency closest to that of the conditioning P50 peak was selected, and its amplitude 
was determined as for the S1 wave. P50 sensory gating was calculated as (S2/S1)×100 (Hall et 
al., 2006; Hall et al., 2011). 
 
Oddball Paradigm 
P300 (P3) ERP components. The P3 wave is an endogenous ERP component elicited in the 
process of decision making. When recorded by electroencephalography (EEG), it surfaces as a 
positive deflection in voltage with a latency (delay between stimulus and response) of roughly 
250 to 500 ms. The signal is typically measured most strongly by the electrodes covering the 
parietal lobe. It reflects processes involved in stimulus evaluation or categorization. The P3 
wave is usually elicited using the oddball paradigm. 
In our study, P3 amplitude and latency ERPs were elicited by the auditory Oddball paradigm 
(400 binaural tones; 50-msec duration, 5 ms rise/fall times; 15% 1500 Hz target tones; 85% 
1000 Hz standard tones). All participants had >90% accuracy. Signal processing was performed 
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off-line using Brain Vision Analyzer software. EEG signals were first re-referenced to linked 
mastoids and zero phase-shift digital low-pass filtered at 8.5Hz (24 dB/Oct). Eye-blink artifacts 
were corrected by using the method of Gratton et al. (Gratton, Coles, & Donchin, 1983). The 
EEG data were segmented into epochs from -100 to 1000 ms relative to stimulus onset and 
baseline corrected using the 100-ms pre-stimulus interval. Epochs containing artifact >100 μV 
were removed. Separate average waves for target and standard tones were calculated. P300 
amplitude and latency components were measured from the average wave for target tones at 
the Pz site between 280 and 650 ms (Hall et al., 2009; Salisbury, Shenton, & McCarley, 1999). 
 
N1P2 ERP components. The N1 ERP component is a large, negative-going evoked potential. It 
peaks in adults between 80 and 120 milliseconds after the onset of a stimulus, and distributed 
mostly over the fronto-central region. It is elicited by any unpredictable stimulus in the absence 
of task demands. It is often referred to with the following P2 wave as the "N1-P2" complex. The 
P2 ERP component is a positive going electrical potential that peaks at about 200 ms (between 
about 150 and 275 ms) after the onset of external stimulus. 
In our study, EEG data were digital low-pass filtered at 20Hz (24 dB/Oct), baseline corrected, 
eye-blink corrected using (Gratton et al., 1983), and artifact rejected if activity exceeding >100 
μV. Peak N1 amplitude was automatically detected as the most negative point from 50 to 200 
ms at Cz. Peak P2 amplitude was automatically detected as the most positive point from 150 to 
300 ms at Cz (Donchin & Coles, 1988; Polich & Kok, 1995; Salisbury, Collins, & McCarley, 2010). 
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Power Calculation for the association between PRS and globally impaired 
 
We used POLYGENESCORE software in R (Dudbridge, 2013) to calculate statistical power for the 
association between each PRS and globally impaired ERP. With known sample sizes (globally 
impaired/ non-globally impaired: 60/323 in the study sample; case/control: 34,752/46,516 in 
the SCZ discovery sample, 7,481/9,250 in the BPD discovery sample, and 22,475/ 78,594 in the 
college education discovery sample; and 12,411 in the childhood intelligence discovery sample), 
we calculated the power for detecting the PRS association when the genetic correlation 
between globally impaired and each discovery phenotype is 0.1, 0.3, or 0.5, under the following 
assumptions:  
(1) The prevalence of globally impaired is 0.04, same as the proportion of globally impaired in 
healthy individuals in our study sample. The prevalence of both SCZ and BPD is 0.01. The 
prevalence of college completion is 0.22, same as the proportion of college completion in the 
college education discovery sample. 
(2) The SNP-based heritability of SCZ, BPD, college completion, and childhood intelligence is 
0.4541, 0.432, 0.0791, and 0.2735, respectively, according to LD score regression analysis 
results reported on the LD Hub website (http://ldsc.broadinstitute.org/lookup/).  
(3) The SNP-based heritability of globally impaired is assumed to be 0.1, 0.3, or 0.5. 
(4) The number of independent SNPs in the gene score is assumed to be 1000 or 10000. 
(5) The Type-I error of the test for association between the PRS and globally impaired in the 
target sample is 0.05.   
 
 
The results of the power analyses are shown in Tables S3a-d. 
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Supplementary Mediation Analyses 
 
Relationship between PRS, Diagnosis, and Globally Impaired ERP 
For each discovery phenotype that gave evidence of PRS association with globally impaired ERP, 
we selected the PRS with a P-value threshold that showed the highest association, and 
examined its relationship with the target phenotypes in our study sample. Because PRS for any 
of the discovery phenotypes may be associated with the diagnosis of psychotic illness (Cross-
Disorder Group of the Psychiatric Genomics, 2013; Okbay et al., 2016), it is possible that the 
observed relationship between a PRS and globally impaired ERP is a secondary consequence of 
the PRS effect on psychotic illness. To understand whether the effect of any associated PRS on 
globally impaired ERP is mediated through “case vs. control status” (i.e., presence vs. absence 
of psychotic illness) or through one specific major mental illness (SCZ vs. BPD among cases), we 
performed a regression-based causal mediation analysis to decompose the total effect of each 
PRS on globally impaired into direct and indirect effects, adjusting for potential confounders. 
 
In the first set of mediation analyses, each associated PRS exposure was categorized into 
quartiles, the potential mediator “case vs. control status” was binary, and the outcome 
“globally impaired ERP” was treated as a binary variable (globally impaired vs. non-globally 
impaired). The total effect of each PRS on globally impaired ERP was decomposed into direct 
and indirect (mediated) effects. These effects were estimated as the odds ratio (OR) for globally 
impaired comparing the highest quartile to the lowest quartile of the PRS, adjusting for age, 
sex, and the top 3 PCs of ancestry, which were potential exposure-mediator or exposure-
outcome confounders. In the second set of mediation analyses, we performed the same 
analyses as above in cases, but replaced the mediator variable with diagnosis (SCZ vs. BPD), 
adjusting for age, sex, and the top 3 PCs of ancestry. We estimated the proportion mediated for 
each of the above on the log odds scale by dividing the log of the estimated indirect effect OR 
by the log of the estimated total effect OR (as an index of the degree of mediation). 
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Sensitivity Analyses of Unmeasured Confounding 
 
The counterfactual-based mediation analysis assumes no unmeasured confounding for the (1) 
exposure-mediator, (2) exposure-outcome, and (3) mediator-outcome relationships 
(Vanderweele, 2015). In our mediation analyses with PRS as the exposures, assumptions (1) and 
(2) were probably plausible, since we had adjusted for the top principal components (PCs) of 
genotypes to address possible population stratification. However, the assumption of no 
unmeasured confounding might be less plausible for the (3) mediator-outcome relationship, 
and the effect estimates would probably be biased.  
 
In order to evaluate the robustness of the mediation analyses to unmeasured confounding 
between mediator and outcome, we conducted sensitivity analyses to calculate how much 
direct and indirect effect estimates would be expected to change under different degrees of 
mediator-outcome confounding. Specifically, given a hypothetical unmeasured confounder of 
the mediator-outcome relationship, U, with particular correlations with the mediator and the 
outcome, we would like to know, if we were able to also adjust for U, what the direct and 
indirect effect estimates would be. 
 
For each mediation analysis, we generated four standard normal variables (i.e., mean=0 and 
variance=1), with particular correlations with the mediator and the outcome, as hypothetical 
confounders (Table S1.4-1.9). The first hypothetical confounder has correlation of 0.1 with the 
mediator and correlation of 0.1 with the outcome. The second hypothetical confounder has 
correlation of 0.3 with the mediator and correlation of 0.1 with the outcome. The third 
hypothetical confounder has correlation of 0.1 with the mediator and correlation of 0.3 with 
the outcome. The fourth hypothetical confounder has correlation of 0.3 with the mediator and 
correlation of 0.3 with the outcome. We compared the direct and indirect effect estimates 
before and after adjusting for each of these hypothetical confounders, to assess the potential 
impact of unmeasured confounding on each mediation analysis. 
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GWAS of globally impaired ERP 
 
We also performed a preliminary GWAS for globally impairer ERP (globally impaired vs. non-
globally impaired). With such a small sample size and lack of replication, we are aware that the 
GWAS results may not be reliable. We did this just to make the best use of our data and hope 
to contribute to future research. 
We tested each genotyped and imputed SNP for association with globally impaired ERP group 
in the form of logistic regression assuming an underlying additive model in PLINK (Purcell et al., 
2007). We included the top 3 PCs from the EIGENSTRAT analysis (Price et al., 2006) as 
covariates. We obtained an estimated odds ratio (OR) and a P-value for the association test for 
each SNP.  
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SUPPLEMENTARY RESULTS 
 
Supplementary Mediation Analyses 
 
Relationship between SCZ-PRS, Diagnosis, and Globally Impaired ERP 
The SCZ-PRS with a P-value threshold of 0.001 (SCZ-PRSPT=0.001) was significantly associated with 
the globally impaired cluster, and this association approached significance after correcting for 
multiple testing. Thus, as described in Supplementary Methods, we then conducted causal 
mediation analyses to determine whether the effect of SCZ-PRSPT=0.001 on globally impaired ERP 
was mediated by the presence of SCZ and BPD (together or individually). The results examining 
whether case vs. control status mediates the relationship between SCZ-PRSPT=0.001 and globally 
impaired ERP are presented in Figure S1.1a. The estimated direct effect OR was 1.76 (95% BCCI: 
0.72, 3.80). The indirect effect OR was 1.29 (95% BCCI: 1.12, 1.54), significantly greater than 1. 
Nearly one-third (30.9%) of the total effect of SCZ-PRSPT=0.001 on globally impaired ERP was 
mediated by the presence of psychotic illness. Adding an exposure-mediator interaction term 
resulted in a minimal change in the effect estimates (direct effect OR =-1.67 [95% BCCI: 0.77, 
3.62]; indirect effect OR=1.36 [95% BCCI: 1.12, 1.65]). 
 
Figure S1.1b presents the results examining in the case only sample whether specific diagnosis 
(SCZ vs. BPD) mediates the relationship between SCZ-PRSPT=0.001 and globally impaired ERP. The 
estimated direct and indirect effects ORs were 2.28 (95% BCCI: 0.94, 6.08) and 1.00 (95% BCCI: 
0.94, 1.10), respectively. The proportion of estimated mediating effect of “SCZ vs. BPD among 
cases” on the total effect of SCZ-PRSPT=0.001 on globally impaired ERP was very close to zero 
(0.2%). 
 
Relationship between college-PRS, Diagnosis, and Globally Impaired ERP 
We found a significant positive association, even after multiple testing correction, between 
college-PRS (at PT = 0.01) and the globally impaired cluster. Since patients with SCZ or BPD were 
more likely to have globally impaired ERP, it is possible that the observed association between 
the college-PRS and globally impaired ERP could be partly explained by the presence of 
psychotic illness. We therefore performed two causal mediation analyses to understand 
whether the effect of college-PRSPT=0.01 on globally impaired ERP was mediated by diagnostic 
status. The results examining whether the effect of college-PRS PT=0.01 on globally impaired ERP 
was mediated by case vs. control status are presented in Figure S1.2a. The estimated direct 
effect OR was 4.09 (95% BCCI: 1.60, 10.59), while the estimated indirect effect OR mediated by 
case vs. control status was 1.19 (95% BCCI: 1.00, 1.46) (Figure 1.2a). When an interaction 
between college-PRS PT=0.01 and case vs. control status was included in the regression model, the 
estimated direct and indirect effect ORs were 4.12 (95% BCCI: 1.66, 10.25) and 1.16 (95% BCCI: 
0.98, 1.38), respectively. The minimal effect of including the interaction term suggests that 
exposure-mediator interaction did not appear to be substantial (Vanderweele, 2015). Overall, 
then, the effect of college-PRS PT=0.01 on globally impaired ERP appeared to be primarily 
explained by the direct (non-mediated) relationship, whereas the proportion of estimated 
mediating effect of psychotic illness on the total effect was small (11.1%). 
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The results examining whether specific diagnosis (SCZ vs. BPD among cases) mediates the 
relationship between college-PRSPT=0.01 and globally impaired ERP are presented in Figure S1.2b. 
The estimated direct and indirect effects ORs were 3.94 (95% BCCI: 1.47, 10.71) and 1.00 (95% 
BCCI: 0.93, 1.08), respectively. The mediating effect due to diagnosis was estimated to be zero, 
indicating that for cases with psychotic illness, the effect of the college-PRSPT=0.01 on globally 
impaired ERP is not mediated by having a diagnosis SCZ or BPD per se. 
 
In the full sample, the effect of college-PRS on globally impaired ERP was only modestly (11.1%) 
mediated by case vs. control status (combining SCZ and BPD cases; Figure S1.2a). While college-
PRSPT=0.01 was associated with globally impaired ERP, it was not associated with psychotic 
illness. One possible explanation is that the diagnosis of psychotic illness is heterogeneous, and 
the ERP phenotype captures the component of psychosis that is correlated with education-
associated genes. If we hypothesize that there is some genetic overlap between higher 
education and psychotic illness, the ERP phenotype may be a better alternative phenotype than 
traditional diagnosis to detect such genetic overlap. Among cases with psychotic illness, the 
effect of college-PRSPT=0.01 on globally impaired ERP did not appear to be mediated by the 
specific diagnosis (SCZ vs. BPD) (Figure S1.2b), implying that the ERP phenotype may potentially 
identify genetically relevant groups independent of the diagnostic boundary between SCZ and 
BPD.  
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Sensitivity Analyses of Unmeasured Confounding 
 
SCZ-PRS as the exposure: 
Sensitivity analyses of unmeasured confounding found similar results after adjusting for 
hypothetical confounders in all three mediation analyses with SCZ-PRS as the exposure (Table 
S1.4-1.6).  
 
In the analysis on patients with SCZ-PRS as the exposure, globally impaired ERP as the mediator, 
and PANSS positive score as the outcome reported in the main text, the estimated direct and 
indirect effects odds ratios (95%CI) before adjusting for the hypothetical unmeasured 
confounder were 2.68 (-0.37, 5.52) and 0.27 (-0.34, 1.23), respectively. The effect estimates 
after adjusting for each hypothetical confounder U are shown in Table S1.4. Under adjustment 
of a strong hypothetical confounder with correlations of 0.3 with both mediator and outcome, 
the estimated direct and indirect effects odds ratios (95%CI) were 2.49 (-0.21, 5.77) and 0.15 (-
0.18, 1.04), respectively, which were very close to the unadjusted effect estimates. 
 
In the supplementary analysis with SCZ-PRS as the exposure, case vs. control status as the 
mediator, and globally impaired ERP profile as the outcome reported in the main text, the 
estimated direct and indirect effects odds ratios (95%CI) before adjusting for the hypothetical 
unmeasured confounder were 1.76 (0.72, 3.80) and 1.29 (1.12, 1.54), respectively. The effect 
estimates after adjusting for each hypothetical confounder U are shown in Table S1.5. Under 
adjustment of a strong hypothetical confounder with correlations of 0.3 with both mediator 
and outcome, the estimated direct and indirect effects odds ratios (95%CI) were 1.75 (0.75, 
3.99) and 1.24 (1.08, 1.50), respectively, which were very close to the unadjusted effect 
estimates.  
 
In the supplementary analysis on patients with SCZ-PRS as the exposure, diagnosis (SCZ vs. BPD) 
as the mediator, and globally impaired ERP profile as the outcome reported in the main text, 
the estimated direct and indirect effects odds ratios (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 2.28 (0.94, 6.08) and 1.00 (0.94, 1.10), respectively. 
The effect estimates after adjusting for each hypothetical confounder U are shown in Table 
S1.6. Under adjustment of a strong hypothetical confounder with correlations of 0.3 with both 
mediator and outcome, the estimated direct and indirect effects odds ratios (95%CI) were 2.47 
(0.69,7.07) and 0.99 (0.82, 1.09), respectively, which were very close to the unadjusted effect 
estimates. 
 
 
College-PRS as the exposure: 
In the mediation analysis with college-PRS as the exposure, globally impaired ERP profile as the 
mediator, and PANSS positive score as the outcome, the estimated direct and indirect effects 
betas (95%CI) before adjusting for the hypothetical unmeasured confounder were 0.03 (-3.57, 
3.69) and 0.90 (0.11, 2.24), respectively. The effect estimates after adjusting for each 
hypothetical confounder U are shown in Table S1.7. Under adjustment of a strong hypothetical 
confounder with correlations of 0.3 with both mediator and outcome, the estimated direct and 
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indirect effects betas (95%CI) were 0.25 (-3.09, 3.83) and 0.49 (0.02, 1.61), respectively. The 
sensitivity analysis for this mediation analysis indicated that existence of unmeasured 
confounding would likely lead to overestimation of the indirect effect and underestimation of 
the direct effect. Nonetheless, the estimated indirect effect remained significant after 
controlling for a strong hypothetical confounder, and the proportion mediated of 66.5% 
supported our conclusion that the majority of the effect of college-PRSPT=0.01 on PANSS-positive 
score was indirect. 
 
Sensitivity analyses of unmeasured confounding found similar results after adjusting for 
hypothetical confounders in the two supplementary mediation analyses with college-PRS as the 
exposure (Table S1.8 & S1.9).  
 
In the supplementary analysis with college-PRS as the exposure, case vs. control status as the 
mediator, and globally impaired ERP profile as the outcome reported in the main text, the 
estimated direct and indirect effects odds ratios (95%CI) before adjusting for the hypothetical 
unmeasured confounder were 4.09 (1.60, 10.59) and 1.19 (1.00, 1.46), respectively. The effect 
estimates after adjusting for each hypothetical confounder U are shown in Table S1.8. Under 
adjustment of a strong hypothetical confounder with correlations of 0.3 with both mediator 
and outcome, the estimated direct and indirect effects odds ratios (95%CI) were 3.81 (1.40, 
10.53) and 1.15 (1.01, 1.41), respectively, which were very close to the unadjusted effect 
estimates.  
 
In the supplementary analysis on patients with college-PRS as the exposure, diagnosis (SCZ vs. 
BPD) as the mediator, and globally impaired ERP profile as the outcome reported in the main 
text, the estimated direct and indirect effects odds ratios (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 3.94 (1.47, 10.71) and 1.00 (0.93, 1.08), 
respectively. The effect estimates after adjusting for each hypothetical confounder U are shown 
in Table S1.9. Under adjustment of a strong hypothetical confounder with correlations of 0.3 
with both mediator and outcome, the estimated direct and indirect effects odds ratios (95%CI) 
were 4.37 (1.31, 13.55) and 1.02 (0.91, 1.24), respectively, which were very close to the 
unadjusted effect estimates. 
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GWAS of globally impaired ERP 
 
The GWAS results of globally impaired cluster showed no evidence for genomic inﬂation 
(lambda-GC of 0.98, Figure S1.3). Although none of the SNPs reached genome-wide signiﬁcance 
(P <5E-08), five independent regions including nine SNPs showed suggestive association levels 
(p < 1E-05) (Figure S1.4; Table S1.10). Among the suggestive associated SNPs, rs1424104 and 
rs4888926 are located in the WWOX gene on chromosome 16, rs4792136 and rs73284773 are 
located in the SHISA6 gene on chromosome 17, and rs1078008 is located in the VIPR1 gene on 
chromosome 3. A gain-type copy number variation (CNV) affecting the WWOX gene has been 
found exclusively in patients with SCZ (Rodriguez-Santiago et al., 2010). Although the other two 
genes have not been reported to be associated with psychotic disorders, both are involved in 
aspects of brain function. 
Again, we are aware that the GWAS is underpowered and the results may not be reliable. 
Therefore, we did not report them in the main text. Replication with larger sample sizes is 
required. 
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SUPPLEMENTARY TABLES 
 
Table S1.1: Socio-demographic characteristics of subject groups  
 SCZ Patients BPD Patients Healthy Controls 
 N=136 N=122 N=125 
Age, yrs 44.26(12.36) 39.81(13.59) 33.15(12.54) 
Female, N (%) 90(66.2) 56(45.9) 55(44.0) 
Education, yrs 14.22(2.12) 14.99(2.30) 15.61(2.17) 
Current Smoker, N 
(%) 
51(38.6) 42(34.7) 8(6.6) 
Age of Onset 22.94(7.85) 22.54(8.86) -- 
CPZ Equivalent 
Dosage (mg) 
516.98(577.33) 214.49(303.28) -- 
PANSS Total 62.45(18.79) 57.96(16.49) -- 
MCAS Total 45.15(7.15) 47.54(5.17) -- 
YMRS Total 6.52(8.55) 10.38(13.42) -- 
MASQ Total 141.09(40.88) 131.75(35.09) 101.20(21.86) 
SHPS 1.93(2.34) 1.58(2.53) 0.35(0.96) 
Note: Values are means (SD) unless otherwise indicated.   
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Table S1.2: Mean (SD) of ERP measures in each cluster 
ERP measures 
 
All Subjects 
Globally Impaired 
N=60 
Intermediate  
N=221 
High Cognitive 
N=102 
P50 Sensory Gating 74.79 (37.76) 66.95 (42.40) 37.26 (25.72) 
Response to S1 2.25 (1.08) 2.22 (0.88) 4.45 (1.48) 
N1 Amplitude -3.64 (2.70) -3.89 (2.34) -6.15 (4.00) 
P2 Amplitude 4.80 (3.00) 4.68 (2.81) 9.81 (3.84) 
P3 Amplitude 5.92 (0.52) 9.39 (4.26) 14.12 (5.85) 
P3 Latency 559.73 (62.43) 377.19 (36.94) 364.15 (34.75)  
Patients Only 
Globally Impaired 
N=55 
Intermediate 
N=162 
High cognitive 
N=41 
P50 Sensory Gating 78.55 (37.06) 73.03 (44.77) 49.55 (28.42) 
Response to S1 2.20 (1.10) 2.22 (0.91) 4.62 (1.52) 
N1 Amplitude -3.56 (2.76) -3.67 (2.24) -5.83 (4.32) 
P2 Amplitude 4.95 (3.01) 4.31 (2.80) 9.17 (3.50) 
P3 Amplitude 5.66 (4.00) 8.70 (4.07) 12.72 (5.83) 
P3 Latency 558.56 (62.98) 380.26 (38.78) 373.06 (35.39) 
For P50 sensory gating, a lower value indicates better inhibition. For the response to S1, P2 
amplitude, and P3 amplitude measures, a higher value indicates larger responses. For the N1 
amplitude, a lower value indicates larger responses. For the P3 latency, a lower value indicates 
faster processing speed.  
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Table S1.3a: Results of power calculation for detecting the association between the SCZ-PRS 
and the globally impaired ERP  
 
The genetic correlation 
between the discovery 
and the target traits 
Heritability of 
globally impaired 
(assumed) 
NSNP 
(assumed) 
R2 P-value Power 
0.1 0.1 1000 9.8E-04 0.26 0.08 
10000 8.7E-04 0.27 0.08 
0.3 1000 0.0030 0.19 0.14 
10000 0.0026 0.20 0.13 
0.5 1000 0.0049 0.13 0.20 
10000 0.0043 0.15 0.18 
0.3 0.1 1000 0.0089 0.07 0.33 
10000 0.0078 0.08 0.29 
0.3 1000 0.027 0.005 0.75 
10000 0.023 0.008 0.69 
0.5 1000 0.044 3.7E-04 0.93 
10000 0.039 8.1E-04 0.89 
0.5 0.1 1000 0.025 0.007 0.71 
10000 0.022 0.01 0.66 
0.3 1000 0.074 5.1E-06 0.99 
10000 0.065 1.9E-05 0.99 
0.5 1000 0.12 3.0E-09 1.00 
10000 0.11 2.9E-08 1.00 
 
NSNP: Different number of independent SNPs included for calculating the PRS, which is 
determined by the selection of P-threshold. 
R2: Squared correlation between the PRS and the globally impaired ERP  
P-value: Expected p-value of the test for association between the PRS and the globally impaired 
ERP 
Power: The power for detecting the association between the PRS and the globally impaired ERP 
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Table S1.3b: Results of power calculation for detecting the association between the BPD-PRS 
and the globally impaired ERP  
 
The genetic correlation 
between the discovery 
and the target traits 
Heritability of 
globally impaired 
(assumed) 
NSNP 
(assumed) 
R2 P-value Power 
0.1 0.1 1000 9.3E-04 0.27 0.08 
10000 5.6E-04 0.28 0.07 
0.3 1000 0.0027 0.19 0.13 
10000 0.0017 0.23 0.10 
0.5 1000 0.0046 0.14 0.19 
10000 0.0028 0.19 0.14 
0.3 0.1 1000 0.0084 0.08 0.31 
10000 0.0051 0.13 0.21 
0.3 1000 0.025 0.006 0.72 
10000 0.015 0.03 0.51 
0.5 1000 0.044 2.5E-05 0.98 
10000 0.038 9.7E-05 0.96 
0.5 0.1 1000 0.023 0.008 0.69 
10000 0.014 0.03 0.48 
0.3 1000 0.070 9.5E-06 0.99 
10000 0.042 5.0E-04 0.91 
0.5 1000 0.12 9.0E-09 1.00 
10000 0.07 8.3E-06 0.99 
 
NSNP: Different number of independent SNPs included for calculating the PRS, which is 
determined by the selection of P-threshold. 
R2: Squared correlation between the PRS and the globally impaired ERP  
P-value: Expected p-value of the test for association between the PRS and the globally impaired 
ERP 
Power: The power for detecting the association between the PRS and the globally impaired ERP 
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Table S1.3c: Results of power calculation for detecting the association between the college-
PRS and the globally impaired ERP  
 
The genetic correlation 
between the discovery 
and the target traits 
Heritability of 
globally impaired 
(assumed) 
NSNP 
(assumed) 
R2 P-value Power 
0.1 0.1 1000 8.0E-04 0.27 0.07 
10000 2.9E-04 0.30 0.06 
0.3 1000 0.0024 0.20 0.12 
10000 8.7E-04 0.27 0.08 
0.5 1000 0.0040 0.15 0.17 
10000 0.0015 0.24 0.09 
0.3 0.1 1000 0.0072 0.09 0.28 
10000 0.0026 0.20 0.13 
0.3 1000 0.022 0.01 0.66 
10000 0.0079 0.08 0.30 
0.5 1000 0.036 0.001 0.87 
10000 0.013 0.04 0.45 
0.5 0.1 1000 0.020 0.01 0.63 
10000 0.0073 0.09 0.28 
0.3 1000 0.060 3.7E-05 0.98 
10000 0.022 0.01 0.66 
0.5 1000 0.10 9.5E-08 1.00 
10000 0.036 0.001 0.87 
 
NSNP: Different number of independent SNPs included for calculating the PRS, which is 
determined by the selection of P-threshold. 
R2: Squared correlation between the PRS and the globally impaired ERP  
P-value: Expected p-value of the test for association between the PRS and the globally impaired 
ERP 
Power: The power for detecting the association between the PRS and the globally impaired ERP 
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Table S1.3d: Results of power calculation for detecting the association between the childhood 
intelligence-PRS and the globally impaired ERP  
 
The genetic correlation 
between the discovery 
and the target traits 
Heritability of 
globally impaired 
(assumed) 
NSNP 
(assumed) 
R2 P-value Power 
0.1 0.1 1000 7.7E-04 0.25 0.08 
10000 2.5E-04 0.29 0.06 
0.3 1000 0.0023 0.17 0.16 
10000 7.6E-04 0.26 0.08 
0.5 1000 0.0039 0.11 0.23 
10000 0.0013 0.22 0.11 
0.3 0.1 1000 0.0070 0.06 0.37 
10000 0.0023 0.17 0.15 
0.3 1000 0.021 0.002 0.81 
10000 0.0068 0.06 0.37 
0.5 1000 0.035 0.0001 0.96 
10000 0.011 0.02 0.56 
0.5 0.1 1000 0.019 0.003 0.78 
10000 0.0063 0.06 0.35 
0.3 1000 0.058 7.2E--07 1.00 
10000 0.019 0.004 0.78 
0.5 1000 0.097 9.4E-11 1.00 
10000 0.032 0.0002 0.94 
 
NSNP: Different number of independent SNPs included for calculating the PRS, which is 
determined by the selection of P-threshold. 
R2: Squared correlation between the PRS and the globally impaired ERP  
P-value: Expected p-value of the test for association between the PRS and the globally impaired 
ERP 
Power: The power for detecting the association between the PRS and the globally impaired ERP 
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Table S1.4:  The estimated direct and indirect effect beta (95% CI) of the relationship between 
the SCZ-PRS, globally impaired ERP profile, and PANSS positive score after adjusting for a 
hypothetical confounder U 
  rUY 
  0.1 0.3 
rUM 0.1 βDE= 2.65 (-0.46, 5.46) 
βIE= 0.26 (-0.26, 1.35) 
βDE= 2.45 (-0.53, 5.39) 
βIE= 0.23 (-0.28, 1.25) 
0.3 βDE= 2.67 (-0.10, 5.62) 
βIE= 0.24 (-0.21, 1.29) 
βDE= 2.49 (-0.21, 5.77) 
βIE= 0.15 (-0.18, 1.04) 
rUM: the point biserial correlation coefficient between the hypothetical confounder and the 
mediator 
rUY: the Pearson’s correlation coefficient between the hypothetical confounder and the 
outcome 
βDE: direct effect beta 
βIE: indirect effect beta 
The estimated direct and indirect effects betas (95%CI) before adjusting for the hypothetical 
unmeasured confounder were 2.68 (-0.37, 5.52) and 0.27 (-0.34, 1.23), respectively. 
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Table S1.5:  The estimated direct and indirect effect odds ratio (95% CI) of the relationship 
between the SCZ-PRS, case-control status, and globally impaired ERP profile after adjusting 
for a hypothetical confounder U 
  rUY 
  0.1 0.3 
rUM 0.1 ORDE= 1.76 (0.73, 3.92) 
ORIE= 1.29 (1.12, 1.53) 
ORDE= 1.74 (0.71, 3.99) 
ORIE= 1.27 (1.08, 1.54) 
0.3 ORDE= 1.76 (0.74, 3.88) 
ORIE= 1.31 (1.12, 1.59) 
ORDE= 1.75 (0.75, 3.99) 
ORIE= 1.24 (1.08, 1.50) 
rUM: the point biserial correlation coefficient between the hypothetical confounder and the 
mediator 
rUY: the point biserial correlation coefficient between the hypothetical confounder and the 
outcome 
ORDE: direct effect odds ratio 
ORIE: indirect effect odds ratio 
The estimated direct and indirect effects odds ratios (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 1.76 (0.72, 3.80) and 1.29 (1.12, 1.54), respectively. 
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Table S1.6:  The estimated direct and indirect effect odds ratio (95% CI) of the relationship 
between the SCZ-PRS, diagnosis (SCZ vs. BPD), and globally impaired ERP profile after 
adjusting for a hypothetical confounder U 
  rUY 
  0.1 0.3 
rUM 0.1 ORDE= 2.33 (0.80, 5.46) 
ORIE= 1.00 (0.93, 1.09) 
ORDE= 2.46 (0.77, 6.73) 
ORIE= 1.00 (0.86, 1.05) 
0.3 ORDE= 2.33 (0.87, 6.04) 
ORIE= 1.00 (0.88, 1.06) 
ORDE= 2.47 (0.69,7.07) 
ORIE= 0.99 (0.82, 1.09) 
rUM: the point biserial correlation coefficient between the hypothetical confounder and the 
mediator 
rUY: the point biserial correlation coefficient between the hypothetical confounder and the 
outcome 
ORDE: direct effect odds ratio 
ORIE: indirect effect odds ratio 
The estimated direct and indirect effects odds ratios (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 2.28 (0.94, 6.08) and 1.00 (0.94, 1.10), respectively. 
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Table S1.7:  The estimated direct and indirect effect beta (95% CI) of the relationship between 
the college-PRS, globally impaired ERP profile, and PANSS positive score after adjusting for a 
hypothetical confounder U 
  rUY 
  0.1 0.3 
rUM 0.1 βDE= 0.13 (-3.45, 3.54) 
βIE= 0.84 (0.18, 2.23) 
βDE= 0.27 (-2.91, 4.04) 
βIE= 0.78 (0.14, 2.16) 
0.3 βDE= 0.09 (-3.56, 3.77) 
βIE= 0.71 (0.11, 2.15) 
βDE= 0.25 (-3.09, 3.83) 
βIE= 0.49 (0.02, 1.61) 
rUM: the point biserial correlation coefficient between the hypothetical confounder and the 
mediator 
rUY: the Pearson’s correlation coefficient between the hypothetical confounder and the 
outcome 
βDE: direct effect beta 
βIE: indirect effect beta 
The estimated direct and indirect effects betas (95%CI) before adjusting for the hypothetical 
unmeasured confounder were 0.03 (-3.57, 3.69) and 0.90 (0.11, 2.24), respectively. 
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Table S1.8:  The estimated direct and indirect effect odds ratio (95% CI) of the relationship 
between the college-PRS, case-control status, and globally impaired ERP profile after 
adjusting for a hypothetical confounder U 
  rUY 
  0.1 0.3 
rUM 0.1 ORDE= 4.02 (1.65, 10.35) 
ORIE= 1.19 (1.02, 1.48) 
ORDE= 3.75 (1.35, 10.87) 
ORIE= 1.17 (1.00, 1.45) 
0.3 ORDE= 4.06 (1.60, 12.03) 
ORIE= 1.21 (1.02, 1.52) 
ORDE= 3.81 (1.40, 10.53) 
ORIE= 1.15 (1.01, 1.41) 
rUM: the point biserial correlation coefficient between the hypothetical confounder and the 
mediator 
rUY: the point biserial correlation coefficient between the hypothetical confounder and the 
outcome 
ORDE: direct effect odds ratio 
ORIE: indirect effect odds ratio 
The estimated direct and indirect effects odds ratios (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 4.09 (1.60, 10.59) and 1.19 (1.00, 1.46), 
respectively. 
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Table S1.9:  The estimated direct and indirect effect odds ratio (95% CI) of the relationship 
between the college-PRS, diagnosis (SCZ vs. BPD), and globally impaired ERP profile after 
adjusting for a hypothetical confounder U 
  rUY 
  0.1 0.3 
rUM 0.1 ORDE= 4.05 (1.48, 10.51) 
ORIE= 1.00 (0.93, 1.08) 
ORDE= 4.35 (1.38, 13.15) 
ORIE= 1.00 (0.92, 1.11) 
0.3 ORDE= 4.06 (1.63, 11.53) 
ORIE= 1.00 (0.93, 1.13) 
ORDE= 4.366 (1.308, 13.554) 
ORIE= 1.02 (0.91, 1.24) 
rUM: the point biserial correlation coefficient between the hypothetical confounder and the 
mediator 
rUY: the point biserial correlation coefficient between the hypothetical confounder and the 
outcome 
ORDE: direct effect odds ratio 
ORIE: indirect effect odds ratio 
The estimated direct and indirect effects odds ratios (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 3.94 (1.47, 10.71) and 1.00 (0.93, 1.08), 
respectively. 
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Table S1.10: Suggestive associated SNPs for Globally Impaired ERP 
CHR SNP A1 A2 FRQ OR SE P 
3 rs1078008 T C 0.7892 0.3075 0.2534 3.27E-06 
6 rs79617003 A G 0.037 9.7991 0.4788 1.88E-06 
8 rs62514812 T C 0.9226 0.2283 0.3321 8.70E-06 
8 chr8_58374581_I I2 D 0.0595 5.5597 0.3819 7.04E-06 
8 rs10081508 T C 0.0771 4.4419 0.3358 8.96E-06 
16 rs4888926 T C 0.3311 2.7612 0.2289 9.09E-06 
16 rs1424104 T C 0.3234 2.8247 0.23 6.35E-06 
17 rs4792136 A C 0.0752 5.098 0.355 4.48E-06 
17 rs73284773 A G 0.0718 4.8004 0.3447 5.34E-06 
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SUPPLEMENTARY FIGURES 
 
Figure S1.1a: Causal Relationship between SCZ-PRS, Case vs. Control Status, and Globally 
Impaired ERP for all subjects 
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Figure S1.1b: Causal Relationship between SCZ-PRS, SCZ vs. BPD Diagnosis, and Globally 
Impaired ERP for patients 
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Figure S1.2a: Causal Relationship between College-PRS, Case vs. Control Status, and Globally 
Impaired ERP for all subjects 
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Figure S1.2b. Causal Relationship between College-PRS, SCZ vs. BPD Diagnosis, and Globally 
Impaired ERP for patients 
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Figure S1.3: Quantile-quantile (Q-Q) plot of observed versus expected P values of the GWAS 
results for globally impaired ERP profile.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The straight line in the Q-Q plot indicates the distribution of SNPs under the null hypothesis. 
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Figure S1.4: Manhattan plot of the GWAS for globally impaired ERP profile.  
 
 
P values (–log10) are plotted against their respective positions on each chromosome. 
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ABSTRACT 
OBJECTIVE:  
Both cerebro- and cardio-vascular disease (collectively “CVD”) may be genetically correlated 
with Alzheimer’s dementia (AD) and late-life cognitive function. In this study, we examined the 
genetic overlap between vascular pathologies and AD dementia, and explored the extent to 
which vascular pathologies mediate the impact of AD dementia-related genetic variants on late-
life cognition. 
 
METHODS: 
For 2,907 stroke- and dementia-free older individuals with genotype data available in the Age 
Gene/Environment Susceptibility (AGES)-Reykjavik Study, we generated genome-wide 
polygenic risk scores for AD dementia (GW-ADPRS), as well as APOE-linkage region polygenic 
risk scores (19q13-ADPRS), and non-APOE polygenic risk scores (non-19q13-ADPRS). We then 
examined the association of each PRS with markers of vascular pathology and cognitive 
function. Where associations were observed, we performed mediation analyses to identify 
whether association between the specific PRS and cognitive function was mediated by a 
vascular pathology. 
 
RESULTS:  
Memory score was significantly associated with GW-ADPRS (R2=0.0029, P=0.001) and non-
19q13-ADPRS (R2=0.0020, P=0.008), and was nominally associated with 19q13-PRS (R2=0.0015, 
P=0.02). GW-ADPRS was nominally associated with global cognition score (R2=0.0015, P=0.02), 
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multiple lobar cerebral microbleeds (CMB) (R2=0.0030, P=0.006), white matter lesion loads 
(WML) (R2=0.0018, P=0.03) and coronary artery calcification (CAC) (R2=0.0014, P=0.03); these 
genetic associations were almost totally explained by SNPs in the 19q13 region. The total effect 
of 19q13-ADPRS on memory was mediated by CMB (7.4%) and WML (5.6%), and its effect on 
global cognition was mediated by CMB (11.3%), WML (4.8%), and CAC (5.0%). The effect of non-
19q13-ADPRS on both memory and global cognition was mediated by CMB (2.1% and 7.5%, 
respectively). 
 
CONCLUSION:  
Our findings support the hypothesis of a genetic overlap, mostly due to APOE, between vascular 
pathologies and AD dementia. The polygenic genetic effect on late-life cognition is partially but 
significantly mediated by CMB, WML, and CAC. 
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INTRODUCTION 
Alzheimer’s disease (AD) dementia is a major cause of morbidity and mortality in older adults 
(Daviglus et al., 2010). The etiology of AD dementia is complex and multifactorial. AD dementia 
refers to the clinical diagnosis of dementia considered likely to be due to underlying AD 
pathology. The major pathological hallmarks of AD are the accumulation of amyloid plaques 
and neurofibrillary tangles, which may lead to neurodegeneration and neuronal cell death 
(Mucke, 2009). However, it is well-established that a large fraction of those with a diagnosis of 
AD dementia also have cerebrovascular pathology, including white matter disease, lacunar and 
other small strokes, and microhemorrhages (Schneider, Arvanitakis, Bang, & Bennett, 2007; 
Toledo et al., 2013). Large clinically-recognized strokes can also be present, but they are more 
likely to have ruled out a diagnosis of “AD dementia,” at least if they occur early in the course of 
disease. Systematically collected cohort-based autopsy data have shown that vascular 
pathology often coexists with AD pathology, adds to the likelihood of cognitive impairment, and 
lowers the threshold of AD pathology for the development of clinically diagnosed AD dementia 
(Schneider, Arvanitakis, Leurgans, & Bennett, 2009; Schneider & Bennett, 2010; Schneider, 
Wilson, Bienias, Evans, & Bennett, 2004).  
 
A variety of cerebral small vessel diseases have been associated with AD dementia. Cerebral 
microbleeds (CMB) have been reported to be associated with the clinical manifestation and 
biochemical hallmarks of AD dementia (Goos et al., 2010; Goos et al., 2009; Vernooij et al., 
2008). The presence of CMB in basal ganglia, thalamus, brainstem, and cerebellum is generally 
ascribed to hypertensive vasculopathy, while a lobar distribution of CMB is associated with 
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cerebral amyloid angiopathy (CAA) (Greenberg et al., 2009), which has been considered as a 
major contributor of the pathogenesis of AD dementia (Cordonnier & van der Flier, 2011). 
White matter lesions (WML), an imaging marker of cerebral small vessel disease, may also play 
a role in the development of AD dementia (Bilello et al., 2015; Inaba et al., 2011; Prins et al., 
2004). A meta-analysis found that WML predicted an increased risk of AD dementia, all-type 
dementia, and stroke (Debette & Markus, 2010). Retinal imaging, a recently emerging tool to 
study cerebral small vessels in vivo, has been related to white matter lesions, brain atrophy, 
and an increased risk of dementia (de Jong et al., 2011; Ikram et al., 2006; Ikram et al., 2013). 
 
Research efforts have also been devoted to the association between large vessel disease and 
AD dementia. Possible mechanisms linking large vessel atherosclerosis to AD dementia include 
shared etiology and brain hypoperfusion (de la Torre, 2010). Several longitudinal studies 
suggest that carotid intima-media thickness (CIMT), a marker of atherosclerosis, is associated 
with a later incidence of AD and dementia (Newman et al., 2005; van Oijen et al., 2007; Wendell 
et al., 2012). Additionally, a higher baseline CIMT and a more rapid progression of carotid 
atherosclerosis may accelerate cognitive decline in patients with AD dementia (Silvestrini et al., 
2009). Atherosclerotic coronary artery calcification (CAC) is another useful marker of large 
vessel disease. Although there have been few reports on the relation between CAC and AD 
dementia, current evidence suggests that larger volume of CAC is associated with brain 
atrophy, loss of white matter microstructural integrity, and worse cognitive function in non-
demented individuals (Bos et al., 2012; Reis et al., 2013). 
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Not surprisingly, epidemiological studies using clinical AD dementia as the outcome show that 
multiple vascular risk factors increase risk for AD (Weuve, 2017). As many risk factors for CVD 
are modifiable, focusing on the elucidation of the relationships and underlying mechanisms 
between vascular pathology and AD dementia might provide insight into the prevention or 
delay of AD-related cognitive decline in older individuals (de la Torre, 2010; Deschaintre, 
Richard, Leys, & Pasquier, 2009; Middleton & Yaffe, 2009).  
 
To further investigate the etiological significance of CVD risk factors in AD dementia, genetic 
studies may also provide clues to understand the biological link between CVD and AD. 
Apolipoprotein E (APOE), the major susceptibility gene for AD (Michaelson, 2014), has been 
reported to be a risk factor for hyperlipidemia, cerebral lobar microbleeds, white matter 
lesions, ischemic stroke, and coronary heart disease (Bennet et al., 2007; Khan et al., 2013; 
Schilling et al., 2013). In addition to APOE, genome-wide association studies (GWAS) of AD 
dementia have identified single nucleotide polymorphisms (SNPs) with known or hypothesized 
relationships to lipid metabolism, such as CLU (clusterin), ABCA7 (ABC transporter member 7), 
and SORL1 (sortilin-related receptor) (Schellenberg & Montine, 2012). Recent studies using 
large-scale GWAS data suggest that AD dementia may be genetically correlated with levels of 
biomarkers for CVD risk (plasma lipids and C-reactive protein) (Desikan et al., 2015) and small 
vessel stroke (Traylor et al., 2016). A gene-based pathway approach to GWAS data has also 
identified shared genetic pathways between CVD and AD dementia (G. Liu et al., 2014). 
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A recent study found that the effect of APOE-e4, the AD-associated allele of APOE, on late-life 
cognition was partially mediated by cerebrovascular pathologies (Sajeev, 2015). In the present 
study, we expand to additional vascular pathologies beyond the brain and full genome data to 
more fully understand the relationship of AD genes and vascular pathology in the development 
of cognitive impairment. We generated genome-wide polygenic risk scores for AD dementia 
(GW-ADPRS) to examine the polygenic overlap between AD dementia and each of the following 
vascular pathologies: lobar CMB, WML, retinal venular diameter (RVD), CIMT, and CAC. We also 
generated two partitioned ADPRS, estimating genetic risk for AD dementia contributed 
separately by the 19q13 region that includes APOE and SNPs in linkage disequilibrium (LD) with 
APOE, and all other SNPs outside of the APOE-linkage region. We tested each ADPRS separately 
for association with cognition scores and with each vascular pathology. For vascular markers 
observed to be genetically correlated with AD dementia, we further performed formal 
mediation analyses to explore the causal relationship among genome-wide and 19q13 region 
ADPRSs, vascular pathology, and cognitive function. 
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METHODS 
Study Sample Overview 
The analyses were performed in data from the Age, Gene/Environment Susceptibility–Reykjavik 
Study (AGES–Reykjavik), a population-based epidemiologic study of genetic, behavioral and 
environmental risk factors for late-life disease and disability in the vascular, neurocognitive, 
musculoskeletal, and metabolic systems. The ascertainment and evaluation of the AGES sample 
has been described elsewhere (Harris et al., 2007). In brief, the AGES-Reykjavik sample was 
drawn from the Reykjavik Study, a population-based cohort study following up 30,795 
randomly sampled Reykjavik residents born between 1905 and 1935. Between 2002 and 2006, 
5,764 surviving participants of the Reykjavik Study were enrolled and evaluated with a 
questionnaire and various clinical, biochemical, and imaging exams. From the full 5,764 
participants in AGES-Reykjavik, a random sample of 3,664 were selected for GWAS, of whom 
were excluded based on sample failure, genotype mismatch with reference panel, and sex 
mismatch, resulting in clean genotype data on 3,219 individuals. 
 
For our phenotypic analyses, from the full AGES-Reykjavik sample of 5,764 participants, we 
excluded those with a history of stroke or vascular dementia, leaving 5,161. Of these 
participants, the 2,907 with clean genotype data available constituted the sample for our 
genetic analyses (see Figure 2.1). 
 
 81 
 
AGES-Reykjavik was approved by the Icelandic National Bioethics Committee (VSN 00-063) and 
the Institutional Review Board of the U.S. National Institute on Aging. A document of informed 
consent was signed by all participants. 
 
Genotyping and Quality Control 
Genotyping was performed using the Illumina HumanCNV370-Duo (Illumina Inc.; San Diego, CA, 
USA) at the Laboratory of Neurogenetics, Intramural Research Program, at the U.S. National 
Institute of Aging. Standard protocols for working with Illumina data were followed, with a 
clustering score greater than 0.4. Prior to genotype imputation, we removed SNPs with call rate 
< 97%, Hardy-Weinberg Equilibrium < 1E-06, mishap < 1E-09, and mismatched positions 
between Illumina, dbSNP and/or HapMap. The quality control steps resulted in a total of 
325,094 autosomal SNPs. 
 
Genotype imputation was performed using the MaCH/ minimac program (Howie, Fuchsberger, 
Stephens, Marchini, & Abecasis, 2012), with the 1,000 Genomes Project dataset (Build: Hg19, 
1000G v3 phase I) as the reference panel. We further filtered imputed SNPs based on 
imputation quality > 0.6, and the final imputed dataset consisted of 8,881,585 autosomal SNPs. 
 
Markers of Vascular Pathologies 
Lobar Cerebral Microbleeds 
CMB were defined as focal hypointense lesions visible on the T2*-weighted GRE images, and 
lobar CMB were those located in the temporal, frontal, parietal, or occipital lobes. MRI 
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acquisition and reading protocol were described in detail previously (Qiu et al., 2008; 
Sveinbjornsdottir et al., 2008). CMB were assessed and recorded by neurologists and 
standardized raters according to previously reported criteria (Qiu et al., 2008; Sveinbjornsdottir 
et al., 2008). Multiple lobar CMB, an indicator of CAA (Greenberg et al., 2009), have been 
shown to be associated with decline in cognitive function in community older adults (Meier et 
al., 2014) or patients with stroke (Gregoire et al., 2012), and faster progression of dementia 
(Nagasawa, Kiyozaka, & Ikeda, 2014). In our analyses, we dichotomized lobar CMB as multiple 
(count > = 2) versus non-multiple (0 or 1). 
 
Brain White Matter Lesion Load 
WML were defined as visible hyperintense lesions on T2-weighted FSE/PD and FLAIR images. 
The whole brain total white matter lesion load was calculated as the summation of white 
matter hyperintensity volumes in the frontal, parietal, occipital, and temporal regions. The 
sample was grouped into quartiles of total white matter lesion load. In our analyses, individuals 
in the upper quartile of WML load were compared to those in the lower three quartiles. In a 
previous study using data from the AGES Reykjavik Study, participants in the upper quartile of 
WML load have been found to perform worse on cognitive tests (Saczynski et al., 2008).  
 
Retinal Venular Diameter 
Participants received digital retinal imaging of the fundus of each eye with a 6.3-megapixel 
Canon CR6 nonmydriatic digital camera (Klein et al., 2004; Qiu et al., 2008). All the retinal 
images were independently assessed by certified graders. The central retinal venular equivalent 
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(Knudtson et al., 2003) was calculated based on the measurement of the six largest venules 
within ½  to 1 disc diameter from the optic disc margin. The central retinal venular equivalent 
represents the average retinal venular diameter of both eyes. If one eye is not gradable, the 
value of the non-missing eye is used. This variable was treated as continuous in our analyses. 
 
Carotid Intima–Media Thickness 
Standard B-mode ultrasound images of the CIMT were acquired for the predefined segment of 
each of the right and left common carotid arteries at defined interrogation angles using the 
Meijers arc. Standard images were recorded from four angles at each site. The mean CIMT of 
the near and far walls were determined from a single image at each interrogation angle for 
both the right and left common carotid arteries. The details of the intima-media thickness 
analysis protocol were described elsewhere (Jonsson et al., 2009). We calculated the mean of 
all CIMT values and used the log-transformed mean of CIMT as a parameter in our analyses.  
 
Coronary Artery Calcification 
Images for calcium scoring were acquired using a Siemens Somatom Sensation 4 multi-detector 
Computed Tomography (CT) scanner (Siemens Medical Solutions, Erlangen, Germany) with 
prospective ECG triggering. Details of Coronary Computed Tomography Angiography acquisition 
and reading protocol were described elsewhere (Gudmundsson et al., 2012). Calcium in the 
coronary arteries was quantified using the Agatston scoring method (Agatston et al., 1990) by 
trained and certified image analysts. The total CAC score was calculated as the sum of the 
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scores for all four coronary arteries. We used the log-transformed total CAC score (log[CAC 
score+1] because there were zero values for the CAC score) as a variable in our analyses. 
 
Cognitive function 
Participants received a comprehensive cognitive assessment battery including tests of memory, 
executive function, and processing speed (Saczynski et al., 2008; Saczynski et al., 2009). 
Composite scores on the three cognitive domains for each subject were constructed by taking 
the mean of the Z-scores on individual tests within that domain. The composite memory score 
was calculated from scores on the California Verbal Learning Test (immediate and delayed 
recall); the composite executive function score was obtained from the Stroop Test (part 3), the 
CANTAB spatial working memory test, and the Digits Backward test; and the composite 
processing speed score was derived from scores on the Stroop Test (parts 1 and 2), Digit Symbol 
Substitution Test and Figure Comparison Test. The inter-rater reliability was high for all tests 
(Spearman correlation coefficients range from 0.96 to 0.99). The composite global cognition 
score was calculated as the mean of the three domain-specific composite scores. The two main 
outcomes used in our analyses were the standardized Z-score of the composite memory score 
and the standardized Z-score of the composite global cognition score. 
 
Other Covariates 
Other covariates used in the analyses included age (years, continuous), sex (binary), education 
(primary, secondary, college, university), smoking status (never, ever, or current), midlife 
physical activity (ideal, intermediate, or poor), diet quality (ideal, intermediate or poor), 
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prevalent diabetes (yes or no), hypertension (no, prehypertension, or hypertension), high LDL 
level (>=130 mg/dL), and obesity (BMI>=30). Levels of physical activity and diet quality were 
determined from brief questionnaires (Sturlaugsdottir et al., 2015) based on the American 
Heart Association guidelines on cardiovascular health (Lloyd-Jones et al., 2010). Diabetes was 
defined as self-reported doctor’s diagnosis of diabetes, use of antidiabetic medication, or with a 
fasting glucose level >7mmol/L. Prehypertension was defined as a systolic blood pressure (SBP) 
from 120 to 139 millimeters of mercury (mmHg) or a diastolic blood pressure (DBP) from 80 to 
89 mmHg, while hypertension was defined as SBP>=140 mmHg, DBP >=90 mmHg, doctor’s 
diagnosis, or use of antihypertensive medication.  
 
Polygenic Risk Scores (PRS) for AD Dementia and Associations with Cognitive or Vascular 
Phenotypes  
Genome-wide polygenic risk score for AD dementia (GW-ADPRS) 
We used the summary statistics from the Alzheimer’s Disease Genetics Consortium (ADGC) 
GWAS (8,309 AD cases and 7,366 controls of European ancestry) (Naj et al., 2011) as the 
discovery dataset to derive genome-wide polygenic risk scores for AD dementia (GW-ADPRS) in 
our study sample. To include only independent association signals from the ADGC GWAS, we 
applied an LD clumping procedure to the discovery datasets: we retained the SNP with smallest 
P-value in each 250 kb window and removed all those in LD (r2> 0.2) with this SNP. We used 
four different association P-value thresholds (PTs), 0.00001, 0.0001, 0.001, and 0.01, to select 
index SNPs from the clumped independent SNPs for generating the PRSs. For each individual, 
and each P-value threshold (PT), we calculated GW-PRS by summing the risk allele counts of the 
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index SNPs, weighted by the log of their association odds ratios estimated from the ADGC 
GWAS results. 
 
19q13-PRS and non-19q13-PRS for AD dementia 
Because APOE is the strongest risk gene for AD dementia, we further partitioned the GW-
ADPRS into an APOE region score and a non-APOE region score to separately assess the 
polygenic effects of SNPs in the APOE-linkage region 19q13 (ch19: 4500000-4580000) and all 
other SNPs. We followed the same steps as for the calculation of the GW-ADPRS to generate a 
19q13-ADPRS (the summation of log-odds ratio weighted risk allele counts of the index SNPs in 
the 19q13 region) and a non-19q13-ADPRS (the summation of log odds ratio weighted risk 
allele counts of the index SNPs across whole genome except the 19q13 region) for each 
individual. The 19q13-ADPRS aggregates the effects of AD dementia-associated SNPs in the 
APOE-linkage region. Despite the clumping procedures, some of these SNPs may merely be 
tagging SNPs in LD with APOE, and others (TOMM40, APOC1, and CD33) may contribute 
independently to the risk of AD dementia. Therefore, we considered the 19q-13-ADPRS as an 
APOE-tagging-ADPRS rather than simply an APOE genetic risk score. However, because the 
APOE effect is very large, we expected that the effects of an APOE genetic risk score would be 
similar. 
 
Data Analysis 
Phenotypic associations of vascular markers with cognitive function 
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We used univariate and multivariate linear regressions to assess the associations of each 
vascular marker with the Z-score of the composite memory score and the Z-score of the 
composite global cognition score. Multivariate models adjusted for age, sex, education, 
diabetes, hypertension, high LDL level, obesity, physical activity, diet quality, and smoking 
status. 
 
Association of ADPRS with vascular and cognitive phenotypes 
We then performed PRS association analyses to examine if any of the PTs generates an ADPRS 
significantly associated with the following phenotypes: The Z-score of the composite memory 
score, the Z-score of the composite global cognition score, and each of the vascular pathologies 
(CMB, WML, RVD, CIMT, and CAC). Associations were tested using linear (for continuous 
phenotypes) or logistic (for binary phenotypes) regression models with baseline age and sex as 
covariates. We tested the association of each phenotype with each of GW-ADPRS, 19q13-
ADPRS, and non-19q13-ADPRS, adjusting for age and sex. The Wald test P-value for each 
association test was reported, and squared semi-partial correlations (R2) were calculated to 
estimate the proportion of variance explained by the PRSs. 
 
Causal Mediation Analyses 
We then explored the causal relationship between vascular pathologies, late-life cognition, and 
the PRS for AD dementia that might explain any observed genetic correlation among these 
factors. We performed causal mediation analyses to examine how much of the effect of an 
ADPRS on cognition score was mediated by a vascular pathology observed to be genetically 
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correlated with AD dementia. We used a method based on the counterfactual framework for 
causal inference (Pearl, 2001; Robins & Greenland, 1992), which is an extension of traditional 
regression-based mediation approaches (Baron & Kenny, 1986), allowing binary mediators and 
outcomes, as well as exposure-mediator interactions (T. J. VanderWeele, 2016).  
 
For each of the ADPRSs (GW-ADPRS, 19q13-ADPRS, and non-19q18_ADPRS) as the exposure, 
we estimated the direct and indirect (mediated) effects of each vascular pathology as the 
mediator, and Z-score of the composite memory or global cognition score as the outcome. In 
order to gain more statistical power, the ADPRS exposures used in the mediation analyses were 
those with a P-value threshold that showed the highest association with each cognitive 
outcome. We adjusted for potential mediator-outcome confounders, including age, sex, 
smoking status, midlife physical activity, diet quality, and other genetic risk scores if necessary. 
A counterfactual outcome variable denotes the outcome that would have been observed had 
an exposure been set to a particular value. In order to compare high and low values of each 
ADPRS in our estimates of the direct and the indirect effects we chose to compare the 75th 
percentile and the 25th percentile of each. 
 
All the mediation analyses were performed by using the PARAMED module in STATA (Emsley & 
Liu, 2013; Valeri & Vanderweele, 2013). We used bootstrap procedures with 200 replications to 
compute a 95% bias-corrected bootstrap confidence interval (95% BCCI) for the direct and 
indirect effects.  
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Finally, we conducted sensitivity analyses. First, we followed the procedures developed by Imai 
et al. (K. Imai, Keele, & Tingley, 2010; K. K. Imai, L.; Yamamoto, T., 2010) to evaluate the 
robustness of the above mediation analyses to unmeasured confounding (see Supplementary 
Methods). Then as a sensitivity analysis of the 75th vs. 25th percentile comparison, we also 
repeated all mediation analyses comparing the effects of the 90th percentile and the 10th 
percentile of each ADPRS. 
 
Correction for Multiple Testing 
In the PRS association analyses, we considered a PRS-wise significant threshold for the 
correction of multiple comparisons (P< 0.008, after Bonferroni correction for the 6 association 
tests between 2 cognitive outcomes and 3 ADPRS for each genomic region; and P<0.003, after 
Bonferroni correction for the 15 association tests between 5 vascular pathologies and 3 ADPRS 
for each genomic region). Bonferroni correction is conservative here, because the vascular and 
cognitive phenotypes are somewhat correlated. 
 
In the mediation analyses, vascular pathologies with a p-value lower than 0.05 for PRS 
associations with AD dementia were tested as potential mediators. While multiple testing 
corrections should be considered when interpreting results of the PRS association analyses, we 
used a nominal significance of 0.05 for our purposes, as we were more concerned that we did 
not miss traits that are genetically correlated with AD dementia but did not achieve statistical 
significance due to a small sample size. 
 
 90 
 
RESULTS 
Sample Characteristics 
Table 2.1 presents descriptive statistics of baseline characteristics for the AGES sample used 
here.  The mean age of all stroke- and dementia-free subjects (n=5,161) was 76.7 (5.8) years. 
Approximately 80% of subjects had hypertension, but vascular pathologies were relatively rare: 
for example, only 2% had multiple lobar CMB.  Subjects with genotype data available (2,907) 
were very similar to the full sample, as would be expected, but those with had somewhat lower 
coronary calcification score (P=0.01).  
 
Phenotypic Associations 
Table 2.2 presents phenotypic associations between each vascular pathology and cognitive 
outcomes. All unadjusted associations were significant. After adjusting for potential 
confounders, CMB, CAC, and WML were significantly associated with memory score, whereas 
the former two were significantly associated with global cognition score. If all potential 
confounders remain constant, those with multiple lobar CMB averagely had 0.19 SD lower 
memory score and 0.26 SD lower global cognition score, than those with 0 or 1 lobar CMB.  
Individuals in the highest quartile of WML load had 0.07 SD lower memory score than others. 
For each one-unit increase in the log-transformed CAC, the mean memory and global cognition 
scores declined by 0.015 SD and 0.023 SD, respectively.      
 
Associations of GW-ADPRS with Cognitive or Vascular Phenotypes  
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We performed PRS association analyses to examine the association between GW-ADPRS and 
each vascular pathology, and the association between GW-ADPRS and each cognitive outcome. 
The results of PRS association analyses are presented in Figure 2.2 and Table 2.3. 
 
Memory score was significantly associated with the GW-ADPRS with a P-value threshold of 
0.0001 (GW-ADPRSPT = 0.0001; P = 0.006, R2 = 0.22%) and the GW-ADPRS with a P-value threshold 
of 0.01 (GW-ADPRSPT = 0.01; P = 0.001, R2 = 0.29%), after the Bonferroni correction for multiple 
comparisons. We also found nominal associations of global cognition score with GW-ADPRSPT = 
0.0001 and GW-ADPRSPT = 0.01. In terms of the association between the GW-ADPRSs and vascular 
pathologies, we found that the GW-ADPRS with at all three PT were nominally associated with 
multiple lobar CMB. There were also nominal associations between GW-ADPRSPT = 0.01 and WML 
and between GW-ADPRSPT = 0.0001 and CAC.  
 
Associations of 19q13-PRS and non-19q13-PRS with Cognitive or Vascular Phenotypes 
Using the two partitions of the GW-ADPRS, the 19q13-ADPRS and the non-19q13-ADPRS at 
each P threshold, we tested for association with each cognitive and vascular phenotype (Table 
2.3). Our data showed that the 19q13-ADPRS at all three P thresholds was significantly 
associated with lobar CMB. We also found nominal associations of 19q13-PRS with WML, CAC, 
and both cognitive outcomes. For non-19q13-PRS, the only association was that between non-
19q13-PRSPT = 0.01 and memory score. 
 
Mediation Analyses 
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Our PRS association analyses suggested possible SNP-based genetic overlap of AD dementia 
with CMB, WML, and CAC. To examine whether the effect of ADPRS on late-life cognition was 
mediated through these vascular pathologies, we performed regression-based causal mediation 
analyses to decompose the total effect of each PRS on each of the cognitive outcomes (i.e., Z-
score of the composite memory score and Z-score of the composite global cognition score) into 
direct and indirect (mediated) effects, adjusting for potential confounders.  In these mediation 
analyses, the PRS that most associated with each cognitive outcome was selected as the 
exposure (GW-ADPRSPT = 0.01, 19q13-ADPRSPT = 0.001, and non-19q13-ADPRSPT = 0.01 for memory; 
GW-ADPRSPT = 0.0001, 19q13-ADPRSPT = 0.001, non-19q13-ADPRSPT = 0.01 for global cognition). 
Vascular pathologies with a p-value lower than 0.05 for PRS associations with AD dementia 
were tested as potential mediators. 
 
Relationship between ADPRS, Vascular Pathologies, and Cognitive Decline 
We estimated the direct and indirect effects on memory and global cognition scores, comparing 
the 75th percentile versus the 25th percentile of the each ADPRS, adjusting for potential 
confounders. Results are shown in Table 2.4. The proportion mediated (PM) was obtained by 
dividing the estimated indirect effect by the estimated total effect, as an index of the degree of 
mediation. The total effect of GW-ADPRS on memory score was significantly mediated by 
multiple lobar CMB (PM= 3.2% [95%CI= 0.7%, 7.8%]) and WML load (PM=2.7% [95%CI= 0.05%, 
8.9%]). Of the five vascular pathologies tested, CMB (PM=10.8% [95%CI= 4.0%, 24.1%]), WML 
(PM=4.0% [95%CI= 0.7%, 15.2%]), and CAC (PM=4.4% [95%CI= 0.2%, 12.4%]) were identified as 
significant mediators of the effects of GW-ADPRS on global cognition score. The total effect of 
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19q13-ADPRS on memory score was significantly mediated by CMB (PM=7.4% [95%CI= 1.3%, 
19.9%]) and WML (PM=5.6% [95%CI= 0.9%, 18.4%]), and its effect on global cognition was 
mediated by CMB (PM=11.3% [95%CI= 3.6%, 35.3%]), WML (PM=4.8% [95%CI= 0.5%, 17.3%]), 
and CAC (PM=5.0% [95CI= 0.1%, 13.2%]). The total effect of non-19q13-ADPRS on both memory 
and global cognition was mediated by CMB (PM= 2.1% [95%CI= 0.1%, 6.8%] and 7.5% [95%CI= 
0.2%, 22.6%], respectively). 
 
When an interaction between the PRS and the marker of vascular pathology was included in 
each mediation model, there was little or no change in the estimated direct and indirect effects, 
so we decided not to include the interaction in the mediation models, as suggested by 
Vanderweele (T.J. Vanderweele, 2015). 
 
Sensitivity Analyses 
Sensitivity analyses of unmeasured confounding suggest that in the presence of unmeasured 
confounders (or residual confounding) associated with better cognition and less severe vascular 
pathology or unmeasured confounders associated with poorer cognition and more severe 
vascular pathology, our estimated PMs would underestimate the true mediation effects of 
vascular pathologies. Under the seemingly less likely scenarios of unmeasured confounders 
associated with better cognition and more severe vascular pathology, or unmeasured 
confounders associated with poorer cognition and less severe vascular pathology, our 
estimated PMs would overestimate the true mediation (see Supplementary Results and Figure 
S2.1). The degree of unmeasured confounding was estimated by the size of the correlation 
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(denoted by rho) between residuals in the equation predicting the mediator and the equation 
predicting the outcome. For example, in the mediation analysis with GW-ADPRS as the 
exposure, CMB as the mediator, and memory score as the outcome, the PM would reduce from 
3.2% to 0 if rho equals to 0.13 and would be greater than 3.2% if rho is less than 0. The rho 
which would reduce the PM to 0 for each mediation model ranges from 0.03 to 0.21 (see 
Supplementary Results and Table S2.2). 
 
Sensitivity analyses for selection of exposure levels for comparison found that mediation 
analyses comparing the effects of the 90th percentile and the 10th percentile of each PRS 
yielded very similar PMs as those shown in Table 2.4 (see Supplementary Table S2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
DISCUSSION 
In a community-based sample of 5,161 stroke- and dementia-free older individuals, we found 
that multiple lobar cerebral microbleeds, higher white matter lesion load, and greater coronary 
artery calcification—but not retinal venular diameter nor carotid intima-media --were 
associated with poorer late-life memory and global cognition. In the 2,907 genotyped 
individuals, we found that a higher genetic risk score for AD dementia was associated with 
these three vascular pathologies and two cognition outcomes. In mediation analyses, we found 
that the effects of APOE and SNPs near APOE on memory may be partially mediated by CMB 
and WML, and their effects on global cognition may be partially mediated by CMB, WML, and 
CAC. With the possible exception of CMB, there was little evidence of an effect of non-APOE AD 
dementia-associated alleles on either memory or global cognition. 
 
Genetic Overlap between AD Dementia and Vascular Pathologies 
In a relatively large sample of older adults, our phenotypic analyses replicated previously 
reported associations of cerebral small vessel disease (Poels et al., 2012; Staals et al., 2015) and 
atherosclerosis (Bos et al., 2012) with cognitive function. We then further examined if shared 
genetic factors contribute to these observed associations. Our results demonstrate genetic 
overlap between AD dementia, vascular pathologies, and cognitive function in older individuals 
free of prevalent dementia or stroke (Table 2.2 and Figure 2.2). We found an association 
between the GW-ADPRS and multiple lobar CMB. The 19q13-ADPRS was even more strongly 
associated (significant after Bonferroni correction) with CMB, suggesting AD dementia 
associated SNPs within and surrounding APOE were associated with having multiple lobar CMB. 
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Similar associations were also observed for GW-ADPRS and 19q13-ADPRS with WML load and 
CAC score, but no association was observed either for RVD or CIMT. Our findings of the 
strongest genetic overlap between AD dementia and CMB are consistent with a recent reported 
genetic correlation between AD and cerebral small vessel disease but not large vessel disease 
(Traylor et al., 2016). Lobar CMB may be caused by CAA (Smith et al., 2010; Yates et al., 2014), 
which is highly prevalent in post-mortem analyses of brains of persons with a clinical diagnosis 
of AD dementia during life (Jellinger, 2002). In addition, the APOE-e4 allele has been associated 
with the presence of CAA (Esiri et al., 2015; Pfeifer, White, Ross, Petrovitch, & Launer, 2002). 
These previous findings may support the possible genetic overlap between lobar CMB and AD 
dementia observed in our data. Since WML (de Leeuw et al., 2002) and CAC (W. Liu et al., 2015) 
may share some common risk factors with CMB, and both have been related to dementia 
(although the evidence is not as strong as that for CMB), a genetic overlap of AD dementia with 
WML and CAC makes sense.  
 
Although both CMB and WML were observed to be genetically correlated with AD, our results 
showed no association between the genetic risk score for AD dementia and RVD, which has 
been reported as an indicator of cerebral small vessel pathology (Ikram et al., 2006). One 
possible explanation is that the central retinal venular equivalent is a more observer-dependent 
measure and may not accurately reflect the degree of retinal venular dilatation, but there is no 
indication of even an attenuated signal in the beta coefficients or the squared semi-partial 
correlations (i.e., R2, the proportion of variance in RVD measure explained by ADPRS). 
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APOE Explains the Genetic Overlap of AD Dementia and Vascular Pathologies 
We separately examined APOE and non-APOE contributions to the association of the genome-
wide polygenic risk score for AD dementia with vascular pathologies and late-life cognition. Our 
results showed that the APOE gene explains most of the SNP-based genetic overlap of AD 
dementia with the vascular pathologies. APOE has been related to cerebrovascular dysfunction 
by affecting cerebral blood flow, blood brain barrier (BBB) integrity, and neuronal-vascular 
coupling (Tai et al., 2016). As mentioned above, the APOE-e4 allele is a risk factor for CAA (Esiri 
et al., 2015; Pfeifer et al., 2002). In terms of peripheral vascular disease, APOE has been shown 
to be an important factor in the development of hyperlipoproteinemia and atherosclerosis 
(Huang & Mahley, 2014; Tai et al., 2016). Our data also showed no association between the 
non-19q13-ADPRS and any of the examined vascular pathologies, despite previously reported 
associations of non-APOE AD risk genes with inflammation and abnormal lipid metabolism, 
which are both risk factors for vascular disease (Karch & Goate, 2015). Future research with 
larger samples are needed to test for association between vascular pathologies and AD 
dementia-associated alleles outside of the APOE-linkage region. 
 
In terms of the association between the ADPRS and performance in cognitive tests, in our 
sample, the APOE gene and its nearby SNPs contributed most of the genetic overlap between 
AD dementia and global cognition, whereas both the APOE- and non-APOE-ADPRS were 
associated with memory. These results were consistent with previous findings on the 
relationship between AD-associated SNPs and different domains of cognitive function. A large-
scale meta-analysis including 77 studies of the association between APOE and cognitive 
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function suggested that carriers of APOE-e4 performed worse on multiple domains of cognitive 
tests, including episodic memory, executive functioning, perceptual speed, and overall global 
cognitive ability (Wisdom, Callahan, & Hawkins, 2011). On the other hand, non-APOE-ADPRS 
calculated by using summary statistics from the International Genomics of Alzheimer’s Project 
(IGAP) was found to be associated with memory but not executive function in non-demented 
subjects in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Mormino et al., 2016). The 
ADNI sample used by Mormino et al., with mean age of 75.3 years, is very similar to ours. It is 
possible that impaired memory was more likely to be detected than deficit in other cognitive 
domains for individuals at this age (at this stage of cognitive decline).  
 
Potential Causal Relationships between PRS for AD Dementia, Vascular Pathologies, and 
Cognition 
Having established a SNP-based genetic overlap between AD dementia, vascular pathologies, 
and late-life cognitive function, we then sought to identify the causal relationships between PRS 
for AD dementia, vascular pathologies, and cognition scores. When considering 19q13-PRS as 
the exposure, we found that lobar CMB, WML load, and CAC significantly mediated the 
polygenic effects on global cognition, while lobar CMB and WML load mediated the effects on 
memory. When considering the non-19q13-ADPRS as the exposure, there was no evidence of 
mediation, except perhaps for lobar CMB. Our findings indicate that AD dementia-associated 
SNPs affect late-life cognition partially through pathways involving vascular pathologies, 
providing insight into potential pathogenic mechanisms in clinical AD dementia. The results also 
may lend further support to interventions to reduce vascular pathologies may be of value in the 
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prevention of AD dementia. It is worth noted that we separately examined the mediation 
effects of lobar CMB, WML load, and CAC. Although measures of these vascular pathologies 
were correlated with each other, their correlations were relatively weak in our sample 
(Kendall's tau-b = 0.07 for CMB-WML, Point-Biserial correlation coefficient = 0.08 for CMB-CAC 
and 0.12 for WML-CAC). Thus, it is reasonable to believe that a certain proportion of AD 
dementia-associated SNP effects on cognitive function was mediated by vascular pathologies 
when considering all vascular mediators together.  
 
The only previous study investigating the mediation role of cerebrovascular imaging markers 
between genetic variants and cognitive function, which used an overlapping sample from the 
same cohort as ours (i.e., the AGES-Reykjavik), reported that about 9% of the total effect of 
APOE4 carriership on global cognition was mediated by CMB and WML volume (Sajeev, 2015). 
Our analyses revealed similar but stronger mediation effect of vascular pathologies on the 
relationship between SNPs and cognitive function. The major strength of the present study is 
that we assessed the effects of PRS, aggregating multiple possible risk alleles for AD across the 
whole genome, within or beyond the APOE-linkage region. Moreover, we considered both 
cerebral small vessel and systemic large vessel imaging markers, which have been previously 
associated with dementia or poor cognition, as potential mediators. 
 
Possible Causal Relationship between Vascular Pathologies and Poorer Cognition  
In our analyses of phenotypic associations between vascular pathologies and cognitive function 
(Table 2.2), although we have considered a number of potential confounders, we cannot 
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completely rule out the possibilities of residual confounding. With the established causal 
mediation relationship between PRS, vascular pathologies, and cognitive performance (Figure 
2.3), PRS for AD dementia appears to affect both vascular pathologies and cognition and may 
confound the causal effect of vascular pathologies on cognition. In addition to the covariates 
included in the phenotypic analyses shown in Table 2.2, we also adjusted for the 19q13- and 
non-19q13-PRS that most associated with the cognitive outcomes (i.e., 19q13-PRSPT = 0.001, and 
non-19q13-PRSPT = 0.01) to account for possible residual confounding by shared genetic factors. 
In the fully-adjusted analyses, the effects from CMB and WML to cognitive outcomes remained 
significant; however, the associations between CAC and cognition were greatly attenuated and 
the association with memory was rendered non-significant after also accounting for the PRS 
(Table 2.5). 
 
Limitations 
Several limitations in the present study should be noted. In the population-based sample, in 
which most subjects were cognitively normal or mildly impaired, mean scores of cognitive tests 
reflect both lifelong cognitive variability and recent pathological changes, and the former may 
overwhelm the latter. However, with our relatively large sample size, we were able to detect 
small signals and parse these signals into what appear to be meaningful mediation 
relationships.  Nonetheless, the sample may have only been large enough to detect APOE-
related signals (even if other causal SNPs are present). In any event, in the setting of small 
signals, another major limitation of the present study is the possible violation of the no-
unmeasured-confounding assumption necessary for causal mediation analyses. However, our 
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sensitivity analyses suggest that given the expected direction of unmeasured confounding, our 
estimated indirect effects may underestimate the true mediated effects. In addition, the 
genetic risk scores, including only common genetic variants, cannot account for all the genetic 
effects on cognitive performance and AD dementia. Although our SNP-based genetic risk scores 
were strongly associated with vascular and cognitive phenotypes, and PRS for AD dementia has 
been reported to be capable to capture nearly all common genetic risk for AD (Escott-Price, 
Shoai, Pither, Williams, & Hardy, 2017), there are still causal genomic variants (e.g., rare 
variants) that are not well-tagged by GWAS SNPs. However, the genetic effects not captured by 
SNP-based risk scores can also be seen as a type of unmeasured mediator-outcome 
confounding. Therefore, the sensitivity analyses mentioned above may help minimize these 
concerns. Finally, although using a sample from the relatively isolated and genetically 
homogeneous Icelandic population (Helgason, Nicholson, Stefansson, & Donnelly, 2003) may 
enhance the power of a genetic epidemiological study (Harris et al., 2007), it limits the 
generalizability of the findings to other ethnic populations. Future research including a broader 
range of ethnic populations is needed. 
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CONCLUSION 
This is the first study, to our knowledge, that combined polygenic profiling and causal 
mediation methods to identify the causal relationship between two genetically correlated 
phenotypes and their shared genetic factors. Our findings support the hypothesis of a genetic 
overlap, mostly due to APOE, between AD dementia and vascular pathologies, especially small 
vessel disease. Our results also showed that in older individuals, CMB, WML, and CAC may 
causally affect cognitive function and partially mediate the polygenic genetic effects of AD-
related genes on cognition, underscoring the potential role of vascular factors in cognitive 
decline, and suggesting vascular pathologies as a target for future mechanistic research in this 
area. 
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Table 2.1: Descriptive statistics of demographic and clinical characteristics 
Characteristics All subjects Subjects with  
genotype data 
 (N=5161) (N=2907) 
Demographic   
Age at AGES I (years), mean (SD)  76.73 (5.83) 76.20 (5.43) 
Sex   
    Female, N (%) 3022 (58.6) 1706 (58.7) 
Education   
    Secondary, N (%) 2406 (49.9) 1441 (49.7) 
    College, N (%) 755 (15.7) 451 (15.6) 
    University, N (%) 547 (11.4) 334 (11.5) 
   
Vascular Pathologies, Baseline   
Lobar cerebral microbleeds   
    Count>=2, N(%) 110 (2.1) 69 (2.7) 
White matter lesion load, median(Q1, Q3) 1.91 (0.51, 5.64) 1.92 (0.50, 5.59) 
Central retinal venular equivalent, mean(SD) 202.19 (19.56) 202.14 (19.50) 
Carotid intima-media thickness, median(Q1,Q3) 0.97 (0.88, 1.06) 0.97 (0.88, 1.06) 
Coronary calcification score, median(Q1, Q3) 271.23 (43.61, 898.78) 253.52 (38.94, 841.53) 
   
Other Covariates, Baseline   
Midlife physical activity   
    Intermediate, N(%) 2166 (46.6) 1327 (47.5) 
    Poor, N(%) 909 (19.5) 524 (18.8) 
Diet quality   
    Intermediate, N(%) 4011 (84.6) 2418 (84.8) 
    Poor, N(%) 354 (7.5) 205 (7.2) 
Smoking   
    Ever, N(%) 2111 (43.9) 1303 (44.8) 
    Current, N(%) 593 (12.3) 372 (12.8) 
Diabetes, N(%) 640 (12.4) 324 (11.2) 
Hypertension   
    Prehypertension, N(%) 758 (14.8) 445 (15.3) 
    Hypertension, N(%) 4112 (80.3) 2318 (79.8) 
LDL level >=130 mg/dL, N(%) 2830 (54.9) 1643 (56.6) 
BMI>=30, N(%) 1139 (22.3) 642 (22.1) 
   
Subjects with genotype data had lower coronary calcification score (P=0.01) than other subjects. 
No significant difference was observed in the distribution of any other baseline characteristic listed in 
the Table between subjects with and without GWAS genotype data available. 
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Table 2.2: Phenotypic associations between vascular pathologies and late-life cognitive function 
 
Lobar CMB: Multiple lobar cerebral microbleeds; count >=2 vs. 0 or 1. 
WML: White matter lesion load; highest quartile vs. other three quartiles of the total volume of white matter lesions. 
RVD: Retinal venular diameter; represented by central retinal venular equivalent, continuous. 
CIMT: Carotid intima-media thickness; log-transformed, continuous. 
CAC: Coronary artery calcification score; log-transformed, continuous. 
 
All multivariate models adjusted for age, sex, education, diabetes, hypertension, high LDL level, obesity, physical activity, diet 
quality, and smoking status. 
 
Asterisk indicates significance at P<0.05. 
 
 
 
 
 
 
 Memory Global Cognition 
 Unadjusted Adjusted Unadjusted Adjusted 
 Beta (S.E.) P Beta (S.E.) P Beta (S.E.) P Beta (S.E.) P 
Lobar CMB -0.3684 (0.0973) 1.5E-04* -0.1868 (0.0857) 0.03* -0.4434 (0.0997) 8.9E-06* -0.2679 (0.0826) 0.001* 
WML -0.1925 (0.0362) 1.1E-07* -0.0696 (0.0328) 0.03* -0.2440 (0.0372) 6.0E-11* -0.0596 (0.0318) 0.06 
RVD  0.0020 (0.0008) 0.01* -0.0005 (0.0007) 0.53  0.0027 (0.0008) 0.001*  0.0004 (0.0007) 0.56 
CIMT -1.1099 (0.1047) 6.3E-26* -0.1066 (0.1015) 0.29 -1.0042 (0.1089) 4.5E-20  0.0731 (0.0987) 0.46 
CAC -0.0858 (0.0059) 1.5E-46* -0.0154 (0.0061) 0.01* -0.0872 (0.0061) 2.4E-45 -0.0232 (0.0059) 7.8E-05* 
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Table 2.3: Associations between polygenic risk scores for AD dementia and each target phenotype 
PRS for AD dementia Target Phenotypes 
Cognitive Outcomes Vascular Markers 
Genomic region P-threshold nSNP Memory 
 
(n=2752) 
Global 
Cognition 
(n=2582) 
Lobar CMB 
 
(n=2562) 
WML 
 
(n=2559) 
RVD 
 
(n=2682) 
CIMT 
 
(n=2777) 
CAC 
 
(n=2869) 
          
GW-ADPRS 
PT < 0.0001 190 R2=0.0022 
P=0.006** 
R2=0.0015 
P=0.02* 
R2=0.0030 
P=0.006* 
R2=0.0012 
P=0.07 
R2=0.0004 
P=0.29 
R2<0.0001 
P=0.71 
R2=0.0014 
P=0.03* 
PT < 0.001 1342 R2=0.0012 
P=0.04* 
R2=0.0006 
P=0.14 
R2=0.0029 
P=0.007* 
R2=0.0011 
P=0.09 
R2<0.0001 
P=0.90 
R2=0.0001 
P=0.61 
R2=0.0004 
P=0.24 
PT < 0.01 8918 R2=0.0029 
P=0.001** 
R2=0.0012 
P=0.04* 
R2=0.0018 
P=0.03* 
R2=0.0018 
P=0.03* 
R2=0.0002 
P=0.49 
R2<0.0001 
P=0.99 
R2=0.0005 
P=0.19 
          
 
 
19q13-ADPRS 
PT < 0.0001 40 R2=0.0015 
P=0.02* 
R2=0.0013 
P=0.04* 
R2=0.0038 
P=0.002** 
R2=0.0014 
P=0.05 
R2=0.0003 
P=0.40 
R2=0.0002 
P=0.46 
R2=0.0012 
P=0.04* 
PT < 0.001 54 R2=0.0015 
P=0.02* 
R2=0.0013 
P=0.04* 
R2=0.0035 
P=0.003** 
R2=0.0018 
P=0.03* 
R2=0.0002 
P=0.48 
R2=0.0002 
P=0.48 
R2=0.0015 
P=0.02* 
PT < 0.01 76 R2=0.0012 
P=0.04* 
R2=0.0011 
P=0.06 
R2=0.0040 
P=0.002** 
R2=0.0019 
P=0.02* 
R2=0.0002 
P=0.46 
R2=0.0003 
P=0.30 
R2=0.0015 
P=0.02* 
          
Non-19q13-ADPRS 
 
PT < 0.0001 150 R2=0.0008 
P=0.10 
R2=0.0002 
P=0.39 
R2<0.0001 
P=0.94 
R2<0.0001 
P=0.82 
R2=0.0002 
P=0.50 
R2=0.0001 
P=0.50 
R2=0.0001 
P=0.49 
PT < 0.001 1288 R2=0.0002 
P=0.45 
R2<0.0001 
P=0.81 
R2=0.0004 
P=0.30 
R2=0.0001 
P=0.68 
R2=0.0001 
P=0.67 
R2<0.0001 
P=0.94 
R2<0.0001 
P=0.71 
PT < 0.01 8842 R2=0.0020 
P=0.008** 
R2=0.0006 
P=0.15 
R2=0.0005 
P=0.27 
R2=0.0008 
P=0.14 
R2=0.0004 
P=0.31 
R2<0.0001 
P=0.70 
R2=0.0001 
P=0.59 
 
P-threshold (PT): the P-value threshold used in the training dataset to select SNPs for calculating the PRS for AD dementia. 
nSNP: different number of independent SNPs included for calculating the PRS for AD dementia, which is determined by the selection of PT. 
Lobar CMB: lobar cerebral microbleeds (count >=2 vs. 0 or 1). 
WML: total brain white matter lesion load (highest quartile vs. other three quartiles of the total volume of white matter lesions). 
RVD: the average retinal venular diameter, represented by central retinal venular equivalent (continuous). 
CIMT: mean of carotid intima-media thickness (log-transformed, continuous). 
CAC: coronary artery calcification score (log-transformed, continuous). 
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R2: squared semi-partial correlation, the proportion of variance in the target phenotype explained by the PRS for AD dementia. 
P: the P-value of the test for association between the PRS and the target phenotype, before multiple testing correction. 
An asterisk indicates significance at P-value <0.05. 
A double asterisk indicates Boferroni-corrected P-value < 0.05. 
Associations were tested using linear (for continuous phenotype) or logistic (for binary phenotype) regression models with age and sex as 
covariates. 
The missing data status of each vascular marker was associated neither with memory / global cognition scores nor with any of the PRS (all P > 
0.20). 
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Table 2.4: Total, direct and indirect effects of PRS for AD dementia on late-life cognitive function mediated by vascular pathologies 
   Memory Global Cognition 
A M N 
Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
           
GW-
ADPRS 
CMB 2308 -.0743 (-.1165, -.0249) -.0719 (-.1145, -.0231) -.0024 (-.0058, -.0005) 3.2% * -.0377 (-.0808,  .0079) -.0336 (-.0763,  .0128) -.0041 (-.0091, -.0015) 10.8% * 
 WML 2307 -.0783 (-.1242, -.0330) -.0762 (-.1228, -.0317) -.0021 (-.0070, -.00004) 2.7% * -.0409 (-.0872,  .0107) -.0393 (-.0847,  .0126) -.0016 (-.0062, -.0003)   4.0% * 
 CAC 2577 -.0685 (-.1118, -.0232) -.0674 (-.1102, -.0220) -.0011 (-.0057,  .00005) 1.6% -.0483 (-.0926,  -.0032) -.0462 (-.0919, -.0014) -.0021 (-.0060, -.0001)   4.4% * 
           
19q13-
ADPRS 
CMB 2308 -.0376 (-.0871,  .0130) -.0348 (-.0848,  .0167) -.0028 (-.0075, -.0005) 7.4% *  -.0363 (-.0902,  .0090) -.0322 (-.0792,  .0151) -.0041 (-.0128, -.0013) 11.3% *  
 WML 2307 -.0434 (-.0912,  .0073) -.0410 (-.0878,  .0098) -.0024 (-.0080, -.0004) 5.6% *  -.0400 (-.0910,  .0079) -.0381 (-.0875,  .0122) -.0019 (-.0069, -.0002)   4.8% *  
 CAC 2577 -.0481 (-.0958, -.0014) -.0463 (-.0932,  .0018) -.0018 (-.0054,  .0004) 3.6% -.0478 (-.0996, -.0025) -.0454 (-.0960, -.0004) 
-.0024 (-.0063, 
-.00005) 
  5.0% * 
           
Non-
19q13-
ADPRS 
CMB 2308 -.0679 (-.1176, -.0219) -.0665 (-.1160, -.0198) -.0014 (-.0046, -.0001) 2.1% * -.0279 (-.0750,  .0163) -.0258 (-.0735,  .0194) 
-.0021 (-.0063, 
-.00005) 
  7.5% *  
 WML 2307 -.0703 (-.1145, -.0223) -.0689 (-.1138, -.0207) -.0014 (-.0050,  .0003) 2.0%  -.0293 (-.0745,  .0165) -.0282 (-.0732,  .0178) -.0011 (-.0050,  .0003)   3.7%  
 CAC 2577 -.0576 (-.1024, -.0129) -.0571 (-.1012, -.0120) -.0005 (-.0037,  .0005) 0.9% -.0314 (-.0779,  .0152) -.0307 (-.0767,  .0151) -.0007 (-.0041,  .0006)   2.2% 
           
Exposure (A): GW-ADPRS, 19q13-ADPRS, and non-19q13-ADPRS (the 75th percentile vs. the 25th percentile)  
Mediator (M): CMB (lobar cerebral microbleeds; >=2 vs. 0 or 1), WML (total brain white matter lesion load; highest quartile vs. other three 
quartiles of the total volume of white matter lesions), or CAC (coronary artery calcification score; log-transformed, continuous) 
Outcome: z-standardized memory composite score (left panel) or z-standardized global cognition composite score (right panel)  
Values for total, direct and indirect effects indicate changes in each outcome. 
BCCI: bias-corrected confidence interval 
PM: proportion mediated=indirect effect beta coefficient/ total effect beta coefficient 
Models for the effects of GW-PRS adjusted for age, sex, smoking status, midlife physical activity, and diet quality.  
Models for the effects of 19q13-ADPRS adjusted for age, sex, smoking status, midlife physical activity, diet quality, and non-19q13-ADPRS 
Models for the effects of non-19q13-ADPRS adjusted for age, sex, smoking status, midlife physical activity, diet quality, and 19q13-ADPRS 
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Table 2.5: Phenotypic associations between vascular pathologies and late-life cognitive 
function, additionally adjusting for shared genetic factors 
 
Lobar CMB: Multiple lobar cerebral microbleeds; count >=2 vs. 0 or 1. 
WML: White matter lesion load; highest quartile vs. other three quartiles of the total volume of 
white matter lesions. 
RVD: Retinal venular diameter; represented by central retinal venular equivalent, continuous. 
CIMT: Carotid intima-media thickness; log-transformed, continuous. 
CAC: Coronary artery calcification score; log-transformed, continuous. 
 
All models adjusted for age, sex, education, diabetes, hypertension, high LDL level, obesity, 
physical activity, diet quality, smoking status, 19q13-ADPRSPT = 0.001, and non-19q13-ADPRSPT = 
0.01. 
 
Asterisk indicates significance at P-value <0.05. 
 
 
 
 Memory Global Cognition 
 Beta (S.E.) P Beta (S.E.) P 
Lobar CMB -0.2269 (0.1070) 0.03* -0.3339 (0.1013) 0.001* 
WML -0.1009 (0.0424) 0.02* -0.0788 (0.0405) 0.05 
RVD -0.0005 (0.0009) 0.58  0.0001 (0.0009) 0.88 
CIMT  0.0017 (0.1292) 0.99  0.1317 (0.1243) 0.29 
CAC -0.0118 (0.0077) 0.13 -0.0152 (0.0075) 0.04* 
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Figure 2.1: The study samples used in the analyses 
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Figure 2.2: Pair-wise polygenic association analyses between GW-ADPRS and (A) cognition scores, (B) vascular pathologies 
 
(A)                                                                                                                                            (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We derived genome-wide PRS for AD dementia using ADGC GWAS as the discovery sample with three different P-value thresholds (PT used to 
select training set SNPs: 0.0001, 0.001, and 0.01) and apply them to (A) Z-score of the composite memory or global cognition score; and (B) each 
of the markers of vascular pathologies. Age and sex were included as covariates in the association analyses.  
Each pair is shown on the x-axis and the proportion of variance explained for each phenotype (estimated via partial correlation R²) on the y-axis. 
Unadjusted P-values are shown on the top of the bars if < 0.05.  
Double asterisks indicate Bonferroni-corrected P-value < 0.05. 
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Figure 2.3: Directed acyclic graph (DAG) for the relationship between PRS for AD dementia, vascular pathologies, and late-life 
cognition 
  
 
 
 
 
 
 
 
 
 
 
Exposure: ADPRS, PRS for AD dementia 
Mediator: vascular pathologies, including CMB, WML, and CAC 
Outcome: late-life memory and global cognition scores 
The path traced by the red arrow represents the direct effect of the ADPRS on cognition, while the path traced by the blue arrows 
represents the indirect (mediated) effect through vascular pathologies. 
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Genetic overlap between vascular pathologies and Alzheimer’s dementia and the potential 
causal mechanisms 
 
Supplementary Information 
 
 
 
SUPPLEMENTARY METHODS 
Sensitivity Analyses of Unmeasured Confounding 
 
The counterfactual-based mediation analysis assumes no unmeasured confounding for the (1) 
exposure-mediator, (2) exposure-outcome, and (3) mediator-outcome relationships 
(Vanderweele, 2015). In our mediation analyses with genetic risk scores as the exposures, 
assumptions (1) and (2) were probably plausible. However, the assumption of no unmeasured 
confounding might be less plausible for the (3) mediator-outcome relationship, and the effect 
estimates would probably be biased.  
 
In order to evaluate the robustness of the mediation analyses to unmeasured confounding 
between mediator and outcome, we conducted sensitivity analyses to calculate how much the 
estimated mediated effects would be expected to change under different degrees of mediator-
outcome confounding. Specifically, a mediator-outcome confounder leads to a correlation 
between the residuals in the two regression models predicting mediator and outcome.  
 
We generalize the regression models for mediation analysis as: 
Mi= α1 + β1Ai + ξ1AXi + ei1 
Yi= α2 + β2Ai + γMi + κAiMi + ξ2AXi + ei2 
 
A = exposure, M = mediator, Y = outcome, X= covariates, e = residual 
 
The residual accounts for the variability in the dependent variable that cannot be explained by 
the linear relationship with the independent variables. The sensitivity parameter, denoted by ρ, 
is the correlation between ei1 and ei2.  
Under the assumption of no unmeasured mediator-outcome confounding, ρ is equal to zero. 
The magnitude of ρ represents the departure from the assumption of no unmeasured 
mediator-outcome confounding. 
 
We explored the sensitivity of mediation results to a hypothetical confounder by systematically 
increasing the correlation between the residuals in the regression models predicting mediator 
and outcome (Imai et al., 2010; Imai, 2010). We used an R program developed by Imai et al. to 
assess how large a confounder effect on the mediator-outcome relation must be to invalidate 
the conclusion for each mediation analysis. 
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SUPPLEMENTARY RESULTS 
 
Sensitivity Analyses of Unmeasured Confounding 
 
Results of sensitivity analyses of unmeasured confounding are presented in Figure S2.1. When 
rho<0, which means there is unmeasured confounding (or residual confounding) associated 
with better cognition and less severe vascular pathology or unmeasured confounding 
associated with poorer cognition and more severe vascular pathology, our estimated PMs 
would underestimate the true mediation effects of vascular pathologies. When rho>0, which 
means there is unmeasured confounding associated with better cognition and more severe 
vascular pathology, or unmeasured confounding associated with poorer cognition and less 
severe vascular pathology, our estimated PMs would overestimate the true mediation. The 
values of rho at which proportion mediated equals to 0 for the mediation models are listed in 
Table S2.2. The value of rho at which proportion mediated equals to 0 represents the degree of 
confounding that would change the conclusion on the mediation effect by vascular pathologies. 
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SUPPLEMENTARY TABLES 
Table S2.1: Total, direct and indirect effects of PRS for AD dementia on late-life cognitive function mediated by vascular pathologies 
   Memory Global Cognition 
A M N 
Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
           
GW-
ADPRS 
CMB 2308 -.1434 (-.2239, -.0469) -.1387 (-.2207, -.0446) -.0047 (-.0119, -.0011) 3.3% * -.0708 (-.1515,  .0148) -.0628 (-.1428,  .0240) -.0080 (-.0201, -.0030) 11.4% * 
 WML 2307 -.1510 (-.2394, -.0635) -.1470 (-.2367, -.0612) -.0040 (-.0135, -.00007) 2.7% * -.0766 (-.1632,  .0201) -.0735 (-.1585,  .0235) -.0030 (-.0117, -.0006)   4.0% * 
 CAC 2577 -.1320 (-.2155, -.0447) -.1300 (-.2125, -.0424) -.0021 (-.0109,  .00009) 1.6% -.0904 (-.1732,  -.0059) -.0864 (-.1718, -.0026) -.0040 (-.0113, -.0002)   4.4% * 
           
19q13-
ADPRS 
CMB 2308 -.0689 (-.1590,  .0234) -.0635 (-.1546,  .0305) -.0054 (-.0157, -.0010) 7.9% *  -.0666 (-.1645,  .0151) -.0586 (-.1443,  .0275) -.0080 (-.0271, -.0026) 12.0% *  
 WML 2307 -.0791 (-.1661,  .0134) -.0747 (-.1601,  .0179) -.0044 (-.0149, -.0007) 5.6% *  -.0729 (-.1658,  .0145) -.0694 (-.1596,  .0223) -.0035 (-.0128, -.0004)   4.8% *  
 CAC 2577 -.0876 (-.1746, -.0025) -.0844 (-.1700,  .0033) -.0032 (-.0098,  .0007) 3.6% -.0871 (-.1815, -.0046) -.0827 (-.1750, -.0008) -.0043 (-.0114, -.0001)   5.0% * 
           
Non-
19q13-
ADPRS 
CMB 2308 -.1337 (-.2317, -.0431) -.1309 (-.2285, -.0391) -.0028 (-.0093, -.0002) 2.1% * -.0549 (-.1422,  .0368) -.0507 (-.1364,  .0428) -.0041(-.0138,-9.6E-06)   7.5% *  
 WML 2307 -.1384 (-.2256, -.0440) -.1357 (-.2242, -.0407) -.0027 (-.0098,  .0005) 2.0%  -.0576 (-.1514,  .0302) -.0555 (-.1492,  .0325) -.0021 (-.0093,  .0007)   3.7%  
 CAC 2577 -.1135 (-.2017, -.0253) -.1125 (-.1993, -.0237) -.0010 (-.0073,  .0010) 0.9% -.0618 (-.1534,  .0299) -.0605 (-.1510,  .0298) -.0013 (-.0080,  .0012)   2.2% 
           
Exposure (A): GW-ADPRS, 19q13-ADPRS, and non-19q13-ADPRS (the 90th percentile vs. the 10th percentile)  
Mediator (M): CMB (lobar cerebral microbleeds; >=2 vs. 0 or 1), WML (total brain white matter lesion load; highest quartile vs. other three 
quartiles of the total volume of white matter lesions), or CAC (coronary artery calcification score; log-transformed, continuous) 
Outcome: z-standardized memory composite score (left panel) or z-standardized global cognition composite score (right panel)  
Values for total, direct and indirect effects indicate changes in each outcome. 
BCCI: bias-corrected confidence interval 
PM: proportion mediated=indirect effect beta coefficient/ total effect beta coefficient 
Models for the effects of GW-PRS adjusted for age, sex, smoking status, midlife physical activity, and diet quality.  
Models for the effects of 19q13-ADPRS adjusted for age, sex, smoking status, midlife physical activity, diet quality, and non-19q13-ADPRS 
Models for the effects of non-19q13-ADPRS adjusted for age, sex, smoking status, midlife physical activity, diet quality, and 19q13-ADP
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Table S2.2: The values of rho at which proportion mediated equals to 0 for mediation models 
Exposure Mediator Outcome Rho at PM=0 
GW-ADPRS CMB Memory 0.13 
WML 0.06 
CAC 0.04 
CMB Global Cognition 0.20 
WML 0.05 
CAC 0.05 
19q13-ADPRS CMB Memory 0.14 
WML 0.06 
CAC 0.03 
CMB Global Cognition 0.20 
WML 0.05 
CAC 0.05 
non-19q13-ADPRS CMB Memory 0.14 
WML 0.06 
CAC 0.04 
CMB Global Cognition 0.21 
WML 0.05 
CAC 0.05 
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SUPPLEMENTARY FIGURES 
Figure S2.1: Sensitivity analyses of unmeasured confounding 
 
A: exposure; GW-ADPRS, 19q13-ADPRS, or non-19q13-ADPRS 
M: mediator; CMB, WML, or CAC 
Y: outcome; memory or global cognition score 
The y-axis is the proportion mediated 
The x-axis, denoted by rho, is the size of the correlation between the residuals in the equation predicting 
M and the equation predicting Y. We assume there is an unmeasured confounder variable that 
introduces this correlation between the residuals. The larger the absolute value of rho, the stronger the 
confounding.  
The solid curve shows the estimated proportion mediated for different values of the correlation 
between the residuals in equations. The shaded part of the plot represents the 95% intervals 
surrounding the mediated effect. The x-intercept represents the value of rho at which proportion 
mediated equals to 0. 
The horizontal broken line denotes the proportion mediated without considering unmeasured 
confounding. When rho is equal to zero, the reported proportion mediated is the same as that we 
estimated in the mediation analysis without considering unmeasured confounding. For other values of 
rho, the proportion mediated is calculated under different levels of unobserved confounding.  
Models for the effects of GW-PRS adjusted for age, sex, smoking status, midlife physical activity, and 
diet quality.  
Models for the effects of 19q13-PRS adjusted for age, sex, smoking status, midlife physical activity, diet 
quality, and non-19q13-PRS. 
Models for the effects of non-19q13-PRS adjusted for age, sex, smoking status, midlife physical activity, 
diet quality, and 19q13-PRS. 
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Causal relationships between genetics, psychological traits and coronary heart 
disease 
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ABSTRACT 
OBJECTIVE:  
Optimism/pessimism and cynical hostility have been linked to the risk of coronary heart disease 
(CHD). In this study, we examined the genetic overlap between these psychological traits and 
CHD, and explored the extent to these traits mediated genetic influences on CHD risk.  
 
METHODS: 
For 6336 African American (AA), 13735 European American (EA), and 2935 Hispanic American 
(HA) relatively healthy women with genotype data available in the Women’s Health Initiative 
(WHI) Study, we generated genome-wide polygenic risk scores for CHD (CHD-PRS), and 
examined the association of CHD-PRS with optimism/pessimism and cynical hostility, 
respectively. Where associations were observed, we performed mediation analyses to 
determine whether the association of CHD-PRS with CHD risk is mediated by these traits. 
 
RESULTS:  
In the EA sample, CHD-PRS was significantly associated with optimism (t=-3.43, P=6.09E-04, 
R2=0.0009) and liability to both all CHD (t=5.87, P=4.51E-09, R2=0.0025) and acute CHD (t=4.38, 
P=1.20E-05, R2=0.0014), but was not associated with cynical hostility. In the AA and HA 
samples, CHD-PRS was associated with liability to CHD but neither optimism nor cynical 
hostility. In the EA sample, the total effect of CHD-PRS on liability to CHD was significantly 
mediated by optimism (proportion mediated=1.4% for all CHD and proportion mediated=1.7% 
for acute CHD). 
 130 
 
 
CONCLUSION:  
Despite several limitations, our findings suggest a genetic overlap between optimism and CHD 
in older women of European ancestry. The polygenic genetic effect on CHD is modestly though 
significantly mediated by optimism. 
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INTRODUCTION 
Coronary heart disease (CHD) is the most common type of heart disease, responsible for more 
than 370,000 deaths annually in the US (NCHS., 2015). (Nikpay et al., 2015)Psychological factors 
have been linked to the risk of developing CHD (Albus, 2010). In particular, dimensions of 
negative affectivity, including anger, hostility, and pessimism have been implicated in CHD risk. 
For example, several prospective cohort studies have found that cynicism, the cognitive 
component of hostility, is associated with increased risk of CHD (Barefoot, Larsen, von der Lieth, 
& Schroll, 1995; Barefoot et al., 1991; Izawa et al., 2011; Wong, Na, Regan, & Whooley, 2013). A 
meta-analysis of prospective observational studies found that hostility was associated with an 
increased CHD risk in healthy populations and with poor prognosis in individuals with CHD 
(Chida & Steptoe, 2009a). In addition, epidemiological evidence supports an association of 
dispositional optimism or pessimism with CHD (Hansen et al., 2010; Kubzansky, Sparrow, 
Vokonas, & Kawachi, 2001; Pankalainen, Kerola, & Hintikka, 2015; Tindle et al., 2009). 
 
There are several possible ways in which cynical hostility and optimism/pessimism could 
directly contribute to the development of CHD. Cynical hostility may increase the risk of CHD via 
dysregulated autonomic nervous system (Chida & Hamer, 2008; Thomas, Nelesen, & Dimsdale, 
2004; Vella & Friedman, 2007), high cortisol levels (Steptoe, Cropley, Griffith, & Kirschbaum, 
2000), and elevated biomarkers of inflammation and coagulation (Markovitz, 1998; Stewart, 
Janicki-Deverts, Muldoon, & Kamarck, 2008). It is also possible that cynical hostility alters 
susceptibility to CHD via behavioral pathways related to unhealthy lifestyle, smoking, sleep 
problems, or poor adherence to treatment (Scherwitz et al., 1992; Shin et al., 2005; Siegler, 
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Peterson, Barefoot, & Williams, 1992). Similarly, pessimism has been shown to be associated 
with impaired stress coping (Scheier, Weintraub, & Carver, 1986), autonomic dysfunction 
(Raikkonen, Matthews, Flory, Owens, & Gump, 1999; Sharot, Riccardi, Raio, & Phelps, 2007), 
higher cortisol awakening response (Chida & Steptoe, 2009b), elevated inflammatory markers 
(O'Donovan et al., 2009; Roy et al., 2010), and thrombogenesis (Roy et al., 2010). Pessimists 
may also tend to have more unhealthy behaviors, such as smoking and less physical activity 
(Steptoe, Wright, Kunz-Ebrecht, & Iliffe, 2006; Tindle et al., 2009), and poor medical adherence 
(Tinker et al., 2007). Although these physiological and behavioral pathways may explain a 
possible causal relationship between psychological traits and CHD, the observed associations of 
CHD with optimism/pessimism and cynical hostility can be confounded by common underlying 
factors. 
 
Genetic studies may give useful information to explain the relationships between psychological 
traits and CHD. It is now well-established that genetic variation contributes to the risk of CHD. 
Genome-wide association studies (GWAS) have identified more than 56 common genetic 
variants that contribute to the heritability of CHD (Nikpay et al., 2015). With the development 
of behavioral genetics, there is growing interest in the genetics of psychological and personality 
traits. Recently, GWAS have been used to identify genetic variants of hostility and proneness to 
anger (Merjonen et al., 2011; Mick et al., 2014). Although no GWAS has been reported for 
optimism/pessimism, a twin/adoption study estimated the heritability of optimism and 
pessimism at 25% (Plomin, 1992). In addition, a recent GWAS suggested that extraversion of 
the Big Five Model of Personality (McCrae & Costa, 1987), which has been shown to negatively 
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correlate with pessimism (Mahasneh, 2013), is a highly polygenic trait (van den Berg et al., 
2016). 
 
Methods have been developed recently to investigate overlap between polygenic traits using 
GWAS data (Andreassen et al., 2013; Bulik-Sullivan et al., 2015; International Schizophrenia et 
al., 2009), and their applications have provided insights into the overlapping genetics of 
numerous traits and disorders. However, to date there has been no study reporting a shared 
genetic basis between CHD and psychological traits. Given the knowledge that both cynical 
hostility and optimism/pessimism are associated with CHD, and all of them are heritable 
complex traits, a logical next step is to examine the genetic correlation between CHD and each 
of the psychological traits. Moreover, it is worthwhile to further explore the causal relationship 
between genetic factors, psychological traits, and CHD. Elucidation of the causal mechanism 
can provide insight into the potential effectiveness of limiting genetic effects on CHD by 
intervening on cynical hostility or pessimism. 
 
In the present study, we hypothesized that there may be polygenic overlap between 
psychological traits and the development of CHD, and some of the genetic effects on CHD may 
be mediated by psychological traits. We analyzed data from the Women's Health Initiative 
(WHI) GWAS genotyped samples to test the above hypotheses. With the availability of large-
scale data sets that combine genome-wide data with psychological measures and CHD 
outcomes, we examined the SNP-based genetic overlap between psychological traits (cynical 
hostility and optimism/pessimism) and CHD. We also performed a causal mediation analysis 
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and quantify how much of the polygenic effect on CHD is mediated by optimism/pessimism or 
cynical hostility. 
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METHODS 
Study Population 
The Women’s Health Initiative Observational Study (WHI-OS) and Clinical Trials (WHI-CT) were 
carried out at 40 US clinical centers between 1993 and 1998 ("Design of the Women's Health 
Initiative clinical trial and observational study. The Women's Health Initiative Study Group," 
1998; Langer et al., 2003). Participants were postmenopausal women aged 50 to 79 years at 
baseline, free from serious cardiac, pulmonary, renal, hepatic, and mental illness, with at least 3 
years’ life expectancy. The WHI-CTs performed randomized controlled trial evaluation of three 
distinct interventions: a low-fat eating pattern, menopausal hormone therapy (HT), and calcium 
plus vitamin D supplementation. The WHI-OS was designed to provide information about 
disease risk factors, including cancer, cardiovascular disease, and fractures. The combined 
studies enrolled 161,808 participants (93,676 in the WHI-OS and 68,132 in the WHI-CTs). 
 
In the present analyses, we used phenotype and genotype data from the six independent 
GWAS sub-studies within the WHI study (Supplementary Table S2.1): (1) the SNP Health 
Association Resource cohort (SHARe) (n=7,470 African Americans [AA] and 3,348 Hispanic 
Americans [HA]), (2) the Genome-Wide Association Studies of Treatment Response in 
Randomized Clinical Trials (GARNET) (n = 3,727 European Americans [EA]), (3) the WHI Memory 
Study (WHIMS+) (n=5,687 EA), (4) the Hip Fracture GWAS (HIPFx) (n=2,841 EA), (5) the 
Modification of PM-Mediated Arrhythmogenesis in Populations (MOPMAP) (n=2,840 EA), and 
(6) the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) (n=2,083 EA).  
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Genotyping and Quality Control 
All sub-studies performed genome-wide genotyping with either Affymetrix (Santa Clara, CA, 
USA) or Illumina (San Diego, CA, USA) arrays, and excluded SNPs and samples with similar 
quality control filters (Supplementary Table S2.1). DNA samples and SNPs with call rates less 
than 90–98%, depending on the sub-study were excluded. Within each sub-study, SNPs with 
minor allele frequencies (MAF) less than 1% or that failed Hardy-Weinberg equilibrium (P <1E-
04 or 1E-06) were excluded (Supplementary Table S2.2). Sex mismatches, duplicate samples, 
one of the first- and second- degree relatives, and subjects whose genetic ethnicity was 
inconsistent with their self-reported ethnicity were excluded. Genotypes were imputed using 
1000 Genomes Phase 1 reference panels, with the MaCH/ minimac program (Howie, 
Fuchsberger, Stephens, Marchini, & Abecasis, 2012) (Supplementary Table S2.2). We filtered 
imputed SNPs based on imputation quality > 0.1. 
 
For the present analyses, we excluded subjects with a history of stroke, myocardial infarction 
(MI), angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass 
graft (CABG), or congestive heart failure (CHF) at baseline. The final study samples consisted of 
6336 AA, 13735 EA, and 2935 HA subjects. All the analyses were performed separately for AA, 
EA and HA WHI subjects. 
 
Measurement of Optimism and Hostility 
At the baseline examination, psychological traits (optimism and cynical hostility) were 
measured by questionnaires for all participants. Optimism was assessed by 6 items of the Life 
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Orientation Test–Revised (Scheier, Carver, & Bridges, 1994). Item ratings were summed to yield 
a total score that ranges from 6 to 30 (higher scores indicate greater optimism, and lower 
scores indicate greater pessimism). Cynical hostility was measured by the cynicism subscale of 
the Cook-Medley Questionnaire (Cook, 1954), containing 13 true/false questions. The cynicism 
score ranges from 0 to 13, with a higher score indicating greater cynical hostility. The 
correlation between optimism and hostility was r= − 0.27 (P<0.0001) for the AA subsample, r= − 
0.30 (P<0.0001) for the EA subsample, and r= − 0.29 (P<0.0001) for the HA subsample. 
 
Measurement of CHD 
Outcomes were adjudicated through 2010 according to a previously described protocol (Curb et 
al., 2003). Incidence of all CHD events (defined as MI, angina, coronary revascularization, or 
CHD death) and acute CHD events (defined as MI or CHD death) were adjudicated locally and 
centrally from medical records including hospital discharge summaries, ICD-9 codes, diagnostic, 
laboratory, surgical, and pathology reports by trained physicians blinded to randomized 
intervention and exposure status. 
 
Since age is one of the most important risk factors for CHD and may also modify genetic risk, we 
used an informed conditioning approach (Zaitlen et al., 2012) to account for the influence of 
age on the genetic risk for CHD. The informed conditioning method uses a liability threshold 
model with parameters informed by published epidemiological statistics, accounting for clinical 
covariates, disease prevalence, and non-random ascertainment of cases in case-control 
association studies. In brief, we computed a conditional liability to all CHD for each individual, 
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based on one’s case-control status (i.e., whether having a CHD event during the follow-up), 
conditioning on age (the age at first CHD event for cases, and the age at end of follow-up for 
non-cases) and considering previously reported age-stratified prevalence of CHD in the U.S. 
(Mozaffarian et al., 2015). We also used the same method to compute a conditional liability to 
acute CHD for each subject. The age-conditional liability to all CHD and acute CHD were the 
main outcomes of the present study. 
 
Measurement of Other Baseline Characteristics 
Other baseline covariates used in the analyses included: age (years, continuous), education 
(less than a high school education, greater than high school but less than college, any college, 
or more than college), living alone (binary, yes or no), annual household income (less than 
$20000, $20000-$49999, $50000-$99999, $100000 or more), religious service attendance (not 
at all, 1 to 3 times per month, or ≥ 1 time per week), diabetes (binary, yes or no), hypertension 
(binary, yes or no), hypercholesterolemia (binary, yes or no), smoking (never, ever, or current), 
alcohol consumption (never, ever, or current), physical activity (< 2.5, 2.5 to < 18.25, or ≥ 18.25 
metabolic equivalents), large waist circumference (binary, ≥ 88 or <88 cm), body mass index 
(continuous), and OS/CT status (binary, observational study or clinical trial).  
 
Statistical Analysis 
Phenotypic associations of psychological traits with CHD 
We used multiple linear regression to examine the associations of each psychological trait with 
the age-conditional liability to all CHD and acute CHD, adjusting for age, education, living alone, 
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annual household income, religious service attendance, diabetes, hypertension, 
hypercholesterolemia, smoking, alcohol consumption, physical activity, waist circumference, 
body mass index, OS/CT status. We performed the analyses separately in each ethnic 
subsample. 
 
PRS for CHD in the European Ancestry sample 
We used the summary statistics from the Coronary ARtery DIsease Genome wide Replication 
and Meta-analysis consortium (CARDIoGRAM) GWAS (22,233 CHD cases and 64,762 controls of 
European ancestry) (Schunkert et al., 2011) as the training dataset to derive genome-wide 
polygenic risk scores for CHD (CHD-PRS) in our WHI-EA sample. To include only independent 
association signals from the CARDIoGRAM GWAS, we applied an LD clumping procedure to the 
training data in which we retained the SNP with smallest P-value in each 250kb window and 
removed all those in LD (r2> 0.2) with this SNP. We used three different association P-value 
thresholds (PTs), 0.0001, 0.001, and 0.01, to select index SNPs from the clumped independent 
SNPs for generating the PRSs. For each individual, and each P-value threshold (PT), we 
calculated a CHD-PRS by summing the risk allele counts of the index SNPs, weighted by the log 
of their association odds ratios estimated from the CARDIoGRAM GWAS results. 
 
PRS for CHD in the African Ancestry and Hispanic Ancestry samples 
The ideal training dataset for PRS construction in the AA and HA samples would be large-scale 
GWAS from the same populations, but such GWAS were not available. In order to improve the 
PRS prediction between ethnically diverse samples, we used a newly developed method 
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MultiPRS (Marquez Luna et al., 2016), combining the training GWAS data from the European 
CARDIoGRAM and cross-validations within each of our WHI AA and HA samples. First, we used 
CARDIoGRAM GWAS results as the training dataset to calculate PRS with European training data 
(EUR-PRS) with different p-value thresholds (0.0001, 0.001, and 0.01) in each of AA and HA 
subsamples. Second, we used a five-fold cross-validation procedure to calculate PRS with AA 
training data (AA-PRS) and PRS with HA training data (HA-PRS) with a p-value threshold of 
0.0001, 0.001, or 0.01 in each ethnic subsample. The procedures for construction of EUR-PRS 
and each TARGET-PRS (i.e., AA-PRS or HA-PRS) were similar to those for generating CHD-PRS in 
the EA subsample, but with different training and target datasets. Third, we built prediction 
models for the CHD outcomes (i.e., the conditional liability to all CHD and acute CHD) using the 
best linear combination of EUR-PRS, TARGET-PRS, and top 10 principal components (PCs) of 
ancestry of the target AA or HA subsamples. We performed a 2-dimensional grid search to 
optimize the linear combination via an in-sample fit on validation samples, with different P-
value thresholds for EA-PRS and TARGET-PRS. We examined the prediction accuracy (adjusted 
R2) of the 9 (3x3) combinations for each ethnic subsample, and used the fitted beta coefficients 
as the weights to generate the final CHD-PRS for each AA and HA participant.  
 
CHD-PRS associations with CHD and each psychological trait in target samples 
As described above, we generated CHD-PRS with different p-value thresholds for each of the 
AA, EA, and HA samples. We then examined their association with the conditional liability to 
CHD within each ethnic sample. We also examined associations  between the CHD-PRS and 
both either optimism and cynicism, respectively, within each ethnic sample. For the EA 
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subsample, associations were tested using linear regression models with the top 10 PCs of 
ancestry as covariates. For the AA and HA subsamples, we did not adjust for PCs because the 
information of PCs was already incorporated into the PRS. The Wald test P-value for each 
association test was reported, and squared semi-partial correlations (for EA) and adjusted R 
squared (for AA and HA) were calculated to estimate the proportion of variance explained by 
the PRSs. 
 
Causal Mediation Analyses 
We then explored the causal relationship between CHD-PRS, psychological traits, and liability to 
all CHD or acute CHD. We performed causal mediation analyses to examine how much of the 
effect of a CHD-PRS on the age-conditional liability to CHD was mediated by a psychological trait 
shown to be associated with CHD-PRS. We used a method based on the counterfactual 
framework for causal inference (Pearl, 2001; Robins & Greenland, 1992), which is an extension 
of traditional regression-based mediation approaches (Baron & Kenny, 1986), allowing 
exposure-mediator interactions (T. J. VanderWeele, 2016).  
 
We estimated the direct and indirect (mediated) effects with CHD-PRS as the exposure, a 
psychological trait (if observed to be associated with CHD-PRS) as the mediator, and the age-
conditional liability to all CHD or acute CHD as the outcome. To maximize statistical power, 
mediation analyses were conducted using the PRS P-value threshold that showed the strongest 
association with the CHD outcome. We adjusted for the top 10 PCs of ancestry and potential 
mediator-outcome confounders, including age, living alone, annual household income, religious 
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service attendance, alcohol consumption, physical activity, and OS/CT status. A counterfactual 
outcome variable denotes the outcome that would have been observed had an exposure been 
set to a particular value. In order to broadly understand the impact of the CHD-PRS as an 
exposure, we selected its 25th and 75th percentile to compare when we estimated the direct 
and the indirect effects. As sensitivity analyses for our selection of exposure levels for 
comparison, we also repeated our mediation analyses comparing the effects of the 90th 
percentile to the 10th percentile of the CHD-PRS. As an index of mediated effects, we 
calculated the proportion mediated (PM) by dividing the estimated indirect effect by the 
estimated total effect. 
 
All the mediation analyses were performed using the PARAMED module in STATA (Emsley & Liu, 
2013; Valeri & Vanderweele, 2013). We used bootstrap procedures with 200 replications to 
compute a 95% bias-corrected bootstrap confidence interval (95% BCCI) for the direct and 
indirect effects. Finally, we conducted sensitivity analyses to evaluate the robustness of the 
above mediation analyses to unmeasured confounding (see Supplementary Methods).  
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RESULTS 
Sample Characteristics 
Table 3.1 presents descriptive statistics of baseline and follow-up characteristics for the WHI-
AA, EA, and HA samples. Among the 6,336 AA participants, 507 (8.0%) had a CHD event 
(including 241 [3.8%] with acute CHD) during the follow-up period (average = 5409 days, range= 
1811 to 7154 days). Among the 13,735 EA participants, 1,664 (12.1%) had a CHD event 
(including 981 [7.1%] with acute CHD) during the follow-up follow-up period (average = 5404 
days, range=254 to 7125 days). Among the 2,935 HA participants, 192 (6.5%) had a CHD event 
(including 80 [2.7%] with acute CHD) during the follow-up follow-up period (average = 5267 
days, range= 1802 to 7052 days). 
 
Phenotypic Associations 
Table 3.2 presents phenotypic associations between each psychological trait and the 
conditional liability to CHD. After adjusting for potential confounders, optimism was 
significantly associated with the liability to both all CHD and acute CHD, while cynicism was 
significantly associated with the liability to acute CHD in the EA subsample. No association 
between psychological traits and CHD outcomes was observed in the AA and HA subsamples. 
 
Associations of CHD-PRS with the liability to CHD and psychological traits  
We performed PRS association analyses to examine the association between CHD-PRS and each 
psychological triat, and the association between CHD-PRS and the conditional liability of all CHD 
or acute CHD.  
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EA subsample 
The results of PRS association analyses for EA participants are presented in Table 3.3. The CHD-
PRS with a p-value threshold of 0.0001 (CHD-PRSPT = 0.0001) was significantly associated with 
optimism (t=-3.43, P=6.09E-04, R2=0.0009) and the liability to both all CHD (t=5.87, P=4.51E-09, 
R2=0.0025) and acute CHD (t=4.38, P=1.20E-05, R2=0.0014). None of the CHD-PRS was 
associated with cynical hostility. 
 
AA and HA subsamples 
The results of PRS association analyses for AA and HA participants are presented in 
Supplementary Table S3.3 and Table S3.4, respectively. For the AA subsample, the CHD-PRS 
with a p-value threshold of 0.0001 for EUR-PRS and a p-value threshold of 0.01 for AA-PRS was 
significantly associated with the liability to both all CHD (t=3.31, P=7.20E-04, R2=0.0011) and 
acute CHD (t=2.98, P=1.53E-03, R2=0.0009). For the HA subsample, the CHD-PRS with a p-value 
threshold of 0.0001 for EUR-PRS and a p-value threshold of 0.001 for HA-PRS was nominally 
associated with the liability to both all CHD (t=2.47, P=0.01, R2=0.0007) and acute CHD (t=2.01 
P=0.04, R2=0.0004). However, in the WHI-AA and HA samples, none of the CHD-PRS was 
associated with optimism or cynical hostility. 
 
Mediation Analyses 
Our PRS association analyses suggested possible SNP-based genetic overlap between optimism 
and CHD in EA individuals. To examine whether the effect of CHD-PRS on the liability of CHD 
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was mediated through optimism, we performed regression-based causal mediation analyses to 
decompose the total effect of PRS on each of the CHD outcomes (i.e., the age-conditional 
liability of all CHD and acute CHD) into direct and indirect (mediated) effects, adjusting for 
potential confounders. The CHD-PRS with a p-value threshold of 0.0001 (CHD-PRSPT = 0.0001) was 
the most associated with the CHD outcomes, and was selected as the exposure in the 
mediation analyses. Optimism score, which was also observed to be associated with CHD-PRSPT 
= 0.0001 was tested as a potential mediator.  
 
The estimated direct and indirect effects on the liability to CHD, comparing the 75th percentile 
versus the 25th percentile and the 90th percentile versus the 10th percentile of the CHD-PRS, are 
shown in Table 3.4. The total effect of CHD-PRS on the liability of CHD was significantly 
mediated by optimism (PM=1.4% for all CHD and PM=1.7% for acute CHD). Different exposure 
levels appeared to yield similar PMs. When an interaction between the CHD-PRS and optimism 
was included in each mediation model, there was very little change in the estimated direct and 
indirect effects, so these were not included in the mediation models, as suggested by 
Vanderweele (T.J. Vanderweele, 2015). 
 
Sensitivity analyses to assess the effect of unmeasured confounding suggested that in the 
presence of an unmeasured confounder associated with higher risk of CHD and greater 
optimism or an unmeasured confounder associated with lower risk of CHD and less optimism, 
our estimated PMs would underestimate the true mediation effects of optimism. For example, 
if there was unmeasured confounding with correlations of 0.1 with optimism score and of 0.1 
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with liability to all CHD, the PM would increase from 1.4% to 1.9%. However, if the associations 
of the unmeasured confounder with optimism and CHD risk were in different directions, our 
estimated PMs would overestimate the true mediation. For example, if there was unmeasured 
confounding with correlations of -0.1 with optimism score and of 0.1 with liability to all CHD, 
the PM would reduce from 1.4% to 1.0% (see Supplementary Tables S3.5 and S3.6). 
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DISCUSSION 
Summary of Main Findings 
Among relatively healthy post-menopausal women of European ancestry in the WHI (WHI-EA 
participants), we found that greater optimism was significantly associated with a lower risk of 
later acute CHD events and all CHD end points. We also observed that cynical hostility was 
significantly associated with acute but not chronic CHD events in WHI-EA participants. We also 
observed a significant association between CHD-PRS and optimism in the WHI-EA sample (P 
=6.09E-04), suggesting some degree of genetic overlap between CHD and optimism. Mediation 
analyses in the WHI-EA subsample showed that a small but significant portion of the effects of 
CHD-associated alleles on both acute and chronic CHD were mediated by optimism. Neither 
phenotypic nor genetic associations between psychological traits and CHD was observed in 
WHI-AA and HA subsamples. 
 
Phenotypic Associations between Psychological Traits and CHD 
Numerous studies have linked CHD to optimism/pessimism (Hansen et al., 2010; Kubzansky et 
al., 2001; Pankalainen et al., 2015) and cynical hostility (Barefoot et al., 1995; Barefoot et al., 
1991; Izawa et al., 2011; Wong et al., 2013), including in the WHI itself (Tindle et al., 2009).   
Our phenotypic analyses (Table 3.2) replicated previously reported associations of optimism 
with both acute and chronic CHD and an association of cynical hostility with acute CHD These 
associations were observed in European American but not African American women, consistent 
with the results of a previous study, using all WHI EA and AA subcohorts with or without GWAS 
data available (Tindle et al., 2009). We also examined the relationship between psychological 
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traits and CHD in women of Hispanic ancestry, and did not detect a significant association. Our 
findings suggest that the impact of psychological traits on CHD risk may differ between ethnic 
populations. It is possible that the non-significant findings in AA and HA subsamples are due to 
the smaller sample sizes, but this is less likely because the point estimates for the effect (i.e., 
the beta coefficients) are small or even opposite in direction.  
 
Genetic Overlap between Optimism and CHD  
As noted above, consistent with prior studies, we observed significant associations between 
psychological traits of optimism and cynical hostility with CHD. However, whether these 
phenotypic links represent underlying common biological etiology had not previously been 
clarified. Using a polygenic approach to GWAS data, we were able to further examine if shared 
genetic factors contribute to the observed phenotypic associations between psychological traits 
and CHD. We found an association between optimism and CHD-PRS, with the strongest signal at 
a P-value threshold of 0.0001, in European American women, suggesting that the relationship 
between CHD and optimism reflects shared genetic influences.  Nevertheless, in the same WHI-
EA sample, there was no genetic correlation between cynical hostility and CHD, implying the 
observed association between cynicism and CHD may be explained by non-genetic common 
factors.  
 
Among AA and HA participants, a trans-ethnic CHD-PRS was not associated with optimism or 
cynical hostility in the WHI-AA and HA subsamples. The small effect sizes in these analyses 
suggest that the smaller sample sizes are unlikely to account for the non-significant findings. 
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Optimism Partially Mediates the Polygenic Effect on CHD 
Having established that polygenic risk of CHD is associated with both optimism and CHD in 
European American women, we performed causal mediation analyses to assess whether this 
cross-trait genetic relationship is due to biological pleiotropy (a causal variant directly affecting 
both traits) or mediated pleiotropy (a causal variant affecting one trait, which in turn affects the 
other trait) (Solovieff, Cotsapas, Lee, Purcell, & Smoller, 2013). We found that a small but 
measurable portion of the CHD-PRS effect on CHD risk was mediated by optimism in non-
Hispanic white women. Our findings indicate that CHD-associated SNPs affect the risk of CHD 
partially through a pathway involving optimism/ pessimism, suggesting that an intervention 
that influences the degree of optimism or pessimism may be effective for the prevention of 
CHD. A recent meta-analysis on 29 studies with a total of 3319 participants indicate that 
psychological interventions, such as the “best possible self” intervention, self-compassion 
training, cognitive-behavioral therapy, and positive-psychology methods, can significantly 
increase optimism (Malouff, 2017). Future research and prevention efforts on these 
psychological interventions may have the potential to develop strategies for lowering the risk of 
CHD for individuals with higher genetic loading. 
 
Potential Causal Relationship from Psychological Traits to CHD 
The established causal mediation relationship between CHD-PRS, optimism, and liability to CHD 
suggest some causal effect of optimism on CHD risk (Figure 3.1). In the analysis that identified 
phenotypic associations between optimism and CHD risk (Table 3.2), although we controlled for 
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a number of potential confounders, we cannot completely rule out the possibility of residual 
confounding. As shown in Figure 3.1, there are causal arrows from CHD-PRS to both optimism 
and CHD, indicating that CHD-PRS may also confound the causal relationship between optimism 
and CHD.  In addition to the covariates included in the phenotypic analyses shown in Table 3.2, 
we could also adjust for the CHD-PRS to account for possible residual confounding by shared 
genetic factors. After additionally adjusting for CHD-PRS, optimism was still significantly 
associated with both the conditional liability to all CHD (beta=-0.0041, SE=0.0018, P=0.03) and 
acute CHD (beta=-0.0033, SE=0.0016, P=0.04).  
 
With respect to the relationship between cynical hostility and CHD risk, we observed evidence 
of a phenotypic association but no genetic correlation. These findings do not rule out a causal 
relationship between the two phenotypes that could be mediated by other genetic or non-
genetic factors. Further research could clarify this possibility. For example, if robust associations 
between genetic variants and cynicism are found in the future, these variants could serve as 
genetic instruments to test a causal relationship between cynicism and CHD in a mendelian 
randomization framework (Figure 3.2) (Smith & Ebrahim, 2003; Solovieff et al., 2013). 
 
Limitations 
The present study has several limitations. First, the PRS method tests only the effect of 
common genetic variants and the additive genetic model of inheritance. Without considering 
rare variants, gene-gene and gene-environment interactions, the genetic contribution captured 
by PRS may underestimate the true genetic effect on phenotypes. Second, the results of 
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mediation analyses might be biased due to violation of the unmeasured confounding 
assumption (T. J. VanderWeele, 2016). Our sensitivity analyses suggest that the evidence for 
mediation can be falsely detected with the existence of strong unmeasured confounders 
correlated with the mediator and the outcome in opposite directions. Finally, the WHI includes 
relatively healthy, post-menopausal women, thus our findings may not generalize to men and 
premenopausal women. 
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CONCLUSION 
Using large-scale genomic resources, we observed genetic overlap between optimism and CHD 
risk among older women. In women of European ancestry, optimism appeared to partly 
mediate the relationship between CHD polygenic risk and CHD outcomes. Our results also 
indicate that cynical hostility, though phenotypically associated with acute CHD, may not share 
common genetic etiology with CHD, suggesting non-heritable shared environmental causes may 
play a more important role in the relationship between cynical hostility and CHD. Identifying 
the psychological traits associated with CHD risk in women will facilitate the identification of 
vulnerable women, and may also inform the development of effective prevention and 
intervention strategies to improve cardiovascular health among women. 
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Table 3.1: Baseline and follow-up characteristics of WHI-AA, EA and HA samples 
 African 
Americans 
(n=6,336) 
European 
Americans 
(n=13,735) 
Hispanic 
Americans 
(n=2,935) 
    
Baseline Characteristics    
    
Age (years), mean (SD)  60.8 (6.7)  66.0 (6.7)  59.8 (6.5) 
Education, N (%)    
    > high school, < college 1950 (31.2) 4797 (35.1) 1091 (37.8) 
    any college 1690 (27.0) 5317 (38.9)   722 (25.0) 
    > college 1897 (30.3) 3451 (25.2)   457 (15.8) 
Annual household income, N (%)    
    20000-49999 2621 (44.0) 6621 (50.9) 1080 (40.3) 
    50000-99999 1612 (27.0) 3240 (24.9)   555 (20.7) 
    ≥ 100000   336 (5.6)   782 (6.0)   141 (5.3) 
Living alone, N (%) 1759 (28.2) 3724 (27.3)   478 (16.6) 
Religious service attendance, N (%)    
    1-3 times/month 1497 (23.8) 2689 (19.6)   675 (23.3) 
    ≥ 1 time/ week 3771 (60.0) 6590 (48.2) 1506 (51.9) 
CT status, N (%) 3582 (56.5) 11600 (84.5) 1517 (51.7) 
Smoking, N (%)    
    ever 2471 (39.7) 5449 (40.1)   873 (30.2) 
    current   673 (10.8)   976 (7.2)   181 (6.3) 
Alcohol consumption, N (%)    
    ever 3097 (49.5) 8231 (60.3) 1648 (56.9) 
    current   271 (4.3) 1756 (12.9)   157 (5.4) 
Physical activity, N (%)    
    middle 2928 (47.3) 6546 (51.0) 1308 (46.8) 
    high 1121 (18.1) 2810 (21.9)   570 (20.4) 
Body mass index (kg/m2), median (Q1, Q3) 29.9 (26.4, 34.6) 27.5 (24.2, 31.6) 27.8 (24.9, 31.6) 
Waist circumference ≥ 88cm, N (%) 3511 (55.6) 6462 (47.2) 1183 (40.5) 
Diabetes, N (%)   664 (10.5)   717 (5.2)   192 (6.6) 
Hypertension, N (%) 2783 (43.9) 3531 (25.7)   565 (19.3) 
Hypercholesterolemia, N (%)   813 (13.4) 1645 (13.0)   335 (12.4) 
Optimism score, mean (SD)  23.5 (3.4)  23.4 (3.3)  22.3 (3.6) 
Cynical hostility score, mean (SD)    4.7 (3.0)    3.5 (2.7)    4.5 (3.3) 
    
    
Follow-up Characteristics    
    
Follow-up duration (days), mean (SD) 5409 (976) 5404 (1013) 5267 (1062) 
Age at end of follow-up (years), mean (SD)  75.6 (6.7)  80.8 (6.5)  74.2 (6.8) 
All CHD events    
  number of all CHD during follow-up, N (%)   507 (8.0) 1664 (12.1)   192 (6.5) 
  age at first all CHD event, mean (SD)  70.6 (7.8)  75.3 (7.6)  70.1 (7.9) 
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Acute CHD events    
  number of acute CHD during follow-up, N (%)   241 (3.8)   981 (7.1)     80 (2.7) 
  age at first acute CHD event, mean (SD)  72.2 (8.2)  76.2 (8.1)  72.2 (8.4) 
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Table 3.2: Associations between the liability of CHD and psychological attitudes 
 Conditional liability of all CHD Conditional liability of acute CHD 
 Beta (S.E.) P Beta (S.E.) P 
Optimism     
    African Americans  0.0031 (0.0023) 0.17  0.0023 (0.0018) 0.19 
    European Americans -0.0043 (0.0018) 0.02 * -0.0034 (0.0016) 0.03 * 
    Hispanic Americans -0.0003 (0.0031) 0.92  0.0003 (0.0022) 0.90 
     
Cynical Hostility     
    African Americans -0.0019 (0.0026) 0.47  0.0007 (0.0020) 0.72 
    European Americans  0.0030 (0.0023) 0.19  0.0039 (0.0019) 0.04 * 
    Hispanic Americans  0.0006 (0.0034) 0.87   0.0008 (0.0024) 0.74 
 
All models adjusted for age, education, living alone, annual household income, religious service 
attendance, diabetes, hypertension, hypercholesterolemia, smoking, alcohol consumption, 
physical activity, waist circumference, body mass index, OS/CT status. 
Asterisk indicates significance at P<0.05. 
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Table 3.3: Associations of CHD-PRS with psychological attitudes and the liability of CHD in the WHI-EA 
sample  
          
 
All models adjusted for the top 10 PCs. 
Single asterisk indicates significance at p<0.05. 
Double asterisks indicate significance after Bonferroni correction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRS for CHD Target Phenotypes 
Psychological Attitudes Conditional Liability of CHD 
P-threshold Optimism Cynical 
hostility 
All CHD Acute CHD 
PT < 0.0001 t=-3.43 
P=6.09E-04** 
R2=0.0009 
t=-0.28 
P=0.78 
R2=5.76E-06 
t=5.87 
P=4.51E-09** 
R2=0.0025 
t=4.38 
P=1.20E-05** 
R2=0.0014 
PT < 0.001 t=-0.57 
P=0.57 
R2=2.40E-05 
t=0.34 
P=0.73 
R2=8.41E-06 
t=2.01 
P=0.05* 
R2=0.0003 
t=0.62 
P=0.53 
R2=2.81E-05 
PT < 0.01 t=0.47 
P=0.64 
R2=1.60E-05 
t=0.65 
P=0.52 
R2=3.14E-05 
t=1.91 
P=0.06 
R2=0.0003 
t=0.18 
P=0.86 
R2=2.25E-06 
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Table 3.4: Total, direct and indirect effects of CHD-PRS on the liability of CHD mediated by 
optimism in the WHI-EA sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exposure Mediator Outcome Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
CHD-PRS 
(75th vs. 25th 
percentiles) 
 
 
 
Optimism 
Liability of 
all CHD 
0.0446 
(0.0281, 0.0596) 
0.0440 
(0.0274, 0.0591) 
0.0006 
(0.0001, 0.0014) 
1.4% 
Liability of 
acute CHD 
0.0293 
(0.0168, 0.0435) 
0.0288 
(0.0164, 0.0430) 
0.0005 
(0.0001, 0.0012) 
1.7% 
CHD-PRS 
(90th vs. 10th 
percentiles) 
Liability of 
all CHD 
0.0842 
(0.0564, 0.1144) 
0.0831 
(0.0541, 0.1133) 
0.0012 
(0.0003, 0.0028) 
1.4% 
Liability of 
acute CHD 
0.0552 
(0.0300, 0.0788) 
0.0543 
(0.0287, 0.0777) 
0.0009 
(0.0001, 0.0021) 
1.7% 
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Figure 3.1: The potential causal relationships between CHD-PRS, optimism, and CHD 
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Figure 3.2: Cynicism-associated genetic variants that are not directly associated with CHD may 
be a potential instrumental variable for Mendelian randomization to determine causal effect of 
cynical hostility on acute CHD 
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SUPPLEMENTARY METHODS 
Sensitivity Analyses of Unmeasured Confounding 
 
The counterfactual-based mediation analysis assumes no unmeasured confounding between 
(1) exposure and mediator, (2) exposure and outcome, and (3) mediator and outcome (T.J. 
Vanderweele, 2015). In our mediation analyses with genetic scores as the exposures, since we 
had adjusted for the top principal components (PCs) of ancestry to address possible population 
stratification, assumptions (1) and (2) would probably hold. However, the assumption of no 
unmeasured confounding between (3) mediator and outcome might be less plausible, and the 
effect estimates would probably be biased. 
 
In order to evaluate the robustness of the mediation analyses to unmeasured confounding for 
the mediator-outcome relationship, we conducted sensitivity analyses to calculate how much 
direct and indirect effect estimates would be expected to change under the existence of 
unmeasured mediator-outcome confounding. Specifically, given a hypothetical unmeasured 
confounder of the mediator-outcome relationship, U, with particular correlations with the 
mediator and the outcome, we examined what the true direct and indirect effect estimates 
would be, if we were able to adjust for U. 
 
For each mediation analysis, we generated four standard normal variables (i.e., mean=0 and 
variance=1), with particular correlations with the mediator and the outcome, as hypothetical 
confounders (Table S3.4-3.5). The first hypothetical confounder has correlation of 0.1 with the 
mediator and correlation of 0.1 with the outcome. The second hypothetical confounder has 
correlation of 0.2 with the mediator and correlation of 0.2 with the outcome. The third 
hypothetical confounder has correlation of -0.1 with the mediator and correlation of 0.1 with 
the outcome. The fourth hypothetical confounder has correlation of -0.2 with the mediator and 
correlation of 0.2 with the outcome. We compared the direct and indirect effect estimates 
before and after adjusting for each of these hypothetical confounders, to assess the potential 
impact of unmeasured confounding on each mediation analysis. 
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SUPPLEMENTARY RESULTS 
Sensitivity Analyses of Unmeasured Confounding 
 
In the mediation analysis for EA individuals, with CHD-PRS as the exposure, optimism score as 
the mediator, and the age-conditional liability of all CHD as the outcome reported in the main 
text, the estimated direct and indirect effects (95%CI) before adjusting for the hypothetical 
unmeasured confounder were 0.0440 (0.0274, 0.0591) and 0.0006 (0.0001, 0.0014), 
respectively. The effect estimates after adjusting for each hypothetical confounder U are shown 
in Table S3.5. Under adjustment of a hypothetical confounder with positive correlations with 
both mediator and outcome, the estimated proportion mediated would be greater than that 
without considering the hypothetical confounder. Under adjustment of a hypothetical 
confounder with correlations of -0.1 and 0.1 with mediator and outcome respectively, the 
estimated proportion mediated would be smaller but remain significantly greater than zero. 
However, under adjustment of a stronger hypothetical confounder with correlations of -0.2 and 
0.2 with mediator and outcome respectively, the estimated proportion mediated would 
become negative, and this may change our conclusions.   
 
In the mediation analysis for EA individuals, with CHD-PRS as the exposure, optimism score as 
the mediator, and the age-conditional liability of acute CHD as the outcome reported in the 
main text, the estimated direct and indirect effects (95%CI) before adjusting for the 
hypothetical unmeasured confounder were 0.0288 (0.0164, 0.0430) and 0.0005 (0.0001, 
0.0012), respectively. The effect estimates after adjusting for hypothetical unmeasured 
confounders are shown in Table S3.6. Similar to the results of sensitivity analysis for the 
mediation analysis with the age-conditional liability of all CHD as the outcome (Table S3.5), in 
the presence of an unmeasured confounder associated with higher risk of CHD and greater 
optimism, the true mediation effect of optimism would be greater than that estimated in the 
original mediation analysis. However, if the associations of the unmeasured confounder with 
optimism and CHD risk were in different directions, our estimated proportion mediated would 
overestimate the true mediation. 
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SUPPLEMENTARY TABLES 
Table S3.1: Description of the six WHI GWAS samples 
 SHARe GARNET WHIMS+ HIPFx MOPMAP GECCO 
Sample size 
7470 AA 
3348 HA 
3727 5687 2841 2840 2083 
Ethnicity 
African 
American and 
Hispanic 
White White White White White 
GWAS 
platform 
Affymetrix 6.0 
Illumina 
HumanOmni1
-Quad v1-0 B 
HumanOmniE
xpressExome-
8v1_B 
Illumina 
550K and 
610K 
Affymetrix 
Gene Titan, 
Axiom 
Genome-
Wide Human 
CEU I Array 
Plate 
Illumina 610 
and 
Cytochip 
370K 
Design Cohort 
Case-control 
(4 case 
groups) 
Cohort Case-control Case-Control Case-control 
Phenotype 
for cases 
NA 
Type 2 
Diabetes, 
Myocardial 
Infarction, 
Stroke, 
Venous 
Thrombosis 
NA Hip Fracture 
Ventricular 
Ectopy (ever) 
Colorectal 
cancer 
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Table S3.2: QC and Imputation for the six WHI GWAS samples 
 SHARe GARNET WHIMS+ HIPFx MOPMAP GECCO 
Minimal sample 
call rate 
95% 98% 97% 98% 95% 97% 
Minimal SNP call 
rate 
90% 98% 98% 98% 90% 98% 
Hardy Weinberg 
P-value cut-off 
below which 
SNPs are 
excluded 
1e-6 1e-4 1e-4 1e-4 1e-6 1e-4 
Samples used for 
Hardy Weinberg 
calculations 
All samples, 
separate for 
AA and HA 
Controls All Controls All Controls 
Minimum allele 
frequency cut-off 
1% None 1% 1% 0.5% 5% 
Imputation 
software 
MACH minimac minimac minimac minimac minimac 
Imputation 
reference panel 
1kGP 
v3.20101123 
1kGP 
v3.20101123 
1kGP 
v3.20101123 
1kGP 
v3.20101123 
1kGP 
v3.20101123 
1kGP 
v2.20101123 
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Table S3.3: Associations of CHD-PRS with psychological attitudes and the liability of CHD in the 
AA subsample  
 
EUR-PRS: We used CARDIoGRAM GWAS results as the training dataset to calculate PRS with European training data 
with different p-value thresholds (0.0001, 0.001, and 0.01) in the WHI-AA target sample.  
AA-PRS: We used a five-fold cross-validation procedure to calculate PRS with a p-value threshold of 0.0001, 0.001, 
or 0.01 in the WHI-AA subsample. 
CHD-PRS, generated by using MultiPRS: We performed a 2-dimensional grid search to optimize the linear 
combination via an in-sample fit on the WHI-AA validation sample, with different P-value thresholds for EUR-PRS 
and AA-PRS. We examined the prediction accuracy (adjusted R2) for the liability of CHD of the 9 (3x3) combinations 
for the WHI-AA sample, and used the fitted beta coefficients as the weights to generate the final CHD-PRS for each 
AA participant. We also tested the association of each CHD-PRS with each psychological attitude. 
 
PRS for CHD Target Phenotypes 
Psychological Attitudes Conditional Liability of CHD 
P-threshold 
for EUR-PRS 
P-threshold 
for AA-PRS 
Optimism Cynical 
hostility 
All CHD Acute CHD 
 
 
 
PT < 0.0001 
PT < 0.0001 t=0.36 
P=0.73 
R2=5.22E-06 
t=0.29 
P=0.77 
R2=4.76E-06 
t=1.67 
P=0.16 
R2=8.23E-05 
t=1.35 
P=0.29 
R2=5.63E-05 
PT < 0.001 t=-0.21 
P=0.82 
R2=3.40E-06 
t=0.30 
P=0.76 
R2=7.58E-06 
t=1.86 
P=0.07 
R2=0.0002 
t=1.52 
P=0.20 
R2=7.81E-05 
PT < 0.01 t=-0.46 
P=0.65 
R2=1.53E-05 
t=0.54 
P=0.59 
R2=2.41E-05 
t=3.31 
P=7.20E-04** 
R2=0.0011 
t=2.98 
P=1.53E-03** 
R2=0.0009 
 
 
 
PT < 0.001 
PT < 0.0001 t=-0.39 
P=0.70 
R2=6.38E-06 
t=0.35 
P=0.74 
R2=5.16E-06 
t=0.24 
P=0.81 
R2=4.79E-06 
t=0.29 
P=0.78 
R2=6.01E-06 
PT < 0.001 t=0.09 
P=0.97 
R2=2.07E-06 
t=0.38 
P=0.72 
R2=6.21E-06 
t=0.58 
P=0.55 
R2=2.21E-05 
t=0.44 
P=0.68 
R2=1.33E-05 
PT < 0.01 t=-0.47 
P=0.64 
R2=1.60E-05 
t=0.65 
P=0.52 
R2=3.14E-05 
t=1.92 
P=0.06 
R2=0.0003 
t=0.21 
P=0.83 
R2=2.54E-06 
 
 
 
PT < 0.01 
PT < 0.0001 t=-0.43 
P=0.65 
R2=7.04E-06 
t=-0.18 
P=0.87 
R2=3.06E-06 
t=0.85 
P=0.37 
R2=5.36E-05 
t=0.32 
P=0.74 
R2=8.67E-06 
PT < 0.001 t=-0.27 
P=0.78 
R2=5.40E-06 
t=0.34 
P=0.73 
R2=8.32E-06 
t=0.27 
P=0.79 
R2=0.0003 
t=0.57 
P=0.55 
R2=2.81E-05 
PT < 0.01 t=-0.24 
P=0.81 
R2=4.60E-06 
t=0.55 
P=0.61 
R2=1.24E-05 
t=0.43 
P=0.68 
R2=9.23E-06 
t=0.54 
P=0.57 
R2=2.25E-05 
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Table S3.4: Associations of CHD-PRS with psychological attitudes and the liability of CHD in the 
HA subsample 
 
EUR-PRS: We used CARDIoGRAM GWAS results as the training dataset to calculate PRS with European 
training data with different p-value thresholds (0.0001, 0.001, and 0.01) in the WHI-HA target sample.  
HA-PRS: We used a five-fold cross-validation procedure to calculate PRS with a p-value threshold of 
0.0001, 0.001, or 0.01 in the WHI-HA sample. 
CHD-PRS, generated by using MultiPRS: We performed a 2-dimensional grid search to optimize the 
linear combination via an in-sample fit on the WHI-HA validation sample, with different P-value 
thresholds for EUR-PRS and AA-PRS. We examined the prediction accuracy (adjusted R2) for the liability 
of CHD of the 9 (3x3) combinations for the WHI-HA sample, and used the fitted beta coefficients as the 
weights to generate the final CHD-PRS for each HA participant. We also tested the association of each 
CHD-PRS with each psychological attitude. 
PRS for CHD Target Phenotypes 
Psychological Attitudes Conditional Liability of CHD 
P-threshold 
for EUR-PRS 
P-threshold 
for HA-PRS 
Optimism Cynical 
hostility 
All CHD Acute CHD 
 
 
 
PT < 0.0001 
PT < 0.0001 t=-0.35 
P=0.73 
R2=5.12E-06 
t=0.12 
P=0.91 
R2=2.36E-06 
t=1.07 
P=0.36 
R2=5.63E-05 
t=0.88 
P=0.46 
R2=3.32E-05 
PT < 0.001 t=-0.41 
P=0.67 
R2=8.40E-06 
t=0.20 
P=0.86 
R2=3.58E-06 
t=2.47 
P=0.01* 
R2=0.0007 
t=2.01 
P=0.04* 
R2=0.0004 
PT < 0.01 t=-0.46 
P=0.65 
R2=1.53E-05 
t=0.54 
P=0.59 
R2=2.41E-05 
t=1.89 
P=0.05 
R2=0.0003 
t=1.42 
P=0.26 
R2=7.45E-05 
 
 
 
PT < 0.001 
PT < 0.0001 t=0.15 
P=0.90 
R2=2.13E-06 
t=0.32 
P=0.76 
R2=4.86E-06 
t=0.43 
P=0.69 
R2=9.36E-06 
t=0.46 
P=0.66 
R2=1.41E-05 
PT < 0.001 t=-0.38 
P=0.70 
R2=4.96E-06 
t=0.04 
P=0.98 
R2=1.20E-06 
t=0.52 
P=0.57 
R2=2.19E-05 
t=0.45 
P=0.66 
R2=1.37E-05 
PT < 0.01 t=-0.57 
P=0.52 
R2=3.21E-05 
t=0.65 
P=0.50 
R2=3.64E-05 
t=0.56 
P=0.53 
R2=2.46E-05 
t=0.20 
P=0.83 
R2=3.01E-06 
 
 
 
PT < 0.01 
PT < 0.0001 t=-0.27 
P=0.77 
R2=5.34E-06 
t=0.08 
P=0.96 
R2=1.66E-06 
t=1.15 
P=0.28 
R2=7.06E-05 
t=0.87 
P=0.47 
R2=3.28E-05 
PT < 0.001 t=-0.07 
P=0.96 
R2=1.49E-06 
t=0.30 
P=0.75 
R2=7.63E-06 
t=0.93 
P=0.39 
R2=4.84E-05 
t=0.67 
P=0.53 
R2=2.79E-05 
PT < 0.01 t=-0.34 
P=0.72 
R2=4.49E-06 
t=0.43 
P=0.68 
R2=7.04E-06 
t=0.40 
P=0.70 
R2=8.14E-06 
t=0.56 
P=0.53 
R2=2.45E-05 
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Table S3.5: The estimated direct and indirect effect beta (95% CI) of the relationship between 
the CHD-PRS, optimism, and the conditional liability of all CHD after adjusting for a hypothetical 
confounder U 
 
rUM: the Pearson’s correlation coefficient between the hypothetical confounder and the mediator 
rUY: the Pearson’s correlation coefficient between the hypothetical confounder and the outcome 
The estimated direct and indirect effects (95%CI) before adjusting for the hypothetical unmeasured 
confounder were 0.0440 (0.0274, 0.0591) and 0.0006 (0.0001, 0.0014), respectively. 
The estimated proportion mediated before adjusting for the hypothetical unmeasured confounder was 
1.4%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unmeasured 
Confounder 
Mediation Analyses after additionally adjusting for the hypothetical unmeasured 
confounder 
rUM rUY Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
 0.1  0.1 0.0438 (0.0282, 0.0580) 0.0430 (0.0274, 0.0569)  0.0008 (0.0003, 0.0018)  1.9% 
 0.2  0.2 0.0425 (0.0275, 0.0576) 0.0409 (0.0259, 0.0560)  0.0016 (0.0006, 0.0028)  3.7% 
-0.1  0.1 0.0435 (0.0284, 0.0593) 0.0431 (0.0277, 0.0583)  0.0004 (0.0001, 0.0011)  1.0% 
-0.2  0.2 0.0411 (0.0257, 0.0570) 0.0413 (0.0258, 0.0572) -0.0002 (-0.0007, 0.0001) -0.5% 
 172 
 
Table S3.6: The estimated direct and indirect effect beta (95% CI) of the relationship between 
the CHD-PRS, optimism, and the conditional liability of acute CHD after adjusting for a 
hypothetical confounder U 
 
 
rUM: the Pearson’s correlation coefficient between the hypothetical confounder and the mediator 
rUY: the Pearson’s correlation coefficient between the hypothetical confounder and the outcome 
The estimated direct and indirect effects (95%CI) before adjusting for the hypothetical unmeasured 
confounder were 0.0288 (0.0164, 0.0430) and 0.0005 (0.0001, 0.0012), respectively. 
The estimated proportion mediated before adjusting for the hypothetical unmeasured confounder was 
1.7%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unmeasured 
Confounder 
Mediation Analyses after additionally adjusting for the hypothetical unmeasured 
confounder 
rUM rUY Total effect 
(95% BCCI) 
Direct effect 
(95% BCCI) 
Indirect effect 
(95% BCCI) 
PM 
 0.1  0.1 0.0287 (0.0155, 0.0425) 0.0280 (0.0149, 0.0423)  0.0007 (0.0002, 0.0015)  2.3% 
 0.2  0.2 0.0278 (0.0150, 0.0411) 0.0266 (0.0134, 0.0396)  0.0013 (0.0005, 0.0023)  4.5% 
-0.1  0.1 0.0283 (0.0163, 0.0425) 0.0281 (0.0161, 0.0422)  0.0003 (8.0E-06, 0.0008)  1.0% 
-0.2  0.2 0.0266 (0.0145, 0.0405) 0.0268 (0.0147, 0.0405) -0.0002 (-0.0007, 0.00003) -0.8% 
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